

.....
(Original Signature of Member)

107TH CONGRESS
2^D SESSION

H. R. _____

IN THE HOUSE OF REPRESENTATIVES

Mr. RANGEL (for himself, Mr. DINGELL, [insert names of additional cospon-
sors from attached list]) introduced the following bill; which was referred
to the Committee on _____

A BILL

To amend titles XVIII and XIX of the Social Security Act
to provide for a voluntary medicare prescription medicine
benefit, to provide greater access to affordable pharma-
ceuticals, to revise and improve payments to providers
of services under the medicare program, and for other
purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE; REFERENCES IN ACT; TABLE**
 2 **OF CONTENTS.**

3 (a) SHORT TITLE.—This Act may be cited as the “Medi-
 4 care Rx Drug Benefit and Discount Act of 2002”.

5 (b) AMENDMENTS TO SOCIAL SECURITY ACT.—Except as
 6 otherwise specifically provided, whenever in title I of this Act
 7 an amendment is expressed in terms of an amendment to or
 8 repeal of a section or other provision, the reference shall be
 9 considered to be made to that section or other provision of the
 10 Social Security Act.

11 (c) BIPA; SECRETARY.—In this Act:

12 (1) BIPA.—The term “BIPA” means the Medicare,
 13 Medicaid, and SCHIP Benefits Improvement and Protec-
 14 tion Act of 2000, as enacted into law by section 1(a)(6) of
 15 Public Law 106–554.

16 (2) SECRETARY.—The term “Secretary” means the
 17 Secretary of Health and Human Services.

18 (d) TABLE OF CONTENTS.—The table of contents of this
 19 Act is as follows:

TITLE I—PRESCRIPTION DRUG PROVISIONS

SUBTITLE A—MEDICARE PRESCRIPTION MEDICINE BENEFIT

Sec. 101. Voluntary medicare outpatient prescription medicine program.

“PART D—VOLUNTARY PRESCRIPTION MEDICINE BENEFIT FOR THE AGED
 AND DISABLED

“Sec. 1859. Medicare outpatient prescription medicine benefit.

“Sec. 1859A. Negotiating fair prices with pharmaceutical manufacturers.

“Sec. 1859B. Contract authority.

“Sec. 1859C. Eligibility; voluntary enrollment; coverage.

“Sec. 1859D. Provision of, and entitlement to, benefits.

“Sec. 1859E. Administration; quality assurance.

“Sec. 1859F. Federal Medicare Prescription Medicine Trust Fund.

“Sec. 1859G. Compensation for employers covering retiree medicine costs.

“Sec. 1859H. Medicare Prescription Medicine Advisory Committee.

Sec. 102. Provision of medicare outpatient prescription medicine coverage
 under the Medicare+Choice program.

Sec. 103. Medigap revisions.

Sec. 104. Transitional assistance for low income beneficiaries.

Sec. 105. Expansion of membership and duties of Medicare Payment Advi-
 sory Commission (MedPAC).

SUBTITLE B—AFFORDABLE PHARMACEUTICALS

PART I—GREATER ACCESS TO AFFORDABLE PHARMACEUTICALS

Sec. 111. Accelerated generic drug competition.

Sec. 112. Patent certification.

Sec. 113. Additional uses.

PART II—NOTIFICATION OF AGREEMENTS AFFECTING THE SALE OR
MARKETING OF GENERIC DRUGS

Sec. 121. Definitions.

Sec. 122. Notification of agreements affecting the sale or marketing of generic drugs.

Sec. 123. Filing deadlines.

Sec. 124. Enforcement.

Sec. 125. Rulemaking.

Sec. 126. Effective dates.

TITLE II—MEDICARE+CHOICE REVITALIZATION AND
MEDICARE+CHOICE COMPETITION PROGRAM

Sec. 201. Medicare+Choice improvements.

Sec. 202. Making permanent change in Medicare+Choice reporting deadlines and annual, coordinated election period.

Sec. 203. Specialized Medicare+Choice plans for special needs beneficiaries.

Sec. 204. Extension of reasonable cost and SHMO contracts.

Sec. 205. Continuous open enrollment and disenrollment.

Sec. 206. Limitation on Medicare+Choice cost-sharing.

Sec. 207. Extension of municipal health service demonstration projects.

TITLE III—RURAL HEALTH CARE IMPROVEMENTS

Sec. 301. Reference to full market basket increase for sole community hospitals.

Sec. 302. Enhanced disproportionate share hospital (DSH) treatment for rural hospitals and urban hospitals with fewer than 100 beds.

Sec. 303. 2-year phased-in increase in the standardized amount in rural and small urban areas to achieve a single, uniform standardized amount.

Sec. 304. More frequent update in weights used in hospital market basket.

Sec. 305. Improvements to critical access hospital program.

Sec. 306. Extension of temporary increase for home health services furnished in a rural area.

Sec. 307. Reference to 10 percent increase in payment for hospice care furnished in a frontier area and rural hospice demonstration project.

Sec. 308. Reference to priority for hospitals located in rural or small urban areas in redistribution of unused graduate medical education residencies.

Sec. 309. GAO study of geographic differences in payments for physicians' services.

Sec. 310. Providing safe harbor for certain collaborative efforts that benefit medically underserved populations.

Sec. 311. Relief for certain non-teaching hospitals.

TITLE IV—PROVISIONS RELATING TO PART A

Subtitle A—Inpatient Hospital Services

Sec. 401. Revision of acute care hospital payment updates.

Sec. 402. Freeze in level of adjustment for indirect costs of medical education (IME) through fiscal year 2007.

Sec. 403. Recognition of new medical technologies under inpatient hospital PPS.

Sec. 404. Phase-in of Federal rate for hospitals in Puerto Rico.

4

- Sec. 405. Reference to provision relating to enhanced disproportionate share hospital (DSH) payments for rural hospitals and urban hospitals with fewer than 100 beds.
- Sec. 406. Reference to provision relating to 2-year phased-in increase in the standardized amount in rural and small urban areas to achieve a single, uniform standardized amount.
- Sec. 407. Reference to provision for more frequent updates in the weights used in hospital market basket.
- Sec. 408. Reference to provision making improvements to critical access hospital program.

Subtitle B—Skilled Nursing Facility Services

- Sec. 411. Payment for covered skilled nursing facility services.

Subtitle C—Hospice

- Sec. 421. Coverage of hospice consultation services.
- Sec. 422. 10 percent increase in payment for hospice care furnished in a frontier area.
- Sec. 423. Rural hospice demonstration project.

Subtitle D—Other Provisions

- Sec. 431. Demonstration project for use of recovery audit contractors for part A services.

TITLE V—PROVISIONS RELATING TO PART B

Subtitle A—Physicians' Services

- Sec. 501. Revision of updates for physicians' services.
- Sec. 502. Studies on access to physicians' services.
- Sec. 503. MedPAC report on payment for physicians' services.
- Sec. 504. 1-year extension of treatment of certain physician pathology services under medicare.
- Sec. 505. Physician fee schedule wage index revision.

Subtitle B—Other Services

- Sec. 511. Competitive acquisition of certain items and services.
- Sec. 512. Payment for ambulance services.
- Sec. 513. 5-year extension of moratorium on therapy caps; provisions relating to reports.
- Sec. 514. Accelerated implementation of 20 percent coinsurance for hospital outpatient department (OPD) services; other OPD provisions.
- Sec. 515. Coverage of an initial preventive physical examination.
- Sec. 516. Renal dialysis services.
- Sec. 517. Improved payment for certain mammography services.
- Sec. 518. Waiver of part B late enrollment penalty for certain military retirees; special enrollment period.
- Sec. 519. Coverage of cholesterol and blood lipid screening.

TITLE VI—PROVISIONS RELATING TO PARTS A AND B

Subtitle A—Home Health Services

- Sec. 601. Elimination of 15 percent reduction in payment rates under the prospective payment system.
- Sec. 602. Update in home health services.
- Sec. 603. OASIS Task Force; suspension of certain OASIS data collection requirements pending Task Force submittal of report.
- Sec. 604. MedPAC study on medicare margins of home health agencies.

Subtitle B—Direct Graduate Medical Education

- Sec. 611. Redistribution of unused resident positions.
 Sec. 612. Increasing for 5 years to 100 percent of the locality adjusted national average per resident amount the payment floor for direct graduate medical education payments under the medicare program.

Subtitle C—Other Provisions

- Sec. 621. Modifications to Medicare Payment Advisory Commission (MedPAC).
 Sec. 622. Demonstration project for disease management for certain medicare beneficiaries with diabetes.
 Sec. 623. Demonstration project for medical adult day care services.
 Sec. 624. Publication on final written guidance concerning prohibitions against discrimination by national origin with respect to health care services.

TITLE VII—MEDICAID PROVISIONS

Subtitle A—Medicaid Provisions

- Sec. 701. DSH provisions.
 Sec. 702. 1-year extension of Q-I1 program.

Subtitle B—Internet Pharmacies

- Sec. 711. Internet sales of prescription drugs. Findings.
 Sec. 712. Internet sales of prescription drugs; consideration by secretary of practices and procedures for certification of legitimate businesses.
 Sec. 713. Effective date.

Subtitle C—Treatment of Rare Diseases

- Sec. 721. NIH Office of Rare Diseases at National Institutes of Health.
 Sec. 722. Rare disease regional centers of excellence.

Subtitle D—Other Provisions Relating to Drugs

- Sec. 731. GAO study regarding direct-to-consumer advertising of prescription drugs.
 Sec. 732. Certain health professions programs regarding practice of pharmacy.

“SUBPART 3—PHARMACIST WORKFORCE PROGRAMS

- “Sec. 771. Public service announcements.
 “Sec. 772. Demonstration project.
 “Sec. 773. Information technology.
 “Sec. 774. Authorization of appropriations.

**TITLE I—PRESCRIPTION
 MEDICINE PROVISIONS
 Subtitle A—MEDICARE PRESCRIPTION MEDICINE BENEFIT**

SEC. 101. VOLUNTARY MEDICARE OUTPATIENT PRESCRIPTION MEDICINE PROGRAM.

(a) IN GENERAL.—Title XVIII (42 U.S.C. 1395 et seq.)
 is amended—

1 (1) by redesignating section 1859 and part D as sec-
2 tion 1858 and part E, respectively; and

3 (2) by inserting after part C the following new part:

4 “PART D—VOLUNTARY PRESCRIPTION MEDICINE BENEFIT

5 FOR THE AGED AND DISABLED

6 “MEDICARE OUTPATIENT PRESCRIPTION MEDICINE BENEFIT

7 “SEC. 1859. Subject to the succeeding provisions of this
8 part, the voluntary prescription medicine benefit program
9 under this part provides the following:

10 “(1) PREMIUM.—The monthly premium is \$25.

11 “(2) DEDUCTIBLE.—The annual deductible is \$100.

12 “(3) COINSURANCE.—The coinsurance is 20 percent.

13 “(4) OUT-OF-POCKET LIMIT.—The annual limit on
14 out-of-pocket spending on covered medicines is \$2,000.

15 “NEGOTIATING FAIR PRICES WITH PHARMACEUTICAL
16 MANUFACTURERS

17 “SEC. 1859A. (a) AUTHORITY TO NEGOTIATE PRICES
18 WITH MANUFACTURERS.—The Secretary shall, consistent with
19 the requirements of this part and the goals of providing quality
20 care and containing costs under this part, negotiate contracts
21 with manufacturers of covered outpatient prescription medi-
22 cines that provide for the maximum prices that may be charged
23 to individuals enrolled under this part by participating phar-
24 macies for dispensing such medicines to such individuals.

25 “(b) PROMOTION OF BREAKTHROUGH MEDICINES.—In
26 conducting negotiations with manufacturers under this part,
27 the Secretary shall take into account the goal of promoting the
28 development of breakthrough medicines (as defined in section
29 1859H(b)).

30 “CONTRACT AUTHORITY

31 “SEC. 1859B. (a) CONTRACT AUTHORITY.—

32 “(1) IN GENERAL.—The Secretary is responsible for
33 the administration of this part and shall enter into con-
34 tracts with appropriate pharmacy contractors on a national
35 or regional basis to administer the benefits under this part.

36 “(2) PROCEDURES.—The Secretary shall establish
37 procedures under which the Secretary—

1 “(A) accepts bids submitted by entities to serve as
2 pharmacy contractors under this part in a region or on
3 a national basis;

4 “(B) awards contracts to such contractors to ad-
5 minister benefits under this part to eligible bene-
6 ficiaries in the region or on a national basis; and

7 “(C) provides for the termination (and non-
8 renewal) of a contract in the case of a contractor’s fail-
9 ure to meet the requirements of the contract and this
10 part.

11 “(3) COMPETITIVE PROCEDURES.—Competitive proce-
12 dures (as defined in section 4(5) of the Office of Federal
13 Procurement Policy Act (41 U.S.C. 403(5))) shall be used
14 to enter into contracts under this part.

15 “(4) TERMS AND CONDITIONS.—Such contracts shall
16 have such terms and conditions as the Secretary shall
17 specify and shall be for such terms (of at least 2 years, but
18 not to exceed 5 years) as the Secretary shall specify con-
19 sistent with this part.

20 “(5) USE OF PHARMACY CONTRACTORS IN PRICE NE-
21 GOTIATIONS.—Such contracts shall require the contractor
22 involved to negotiate contracts with manufacturers that
23 provide for maximum prices for covered outpatient pre-
24 scription medicines that are lower than the maximum
25 prices negotiated under section 1859A(a), if applicable. The
26 price reductions shall be passed on to eligible beneficiaries
27 and the Secretary shall hold the contractor accountable for
28 meeting performance requirements with respect to price re-
29 ductions and limiting price increases.

30 “(6) AREA FOR CONTRACTS.—

31 “(A) REGIONAL BASIS.—

32 “(i) IN GENERAL.—Except as provided in
33 clause (ii) and subject to subparagraph (B), the
34 contract entered into between the Secretary and a
35 pharmacy contractor shall require the contractor to
36 administer the benefits under this part in a region

determined by the Secretary under subparagraph (B) or on a national basis.

“(ii) PARTIAL REGIONAL BASIS.—

“(I) IN GENERAL.—If determined appropriate by the Secretary, the Secretary may permit the benefits to be administered in a partial region determined appropriate by the Secretary.

“(II) REQUIREMENTS.—If the Secretary permits administration pursuant to subclause (I), the Secretary shall ensure that the partial region in which administration is effected is no smaller than a State and is at least the size of the commercial service area of the contractor for that area.

“(B) DETERMINATION.—

“(i) IN GENERAL.—In determining regions for contracts under this part, the Secretary shall—

“(I) take into account the number of individuals enrolled under this part in an area in order to encourage participation by pharmacy contractors; and

“(II) ensure that there are at least 10 different regions in the United States.

“(ii) NO ADMINISTRATIVE OR JUDICIAL REVIEW.—The determination of administrative areas under this paragraph shall not be subject to administrative or judicial review.

“(7) SUBMISSION OF BIDS.—

“(A) SUBMISSION.—

“(i) IN GENERAL.—Subject to subparagraph (B), each entity desiring to serve as a pharmacy contractor under this part in an area shall submit a bid with respect to such area to the Secretary at such time, in such manner, and accompanied by such information as the Secretary may reasonably require.

1 “(ii) BID THAT COVERS MULTIPLE AREAS.—

2 The Secretary shall permit an entity to submit a
3 single bid for multiple areas if the bid is applicable
4 to all such areas.

5 “(B) REQUIRED INFORMATION.—The bids de-
6 scribed in subparagraph (A) shall include—

7 “(i) a proposal for the estimated prices of cov-
8 ered outpatient prescription medicines and the pro-
9 jected annual increases in such prices, including
10 the additional reduction in price negotiated below
11 the Secretary’s maximum price and differentials be-
12 tween preferred and nonpreferred prices, if applica-
13 ble;

14 “(ii) a statement regarding the amount that
15 the entity will charge the Secretary for admin-
16 istering the benefits under the contract;

17 “(iii) a statement regarding whether the entity
18 will reduce the applicable coinsurance percentage
19 pursuant to section 1859E(a)(1)(A)(ii) and if so,
20 the amount of such reduction and how such reduc-
21 tion is tied to the performance requirements de-
22 scribed in subsection (c)(4)(A)(ii);

23 “(iv) a detailed description of the performance
24 requirements for which the administrative fee of
25 the entity will be subject to risk pursuant to sub-
26 section (c)(4)(A)(ii);

27 “(v) a detailed description of access to phar-
28 macy services provided by the entity, including in-
29 formation regarding whether the pharmacy con-
30 tractor will use a preferred pharmacy network, and,
31 if so, how the pharmacy contractor will ensure ac-
32 cess to pharmacies that choose to be outside of that
33 network, and whether there will be increased cost-
34 sharing for beneficiaries if they obtain medicines at
35 such pharmacies;

36 “(vi) a detailed description of the procedures
37 and standards the entity will use for—

1 “(I) selecting preferred prescription medi-
2 cines; and

3 “(II) determining when and how often the
4 list of preferred prescription medicines should
5 be modified;

6 “(vii) a detailed description of any ownership
7 or shared financial interests with pharmaceutical
8 manufacturers, pharmacies, and other entities in-
9 volved in the administration or delivery of benefits
10 under this part as proposed in the bid;

11 “(viii) a detailed description of the entity’s es-
12 timated marketing and advertising expenditures re-
13 lated to enrolling and retaining eligible bene-
14 ficiaries; and

15 “(ix) such other information that the Sec-
16 retary determines is necessary in order to carry out
17 this part, including information relating to the bid-
18 ding process under this part.

19 The procedures under clause (vi) shall include the use
20 of a pharmaceutical and therapeutics committee the
21 members of which include practicing pharmacists.

22 “(8) AWARDING OF CONTRACTS.—

23 “(A) NUMBER OF CONTRACTS.—The Secretary
24 shall, consistent with the requirements of this part and
25 the goals of providing quality care and of containing
26 costs under this part, award in a competitive manner
27 at least 2 contracts to administer benefits under this
28 part in each area specified under paragraph (6), unless
29 only 1 pharmacy contractor submitting a bid meets the
30 minimum standards specified under this part and by
31 the Secretary.

32 “(B) DETERMINATION.—In determining which of
33 the pharmacy contractors that submitted bids that
34 meet the minimum standards specified under this part
35 and by the Secretary to award a contract, the Sec-
36 retary shall consider the comparative merits of each

1 bid, as determined on the basis of relevant factors, with
2 respect to—

3 “(i) how well the contractor meets such min-
4 imum standards;

5 “(ii) the amount that the contractor will
6 charge the Secretary for administering the benefits
7 under the contract;

8 “(iii) the performance standards established
9 under subsection (c)(2) and performance require-
10 ments for which the administrative fee of the entity
11 will be subject to risk pursuant to subsection
12 (c)(4)(A)(ii);

13 “(iv) the proposed negotiated prices of covered
14 outpatient medicines and annual increases in such
15 prices;

16 “(v) factors relating to benefits, quality and
17 performance, beneficiary cost-sharing, and con-
18 sumer satisfaction;

19 “(vi) past performance and prior experience of
20 the contractor in administering a prescription med-
21 icine benefit program;

22 “(vii) effectiveness of the contractor in con-
23 taining costs through pricing incentives and utiliza-
24 tion management; and

25 “(viii) such other factors as the Secretary
26 deems necessary to evaluate the merits of each bid.

27 “(C) EXCEPTION TO CONFLICT OF INTEREST
28 RULES.—In awarding contracts with pharmacy contrac-
29 tors under this part, the Secretary may waive conflict
30 of interest laws generally applicable to Federal acqui-
31 sitions (subject to such safeguards as the Secretary may
32 find necessary to impose) in circumstances where the
33 Secretary finds that such waiver—

34 “(i) is not inconsistent with the—

35 “(I) purposes of the programs under this
36 part; or

1 “(II) best interests of beneficiaries en-
2 rolled under this part; and

3 “(ii) permits a sufficient level of competition
4 for such contracts, promotes efficiency of benefits
5 administration, or otherwise serves the objectives of
6 the program under this part.

7 “(D) NO ADMINISTRATIVE OR JUDICIAL RE-
8 VIEW.—The determination of the Secretary to award or
9 not award a contract to a pharmacy contractor under
10 this part shall not be subject to administrative or judi-
11 cial review.

12 “(9) ACCESS TO BENEFITS IN CERTAIN AREAS.—

13 “(A) AREAS NOT COVERED BY CONTRACTS.—The
14 Secretary shall develop procedures for the provision of
15 covered outpatient prescription medicines under this
16 part to each eligible beneficiary enrolled under this part
17 that resides in an area that is not covered by any con-
18 tract under this part.

19 “(B) BENEFICIARIES RESIDING IN DIFFERENT LO-
20 CATIONS.—The Secretary shall develop procedures to
21 ensure that each eligible beneficiary enrolled under this
22 part that resides in different areas in a year is provided
23 the benefits under this part throughout the entire year.

24 “(b) QUALITY, FINANCIAL, AND OTHER STANDARDS AND
25 PROGRAMS.—In consultation with appropriate pharmacy con-
26 tractors, pharmacists, and health care professionals with exper-
27 tise in prescribing, dispensing, and the appropriate use of pre-
28 scription medicines, the Secretary shall establish standards and
29 programs for the administration of this part to ensure appro-
30 priate prescribing, dispensing, and utilization of outpatient
31 medicines under this part, to avoid adverse medicine reactions,
32 and to continually reduce errors in the delivery of medically ap-
33 propriate covered benefits. The Secretary shall not award a
34 contract to a pharmacy contractor under this part unless the
35 Secretary finds that the contractor agrees to comply with such
36 standards and programs and other terms and conditions as the
37 Secretary shall specify. The standards and programs under this

1 subsection shall be applied to any administrative agreements
2 described in subsection (a) the Secretary enters into. Such
3 standards and programs shall include the following:

4 “(1) ACCESS.—

5 “(A) IN GENERAL.—The pharmacy contractor
6 shall ensure that covered outpatient prescription medi-
7 cines are accessible and convenient to eligible bene-
8 ficiaries enrolled under this part for whom benefits are
9 administered by the pharmacy contractor, including by
10 offering the services 24 hours a day and 7 days a week
11 for emergencies.

12 “(B) ON-LINE REVIEW.—The pharmacy contractor
13 shall provide for on-line prospective review available 24
14 hours a day and 7 days a week in order to evaluate
15 each prescription for medicine therapy problems due to
16 duplication, interaction, or incorrect dosage or duration
17 of therapy.

18 “(C) GUARANTEED ACCESS TO MEDICINES IN
19 RURAL AND HARD-TO-SERVE AREAS.—The Secretary
20 shall ensure that all beneficiaries have guaranteed ac-
21 cess to the full range of pharmaceuticals under this
22 part, and shall give special attention to access, phar-
23 macist counseling, and delivery in rural and hard-to-
24 serve areas, including through the use of incentives
25 such as bonus payments to retail pharmacists in rural
26 areas and extra payments to the pharmacy contractor
27 for the cost of rapid delivery of pharmaceuticals and
28 any other actions necessary.

29 “(D) PREFERRED PHARMACY NETWORKS.—

30 “(i) IN GENERAL.—If a pharmacy contractor
31 uses a preferred pharmacy network to deliver bene-
32 fits under this part, such network shall meet min-
33 imum access standards established by the Sec-
34 retary.

35 “(ii) STANDARDS.—In establishing standards
36 under clause (i), the Secretary shall take into ac-

1 count reasonable distances to pharmacy services in
2 both urban and rural areas.

3 “(E) ADHERENCE TO NEGOTIATED PRICES.—The
4 pharmacy contractor shall have in place procedures to
5 assure compliance of pharmacies with the requirements
6 of subsection (d)(3)(C) (relating to adherence to nego-
7 tiated prices).

8 “(F) CONTINUITY OF CARE.—

9 “(i) IN GENERAL.—The pharmacy contractor
10 shall ensure that, in the case of an eligible bene-
11 ficiary who loses coverage under this part with such
12 entity under circumstances that would permit a
13 special election period (as established by the Sec-
14 retary under section 1859C(b)(3)), the contractor
15 will continue to provide coverage under this part to
16 such beneficiary until the beneficiary enrolls and
17 receives such coverage with another pharmacy con-
18 tractor under this part or, if eligible, with a
19 Medicare+Choice organization.

20 “(ii) LIMITED PERIOD.—In no event shall a
21 pharmacy contractor be required to provide the ex-
22 tended coverage required under clause (i) beyond
23 the date which is 30 days after the coverage with
24 such contractor would have terminated but for this
25 subparagraph.

26 “(2) ENROLLEE GUIDELINES.—The pharmacy con-
27 tractor shall, consistent with State law, apply guidelines for
28 counseling enrollees regarding—

29 “(A) the proper use of covered outpatient prescrip-
30 tion medicine; and

31 “(B) interactions and contra-indications.

32 “(3) EDUCATION.—The pharmacy contractor shall
33 apply methods to identify and educate providers, phar-
34 macists, and enrollees regarding—

35 “(A) instances or patterns concerning the unneces-
36 sary or inappropriate prescribing or dispensing of cov-
37 ered outpatient prescription medicines;

1 “(B) instances or patterns of substandard care;
2 “(C) potential adverse reactions to covered out-
3 patient prescription medicines;
4 “(D) inappropriate use of antibiotics;
5 “(E) appropriate use of generic products; and
6 “(F) the importance of using covered outpatient
7 prescription medicines in accordance with the instruc-
8 tion of prescribing providers.

9 “(4) COORDINATION.—The pharmacy contractor shall
10 coordinate with State prescription medicine programs,
11 other pharmacy contractors, pharmacies, and other relevant
12 entities as necessary to ensure appropriate coordination of
13 benefits with respect to enrolled individuals when such indi-
14 vidual is traveling outside the home service area, and under
15 such other circumstances as the Secretary may specify.

16 “(5) COST DATA.—

17 “(A) The pharmacy contractor shall make data on
18 prescription medicine negotiated prices (including data
19 on discounts) available to the Secretary.

20 “(B) The Secretary shall require, either directly or
21 through a pharmacy contractor, that participating
22 pharmacists, physicians, and manufacturers—

23 “(i) maintain their prescription medicine cost
24 data (including data on discounts) in a form and
25 manner specified by the Secretary;

26 “(ii) make such prescription medicine cost
27 data available for review and audit by the Sec-
28 retary; and

29 “(iii) certify that the prescription medicine
30 cost data are current, accurate, and complete, and
31 reflect all discounts obtained by the pharmacist or
32 physician in the purchasing of covered outpatient
33 prescription medicines.

34 Discounts referred to in subparagraphs (A) and (B) shall
35 include all volume discounts, manufacturer rebates, prompt
36 payment discounts, free goods, in-kind services, or any
37 other thing of financial value provided explicitly or implic-

1 itly in exchange for the purchase of a covered outpatient
2 prescription medicine.

3 “(6) REPORTING.—The pharmacy contractor shall
4 provide the Secretary with periodic reports on—

5 “(A) the contractor’s costs of administering this
6 part;

7 “(B) utilization of benefits under this part;

8 “(C) marketing and advertising expenditures re-
9 lated to enrolling and retaining individuals under this
10 part; and

11 “(D) grievances and appeals.

12 “(7) RECORDS AND AUDITS.—The pharmacy con-
13 tractor shall maintain adequate records related to the ad-
14 ministration of benefits under this part and afford the Sec-
15 retary access to such records for auditing purposes.

16 “(8) APPROVAL OF MARKETING MATERIAL AND APPLI-
17 CATION FORMS.—The pharmacy contractor shall comply
18 with requirements of section 1851(h) (relating to mar-
19 keting material and application forms) with respect to this
20 part in the same manner as such requirements apply under
21 part C, except that the provisions of paragraph (4)(A) of
22 such section shall not apply with respect to discounts or re-
23 bates provided in accordance with this part.

24 “(c) INCENTIVES FOR COST AND UTILIZATION MANAGE-
25 MENT AND QUALITY IMPROVEMENT.—

26 “(1) IN GENERAL.—The Secretary shall include in a
27 contract awarded under subsection (b) with a pharmacy
28 contractor such incentives for cost and utilization manage-
29 ment and quality improvement as the Secretary may deem
30 appropriate. The contract may provide financial or other
31 incentives to encourage greater savings to the program
32 under this part.

33 “(2) PERFORMANCE STANDARDS.—The Secretary shall
34 provide for performance standards (which may include
35 monetary bonuses if the standards are met and penalties
36 if the standards are not met), including standards relating
37 to the time taken to answer member and pharmacy inquir-

ies (written or by telephone), the accuracy of responses, claims processing accuracy, online system availability, appeal procedure turnaround time, system availability, the accuracy and timeliness of reports, and level of beneficiary satisfaction.

“(3) OTHER INCENTIVES.—Such incentives under this subsection may also include—

“(A) financial incentives under which savings derived from the substitution of generic and other preferred multi-source medicines in lieu of nongeneric and nonpreferred medicines are made available to pharmacy contractors, pharmacies, beneficiaries, and the Federal Medicare Prescription Medicine Trust Fund; and

“(B) any other incentive that the Secretary deems appropriate and likely to be effective in managing costs or utilization or improving quality that does not reduce the access of beneficiaries to medically necessary covered outpatient medicines.

“(4) REQUIREMENTS FOR PROCEDURES.—

“(A) IN GENERAL.—The Secretary shall establish procedures for making payments to each pharmacy contractor with a contract under this part for the administration of the benefits under this part. The procedures shall provide for the following:

“(i) ADMINISTRATIVE PAYMENT.—Payment of administrative fees for such administration.

“(ii) RISK REQUIREMENT.—An adjustment of a percentage (determined under subparagraph (B)) of the administrative fee payments made to a pharmacy contractor to ensure that the contractor, in administering the benefits under this part, pursues performance requirements established by the Secretary, including the following:

“(I) QUALITY SERVICE.—The contractor provides eligible beneficiaries for whom it administers benefits with quality services, as measured by such factors as sustained phar-

1 macy network access, timeliness and accuracy
2 of service delivery in claims processing and
3 card production, pharmacy and member service
4 support access, and timely action with regard
5 to appeals and current beneficiary service sur-
6 veys.

7 “(II) QUALITY CLINICAL CARE.—The con-
8 tractor provides such beneficiaries with quality
9 clinical care, as measured by such factors as
10 providing notification to such beneficiaries and
11 to providers in order to prevent adverse drug
12 reactions and reduce medication errors and
13 specific clinical suggestions to improve health
14 and patient and prescriber education as appro-
15 priate.

16 “(III) CONTROL OF MEDICARE COSTS.—
17 The contractor contains costs under this part
18 to the Federal Medicare Prescription Medicine
19 Trust Fund and enrollees, as measured by ge-
20 neric substitution rates, price discounts, and
21 other factors determined appropriate by the
22 Secretary that do not reduce the access of
23 beneficiaries to medically necessary covered
24 outpatient prescription medicines.

25 “(B) PERCENTAGE OF PAYMENT TIED TO RISK.—

26 “(i) IN GENERAL.—Subject to clause (ii), the
27 Secretary shall determine the percentage of the ad-
28 ministrative payments to a pharmacy contractor
29 that will be tied to the performance requirements
30 described in subparagraph (A)(ii).

31 “(ii) LIMITATION ON RISK TO ENSURE PRO-
32 GRAM STABILITY.—In order to provide for program
33 stability, the Secretary may not establish a percent-
34 age to be adjusted under this paragraph at a level
35 that jeopardizes the ability of a pharmacy con-
36 tractor to administer the benefits under this part
37 or administer such benefits in a quality manner.

1 “(C) RISK ADJUSTMENT OF PAYMENTS BASED ON
2 ENROLLEES IN PLAN.—To the extent that a pharmacy
3 contractor is at risk under this paragraph, the proce-
4 dures established under this paragraph may include a
5 methodology for risk adjusting the payments made to
6 such contractor based on the differences in actuarial
7 risk of different enrollees being served if the Secretary
8 determines such adjustments to be necessary and ap-
9 propriate.

10 “(d) AUTHORITY RELATING TO PHARMACY PARTICIPA-
11 TION.—

12 “(1) IN GENERAL.—Subject to the succeeding provi-
13 sions of this subsection, a pharmacy contractor may estab-
14 lish consistent with this part conditions for the participa-
15 tion of pharmacies, including conditions relating to quality
16 (including reduction of medical errors) and technology.

17 “(2) AGREEMENTS WITH PHARMACIES.—Each phar-
18 macy contractor shall enter into a participation agreement
19 with any pharmacy that meets the requirements of this
20 subsection and section 1859E to furnish covered outpatient
21 prescription medicines to individuals enrolled under this
22 part.

23 “(3) TERMS OF AGREEMENT.—An agreement under
24 this subsection shall include the following terms and condi-
25 tions:

26 “(A) APPLICABLE REQUIREMENTS.—The phar-
27 macy shall meet (and throughout the contract period
28 continue to meet) all applicable Federal requirements
29 and State and local licensing requirements.

30 “(B) ACCESS AND QUALITY STANDARDS.—The
31 pharmacy shall comply with such standards as the Sec-
32 retary (and such a pharmacy contractor) shall establish
33 concerning the quality of, and enrolled individuals’ ac-
34 cess to, pharmacy services under this part. Such stand-
35 ards shall require the pharmacy—

1 “(i) not to refuse to dispense covered out-
2 patient prescription medicines to any individual en-
3 rolled under this part;

4 “(ii) to keep patient records (including records
5 on expenses) for all covered outpatient prescription
6 medicines dispensed to such enrolled individuals;

7 “(iii) to submit information (in a manner spec-
8 ified by the Secretary to be necessary to administer
9 this part) on all purchases of such medicines dis-
10 pensed to such enrolled individuals; and

11 “(iv) to comply with periodic audits to assure
12 compliance with the requirements of this part and
13 the accuracy of information submitted.

14 “(C) ADHERENCE TO NEGOTIATED PRICES.—(i)
15 The total charge for each medicine dispensed by the
16 pharmacy to an enrolled individual under this part,
17 without regard to whether the individual is financially
18 responsible for any or all of such charge, shall not ex-
19 ceed the price negotiated under section 1859A(a) or, if
20 lower, negotiated under subsection (a)(5) (or, if less,
21 the retail price for the medicine involved) with respect
22 to such medicine plus a reasonable dispensing fee de-
23 termined contractually with the pharmacy contractor.

24 “(ii) The pharmacy does not charge (or collect
25 from) an enrolled individual an amount that exceeds
26 the individual’s obligation (as determined in accordance
27 with the provisions of this part) of the applicable price
28 described in clause (i).

29 “(D) ADDITIONAL REQUIREMENTS.—The phar-
30 macy shall meet such additional contract requirements
31 as the applicable pharmacy contractor specifies under
32 this section.

33 “(4) APPLICABILITY OF FRAUD AND ABUSE PROVI-
34 SIONS.—The provisions of section 1128 through 1128C (re-
35 lating to fraud and abuse) apply to pharmacies partici-
36 pating in the program under this part.

1 “ELIGIBILITY; VOLUNTARY ENROLLMENT; COVERAGE

2 “SEC. 1859C. (a) ELIGIBILITY.—Each individual who is
3 entitled to hospital insurance benefits under part A or is eligi-
4 ble to be enrolled in the medical insurance program under part
5 B is eligible to enroll in accordance with this section for out-
6 patient prescription medicine benefits under this part.

7 “(b) VOLUNTARY ENROLLMENT.—

8 “(1) IN GENERAL.—An individual may enroll under
9 this part only in such manner and form as may be pre-
10 scribed by regulations, and only during an enrollment pe-
11 riod prescribed in or under this subsection.

12 “(2) INITIAL ENROLLMENT PERIOD.—

13 “(A) INDIVIDUALS CURRENTLY COVERED.—In the
14 case of an individual who satisfies subsection (a) as of
15 November 1, 2004, the initial general enrollment period
16 shall begin on August 1, 2004, and shall end on March
17 1, 2005.

18 “(B) INDIVIDUAL COVERED IN FUTURE.—In the
19 case of an individual who first satisfies subsection (a)
20 on or after November 1, 2004, the individual’s initial
21 enrollment period shall begin on the first day of the
22 third month before the month in which such individual
23 first satisfies such paragraph and shall end seven
24 months later. The Secretary shall apply rules similar to
25 the rule described in the second sentence of section
26 1837(d).

27 “(3) SPECIAL ENROLLMENT PERIODS (WITHOUT PRE-
28 MIUM PENALTY).—

29 “(A) EMPLOYER COVERAGE AT TIME OF INITIAL
30 GENERAL ENROLLMENT PERIOD.—In the case of an in-
31 dividual who—

32 “(i) at the time the individual first satisfies
33 subsection (a) is enrolled in a group health plan
34 (including continuation coverage) that provides out-
35 patient prescription medicine coverage by reason of
36 the individual’s (or the individual’s spouse’s) cur-

1 rent (or, in the case of continuation coverage,
2 former) employment status, and

3 “(ii) has elected not to enroll (or to be deemed
4 enrolled) under this subsection during the individ-
5 ual’s initial enrollment period,

6 there shall be a special enrollment period of 6 months
7 beginning with the first month that includes the date
8 of the individual’s (or individual’s spouse’s) retirement
9 from or termination of current employment status with
10 the employer that sponsors the plan, or, in the case of
11 continuation coverage, that includes the date of termi-
12 nation of such coverage, or that includes the date the
13 plan substantially terminates outpatient prescription
14 medicine coverage.

15 “(B) DROPPING OF RETIREE PRESCRIPTION MEDI-
16 CINE COVERAGE.—In the case of an individual who—

17 “(i) at the time the individual first satisfies
18 subsection (a) is enrolled in a group health plan
19 that provides outpatient prescription medicine cov-
20 erage other than by reason of the individual’s (or
21 the individual’s spouse’s) current employment; and

22 “(ii) has elected not to enroll (or to be deemed
23 enrolled) under this subsection during the individ-
24 ual’s initial enrollment period,

25 there shall be a special enrollment period of 6 months
26 beginning with the first month that includes the date
27 that the plan substantially terminates outpatient pre-
28 scription medicine coverage and ending 6 months later.

29 “(C) LOSS OF MEDICARE+CHOICE PRESCRIPTION
30 MEDICINE COVERAGE.—In the case of an individual
31 who is enrolled under part C in a Medicare+Choice
32 plan that provides prescription medicine benefits, if
33 such enrollment is terminated because of the termi-
34 nation or reduction in service area of the plan, there
35 shall be a special enrollment period of 6 months begin-
36 ning with the first month that includes the date that

1 such plan is terminated or such reduction occurs and
2 ending 6 months later.

3 “(D) LOSS OF MEDICAID PRESCRIPTION MEDICINE
4 COVERAGE.—In the case of an individual who—

5 “(i) satisfies subsection (a);

6 “(ii) loses eligibility for benefits (that include
7 benefits for prescription medicine) under a State
8 plan after having been enrolled (or determined to
9 be eligible) for such benefits under such plan; and

10 “(iii) is not otherwise enrolled under this sub-
11 section at the time of such loss of eligibility,

12 there shall be a special enrollment period specified by
13 the Secretary of not less than 6 months beginning with
14 the first month that includes the date that the indi-
15 vidual loses such eligibility.

16 “(4) LATE ENROLLMENT WITH PREMIUM PENALTY.—
17 The Secretary shall permit an individual who satisfies sub-
18 section (a) to enroll other than during the initial enrollment
19 period under paragraph (2) or a special enrollment period
20 under paragraph (3). But, in the case of such an enroll-
21 ment, the amount of the monthly premium of the individual
22 is subject to an increase under section 1859C(e)(1).

23 “(5) INFORMATION.—

24 “(A) IN GENERAL.—The Secretary shall broadly
25 distribute information to individuals who satisfy sub-
26 section (a) on the benefits provided under this part.
27 The Secretary shall periodically make available infor-
28 mation on the cost differentials to enrollees for the use
29 of generic medicines and other medicines.

30 “(B) TOLL-FREE HOTLINE.—The Secretary shall
31 maintain a toll-free telephone hotline (which may be a
32 hotline already used by the Secretary under this title)
33 for purposes of providing assistance to beneficiaries in
34 the program under this part, including responding to
35 questions concerning coverage, enrollment, benefits,
36 grievances and appeals procedures, and other aspects of
37 such program.

1 “(6) ENROLLEE DEFINED.—For purposes of this part,
2 the term ‘enrollee’ means an individual enrolled for benefits
3 under this part.

4 “(c) COVERAGE PERIOD.—

5 “(1) IN GENERAL.—The period during which an indi-
6 vidual is entitled to benefits under this part (in this sub-
7 section referred to as the individual’s ‘coverage period’)
8 shall begin on such a date as the Secretary shall establish
9 consistent with the type of coverage rules described in sub-
10 sections (a) and (e) of section 1838, except that in no case
11 shall a coverage period begin before January 1, 2005. No
12 payments may be made under this part with respect to the
13 expenses of an individual unless such expenses were in-
14 curred by such individual during a period which, with re-
15 spect to the individual, is a coverage period.

16 “(2) TERMINATION.—The Secretary shall provide for
17 the application of provisions under this subsection similar
18 to the provisions in section 1838(b).

19 “(d) PROVISION OF BENEFITS TO MEDICARE+CHOICE
20 ENROLLEES.—In the case of an individual who is enrolled
21 under this part and is enrolled in a Medicare+Choice plan
22 under part C, the individual shall be provided the benefits
23 under this part through such plan and not through payment
24 under this part.

25 “(e) LATE ENROLLMENT PENALTIES; PAYMENT OF PRE-
26 MIUMS.—

27 “(1) LATE ENROLLMENT PENALTY.—

28 “(A) IN GENERAL.—In the case of a late enroll-
29 ment described in subsection (b)(4), subject to the suc-
30 ceeding provisions of this paragraph, the Secretary
31 shall establish procedures for increasing the amount of
32 the monthly premium under this part applicable to
33 such enrollee by an amount that the Secretary deter-
34 mines is actuarially sound for each such period.

35 “(B) PERIODS TAKEN INTO ACCOUNT.—For pur-
36 poses of calculating any 12-month period under sub-
37 paragraph (A), there shall be taken into account

1 months of lapsed coverage in a manner comparable to
2 that applicable under the second sentence of section
3 1839(b).

4 “(C) PERIODS NOT TAKEN INTO ACCOUNT.—

5 “(i) IN GENERAL.—For purposes of calcu-
6 lating any 12-month period under subparagraph
7 (A), subject to clause (ii), there shall not be taken
8 into account months for which the enrollee can
9 demonstrate that the enrollee was covered under a
10 group health plan that provides coverage of the
11 cost of prescription medicines whose actuarial value
12 (as defined by the Secretary) to the enrollee equals
13 or exceeds the actuarial value of the benefits pro-
14 vided to an individual enrolled in the outpatient
15 prescription medicine benefit program under this
16 part.

17 “(ii) APPLICATION.—This subparagraph shall
18 only apply with respect to a coverage period the en-
19 rollment for which occurs before the end of the 60-
20 day period that begins on the first day of the
21 month which includes the date on which the plan
22 terminates or reduces its service area (in a manner
23 that results in termination of enrollment), ceases to
24 provide, or reduces the value of the prescription
25 medicine coverage under such plan to below the
26 value of the coverage provided under the program
27 under this part.

28 “(2) INCORPORATION OF PREMIUM PAYMENT AND
29 GOVERNMENT CONTRIBUTIONS PROVISIONS.—The provi-
30 sions of sections 1840 and 1844(a)(1) shall apply to enroll-
31 ees under this part in the same manner as they apply to
32 individuals 65 years of age or older enrolled under part B.
33 For purposes of this subsection, any reference in a section
34 referred to in a previous subsection to the Federal Supple-
35 mentary Medical Insurance Trust Fund is deemed a ref-
36 erence to the Federal Medicare Prescription Medicine Trust
37 Fund.

1 “(f) ELECTION OF PHARMACY CONTRACTOR TO ADMIN-
2 ISTER BENEFITS.—The Secretary shall establish a process
3 whereby each individual enrolled under this part and residing
4 in a region may elect the pharmacy contractor that will admin-
5 ister the benefits under this part with respect to the individual.
6 Such process shall permit the individual to make an initial elec-
7 tion and to change such an election on at least an annual basis
8 and under such other circumstances as the Secretary shall
9 specify.

10 “PROVISION OF, AND ENTITLEMENT TO, BENEFITS

11 “SEC. 1859D. (a) BENEFITS.—Subject to the succeeding
12 provisions of this section, the benefits provided to an enrollee
13 by the program under this part shall consist of the following:

14 “(1) COVERED OUTPATIENT PRESCRIPTION MEDICINE
15 BENEFITS.—Entitlement to have payment made on the in-
16 dividual’s behalf for covered outpatient prescription medi-
17 cines.

18 “(2) LIMITATION ON COST-SHARING FOR PART B OUT-
19 PATIENT PRESCRIPTION MEDICINES.—

20 “(A) IN GENERAL.—Once an enrollee has incurred
21 aggregate countable cost-sharing (as defined in sub-
22 paragraph (B)) equal to the stop-loss limit specified in
23 subsection (c)(4) for expenses in a year, entitlement to
24 the elimination of cost-sharing otherwise applicable
25 under part B for additional expenses incurred in the
26 year for outpatient prescription medicines or biologicals
27 for which payment is made under part B.

28 “(B) COUNTABLE COST-SHARING DEFINED.—For
29 purposes of this part, the term ‘countable cost-sharing’
30 means—

31 “(i) out-of-pocket expenses for outpatient pre-
32 scription medicines with respect to which benefits
33 are payable under part B, and

34 “(ii) cost-sharing under subsections (c)(3)(B)
35 and (c)(3)(C)(i).

36 “(b) COVERED OUTPATIENT PRESCRIPTION MEDICINE
37 DEFINED.—

1 “(1) IN GENERAL.—Except as provided in paragraph
2 (2), for purposes of this part the term ‘covered outpatient
3 prescription medicine’ means any of the following products:

4 “(A) A medicine which may be dispensed only
5 upon prescription, and—

6 “(i) which is approved for safety and effective-
7 ness as a prescription medicine under section 505
8 of the Federal Food, Drug, and Cosmetic Act;

9 “(ii)(I) which was commercially used or sold in
10 the United States before the date of enactment of
11 the Drug Amendments of 1962 or which is iden-
12 tical, similar, or related (within the meaning of sec-
13 tion 310.6(b)(1) of title 21 of the Code of Federal
14 Regulations) to such a medicine, and (II) which
15 has not been the subject of a final determination
16 by the Secretary that it is a ‘new drug’ (within the
17 meaning of section 201(p) of the Federal Food,
18 Drug, and Cosmetic Act) or an action brought by
19 the Secretary under section 301, 302(a), or 304(a)
20 of such Act to enforce section 502(f) or 505(a) of
21 such Act; or

22 “(iii)(I) which is described in section 107(c)(3)
23 of the Drug Amendments of 1962 and for which
24 the Secretary has determined there is a compelling
25 justification for its medical need, or is identical,
26 similar, or related (within the meaning of section
27 310.6(b)(1) of title 21 of the Code of Federal Reg-
28 ulations) to such a medicine, and (II) for which the
29 Secretary has not issued a notice of an opportunity
30 for a hearing under section 505(e) of the Federal
31 Food, Drug, and Cosmetic Act on a proposed order
32 of the Secretary to withdraw approval of an appli-
33 cation for such medicine under such section be-
34 cause the Secretary has determined that the medi-
35 cine is less than effective for all conditions of use
36 prescribed, recommended, or suggested in its label-
37 ing.

- 1 “(B) A biological product which—
2 “(i) may only be dispensed upon prescription;
3 “(ii) is licensed under section 351 of the Pub-
4 lic Health Service Act; and
5 “(iii) is produced at an establishment licensed
6 under such section to produce such product.
7 “(C) Insulin approved under appropriate Federal
8 law, and needles, syringes, and disposable pumps for
9 the administration of such insulin.
10 “(D) A prescribed medicine or biological product
11 that would meet the requirements of subparagraph (A)
12 or (B) but that is available over-the-counter in addition
13 to being available upon prescription, but only if the
14 particular dosage form or strength prescribed and re-
15 quired for the individual is not available over-the-
16 counter.
17 “(E) Smoking cessation agents (as specified by the
18 Secretary).
19 “(2) EXCLUSION.—The term ‘covered outpatient pre-
20 scription medicine’ does not include—
21 “(A) medicines or classes of medicines, or their
22 medical uses, which may be excluded from coverage or
23 otherwise restricted under section 1927(d)(2), other
24 than subparagraph (E) thereof (relating to smoking
25 cessation agents), as the Secretary may specify and
26 does not include such other medicines, classes, and uses
27 as the Secretary may specify consistent with the goals
28 of providing quality care and containing costs under
29 this part;
30 “(B) except as provided in paragraphs (1)(D) and
31 (1)(E), any product which may be distributed to indi-
32 viduals without a prescription;
33 “(C) any product when furnished as part of, or as
34 incident to, a diagnostic service or any other item or
35 service for which payment may be made under this
36 title; or

1 “(D) any product that is covered under part B of
2 this title.

3 “(c) PAYMENT OF BENEFITS.—

4 “(1) COVERED OUTPATIENT PRESCRIPTION MEDI-
5 CINES.—There shall be paid from the Federal Medicare
6 Prescription Medicine Trust Fund, in the case of each en-
7 rollee who incurs expenses for medicines with respect to
8 which benefits are payable under this part under subsection
9 (a)(1), amounts equal to the sum of—

10 “(A) the price for which the medicine is made
11 available under this part (consistent with sections
12 1859A and 1859B), reduced by any applicable cost-
13 sharing under paragraphs (2) and (3); and

14 “(B) a reasonable dispensing fee.

15 The price under subparagraph (A) shall in no case exceed
16 the retail price for the medicine involved.

17 “(2) DEDUCTIBLE.—The amount of payment under
18 paragraph (1) for expenses incurred in a year, beginning
19 with 2005, shall be reduced by an annual deductible equal
20 to the amount specified in section 1859(2) (subject to ad-
21 justment under paragraph (8)). Only expenses for count-
22 able cost-sharing (as defined in subsection (a)(2)(B)) shall
23 be taken into account in applying this paragraph.

24 “(3) COINSURANCE.—

25 “(A) IN GENERAL.—The amount of payment
26 under paragraph (1) for expenses incurred in a year
27 shall be further reduced (subject to the stop-loss limit
28 under paragraph (4)) by coinsurance as provided under
29 this paragraph.

30 “(B) PREFERRED MEDICINES.—The coinsurance
31 under this paragraph in the case of a preferred medi-
32 cine (including a medicine treated as a preferred medi-
33 cine under paragraph (5)), is equal to 20 percent of the
34 price applicable under paragraph (1)(A) (or such lower
35 percentage as may be provided for under section
36 1859E(a)(1)(A)(ii)). In this part, the term ‘preferred
37 medicine’ means, with respect to medicines classified

1 within a therapeutic class, those medicines which have
2 been designated as a preferred medicine by the Sec-
3 retary or the pharmacy contractor involved with respect
4 to that class and (in the case of a nongeneric medicine)
5 with respect to which a contract has been negotiated
6 under this part.

7 “(C) NONPREFERRED MEDICINES.—The coinsur-
8 ance under this paragraph in the case of a nonpre-
9 ferred medicine that is not treated as a preferred medi-
10 cine under paragraph (5) is equal to the sum of—

11 “(i) 20 percent of the price for lowest price
12 preferred medicine that is within the same thera-
13 peutic class; and

14 “(ii) the amount by which—

15 “(I) the price at which the nonpreferred
16 medicine is made available to the enrollee; ex-
17 ceeds

18 “(II) the price of such lowest price pre-
19 ferred medicine.

20 “(4) NO COINSURANCE ONCE OUT-OF-POCKET EX-
21 PENDITURES EQUAL STOP-LOSS LIMIT.—Once an enrollee
22 has incurred aggregate countable cost-sharing under para-
23 graph (3) (including cost-sharing under part B attributable
24 to outpatient prescription drugs or biologicals) equal to the
25 amount specified in section 1859(4) (subject to adjustment
26 under paragraph (8)) for expenses in a year—

27 “(A) there shall be no coinsurance under para-
28 graph (3) for additional expenses incurred in the year
29 involved; and

30 “(B) there shall be no coinsurance under part B
31 for additional expenses incurred in the year involved for
32 outpatient prescription drugs and biologicals.

33 “(5) APPEALS RIGHTS RELATING TO COVERAGE OF
34 NONPREFERRED MEDICINES.—

35 “(A) PROCEDURES REGARDING THE DETERMINA-
36 TION OF MEDICINES THAT ARE MEDICALLY NEC-
37 ESSARY.—Each pharmacy contractor shall have in

1 place procedures on a case-by-case basis to treat a non-
2 preferred medicine as a preferred medicine under this
3 part if the preferred medicine is determined to be not
4 as effective for the enrollee or to have significant ad-
5 verse effect on the enrollee. Such procedures shall re-
6 quire that such determinations are based on profes-
7 sional medical judgment, the medical condition of the
8 enrollee, and other medical evidence.

9 “(B) PROCEDURES REGARDING DENIALS OF
10 CARE.—Such contractor shall have in place procedures
11 to ensure—

12 “(i) a timely internal review for resolution of
13 denials of coverage (in whole or in part and includ-
14 ing those regarding the coverage of nonpreferred
15 medicines) in accordance with the medical exigen-
16 cies of the case and a timely resolution of com-
17 plaints, by enrollees in the plan, or by providers,
18 pharmacists, and other individuals acting on behalf
19 of each such enrollee (with the enrollee’s consent)
20 in accordance with requirements (as established by
21 the Secretary) that are comparable to such require-
22 ments for Medicare+Choice organizations under
23 part C;

24 “(ii) that the entity complies in a timely man-
25 ner with requirements established by the Secretary
26 that (I) provide for an external review by an inde-
27 pendent entity selected by the Secretary of denials
28 of coverage described in clause (i) not resolved in
29 the favor of the beneficiary (or other complainant)
30 under the process described in such clause and (II)
31 are comparable to the external review requirements
32 established for Medicare+Choice organizations
33 under part C; and

34 “(iii) that enrollees are provided with informa-
35 tion regarding the appeals procedures under this
36 part at the time of enrollment with a pharmacy

1 contractor under this part and upon request there-
2 after.

3 “(6) TRANSFER OF FUNDS TO COVER COSTS OF PART
4 B PRESCRIPTION MEDICINE CATASTROPHIC BENEFIT.—
5 With respect to benefits described in subsection (a)(2),
6 there shall transferred from the Federal Medicare Prescrip-
7 tion Medicine Trust Fund to the Federal Supplementary
8 Medical Insurance Trust Fund amounts equivalent to the
9 elimination of cost-sharing described in such subsection.

10 “(7) PERMITTING APPLICATION UNDER PART B OF
11 NEGOTIATED PRICES.—For purposes of making payment
12 under part B for medicines that would be covered out-
13 patient prescription medicines but for the exclusion under
14 subparagraph (B) or (C) of subsection (b)(2), the Secretary
15 may elect to apply the payment basis used for payment of
16 covered outpatient prescription medicines under this part
17 instead of the payment basis otherwise used under such
18 part, if it results in a lower cost to the program.

19 “(8) INFLATION ADJUSTMENT.—

20 “(A) IN GENERAL.—With respect to expenses in-
21 curred in a year after 2005—

22 “(i) the deductible under paragraph (2) is
23 equal to the deductible determined under such
24 paragraph (or this subparagraph) for the previous
25 year increased by the percentage increase in per
26 capita program expenditures (as estimated in ad-
27 vance for the year involved under subparagraph
28 (B)); and

29 “(ii) the stop-loss limit under paragraph (3) is
30 equal to the stop-loss limit determined under such
31 paragraph (or this subparagraph) for the previous
32 year increased by such percentage increase.

33 The Secretary shall adjust such percentage increase in
34 subsequent years to take into account misestimations
35 made of the per capita program expenditures under
36 clauses (i) and (ii) in previous years. Any increase

1 under this subparagraph that is not a multiple of \$10
2 shall be rounded to the nearest multiple of \$10.

3 “(B) ESTIMATION OF INCREASE IN PER CAPITA
4 PROGRAM EXPENDITURES.—The Secretary shall before
5 the beginning of each year (beginning with 2006) esti-
6 mate the percentage increase in average per capita ag-
7 gregate expenditures from the Federal Medicare Pre-
8 scription Medicine Trust Fund for the year involved
9 compared to the previous year.

10 “(C) RECONCILIATION.—The Secretary shall also
11 compute (beginning with 2007) the actual percentage
12 increase in such aggregate expenditures in order to
13 provide for reconciliation of deductibles, stop-loss lim-
14 its, and premiums under the second sentence of sub-
15 paragraph (A) and under section 1859D(d)(2).

16 “(d) AMOUNT OF PREMIUMS.—

17 “(1) MONTHLY PREMIUM RATE IN 2005.—The monthly
18 premium rate in 2005 for prescription medicine benefits
19 under this part is the amount specified in section 1859(1).

20 “(2) INFLATION ADJUSTMENT FOR SUBSEQUENT
21 YEARS.—The monthly premium rate for a year after 2005
22 for prescription medicine benefits under this part is equal
23 to the monthly premium rate for the previous year under
24 this subsection increased by the percentage increase in per
25 capita program expenditures (as estimated in advance for
26 the year involved under subsection (c)(8)(B)). The Sec-
27 retary shall adjust such percentage in subsequent years to
28 take into account misestimations made of the per capita
29 program expenditures under the previous sentence in pre-
30 vious years. Any increase under this paragraph that is not
31 a multiple of \$1 shall be rounded to the nearest multiple
32 of \$1.

33 “ADMINISTRATION; QUALITY ASSURANCE

34 “SEC. 1859E. (a) RULES RELATING TO PROVISION OF
35 BENEFITS.—

36 “(1) PROVISION OF BENEFITS.—

1 “(A) IN GENERAL.—In providing benefits under
2 this part, the Secretary (directly or through the con-
3 tracts with pharmacy contractors) shall employ mecha-
4 nisms to provide benefits appropriately and efficiently,
5 and those mechanisms may include—

6 “(i) the use of—

7 “(I) price negotiations (consistent with
8 subsection (b));

9 “(II) reduced coinsurance (below 20 per-
10 cent) to encourage the utilization of appro-
11 priate preferred medicines; and

12 “(III) methods to reduce medication errors
13 and encourage appropriate use of medications;
14 and

15 “(ii) permitting pharmacy contractors, as ap-
16 proved by the Secretary, to make exceptions to sec-
17 tion 1859D(c)(3)(C) (relating to cost-sharing for
18 non-preferred medicines) to secure best prices for
19 enrollees so long as the payment amount under sec-
20 tion 1859D(c)(1) does not equal zero.

21 “(B) CONSTRUCTION.—Nothing in this subsection
22 shall be construed to prevent the Secretary (directly or
23 through the contracts with pharmacy contractors) from
24 using incentives to encourage enrollees to select generic
25 or other cost-effective medicines, so long as—

26 “(i) such incentives are designed not to result
27 in any increase in the aggregate expenditures under
28 the Federal Medicare Prescription Medicine Trust
29 Fund; and

30 “(ii) a beneficiary’s coinsurance shall be no
31 greater than 20 percent in the case of a preferred
32 medicine (including a nonpreferred medicine treat-
33 ed as a preferred medicine under section
34 1859D(c)(5)).

35 “(2) CONSTRUCTION.—Nothing in this part shall pre-
36 clude the Secretary or a pharmacy contractor from—

1 “(A) educating prescribing providers, pharmacists,
2 and enrollees about medical and cost benefits of pre-
3 ferred medicines;

4 “(B) requesting prescribing providers to consider a
5 preferred medicine prior to dispensing of a nonpre-
6 ferred medicine, as long as such request does not un-
7 duly delay the provision of the medicine;

8 “(C) using mechanisms to encourage enrollees
9 under this part to select cost-effective medicines or less
10 costly means of receiving or administering medicines,
11 including the use of therapeutic interchange programs,
12 disease management programs, and notification to the
13 beneficiary that a more affordable generic medicine
14 equivalent was not selected by the prescribing provider
15 and a statement of the lost cost savings to the bene-
16 ficiary;

17 “(D) using price negotiations to achieve reduced
18 prices on covered outpatient prescription medicines, in-
19 cluding new medicines, medicines for which there are
20 few therapeutic alternatives, and medicines of par-
21 ticular clinical importance to individuals enrolled under
22 this part; and

23 “(E) utilizing information on medicine prices of
24 OECD countries and of other payors in the United
25 States in the negotiation of prices under this part.

26 “(b) PRICE NEGOTIATIONS PROCESS.—

27 “(1) REQUIREMENTS WITH RESPECT TO PREFERRED
28 MEDICINES.—Negotiations of contracts with manufacturers
29 with respect to covered outpatient prescription medicines
30 under this part shall be conducted in a manner so that—

31 “(A) there is at least a contract for a medicine
32 within each therapeutic class (as defined by the Sec-
33 retary in consultation with such Medicare Prescription
34 Medicine Advisory Committee);

35 “(B) if there is more than 1 medicine available in
36 a therapeutic class, there are contracts for at least 2
37 medicines within such class unless determined clinically

1 inappropriate in accordance with standards established
2 by the Secretary; and

3 “(C) if there are more than 2 medicines available
4 in a therapeutic class, there is a contract for at least
5 2 medicines within such class and a contract for ge-
6 neric medicine substitute if available unless determined
7 clinically inappropriate in accordance with standards
8 established by the Secretary.

9 “(2) ESTABLISHMENT OF THERAPEUTIC CLASSES.—
10 The Secretary, in consultation with the Medicare Prescrip-
11 tion Medicine Advisory Committee (established under sec-
12 tion 1859H), shall establish for purposes of this part thera-
13 peutic classes and assign to such classes covered outpatient
14 prescription medicines.

15 “(3) DISCLOSURE CONCERNING PREFERRED MEDI-
16 CINES.—The Secretary shall provide, through pharmacy
17 contractors or otherwise, for—

18 “(A) disclosure to current and prospective enroll-
19 ees and to participating providers and pharmacies in
20 each service area a list of the preferred medicines and
21 differences in applicable cost-sharing between such
22 medicines and nonpreferred medicines; and

23 “(B) advance disclosure to current enrollees and
24 to participating providers and pharmacies in each serv-
25 ice area of changes to any such list of preferred medi-
26 cines and differences in applicable cost-sharing.

27 “(4) NO REVIEW.—The Secretary’s establishment of
28 therapeutic classes and the assignment of medicines to such
29 classes and the Secretary’s determination of what is a
30 breakthrough medicine are not subject to administrative or
31 judicial review.

32 “(c) CONFIDENTIALITY.—The Secretary shall ensure that
33 the confidentiality of individually identifiable health information
34 relating to the provision of benefits under this part is pro-
35 tected, consistent with the standards for the privacy of such in-
36 formation promulgated by the Secretary under the Health In-
37 surance Portability and Accountability Act of 1996, or any sub-

1 sequent comprehensive and more protective set of confiden-
2 tiality standards enacted into law or promulgated by the Sec-
3 retary. Nothing in this subsection shall be construed as pre-
4 venting the coordination of data with a State prescription medi-
5 cine program so long as such program has in place confiden-
6 tiality standards that are equal to or exceed the standards used
7 by the Secretary.

8 “(d) FRAUD AND ABUSE SAFEGUARDS.—The Secretary,
9 through the Office of the Inspector General, is authorized and
10 directed to issue regulations establishing appropriate safe-
11 guards to prevent fraud and abuse under this part. Such safe-
12 guards, at a minimum, should include compliance programs,
13 certification data, audits, and recordkeeping practices. In devel-
14 oping such regulations, the Secretary shall consult with the At-
15 torney General and other law enforcement and regulatory agen-
16 cies.

17 “FEDERAL MEDICARE PRESCRIPTION MEDICINE TRUST FUND

18 “SEC. 1859F. (a) ESTABLISHMENT.—There is hereby cre-
19 ated on the books of the Treasury of the United States a trust
20 fund to be known as the ‘Federal Medicare Prescription Medi-
21 cine Trust Fund’ (in this section referred to as the ‘Trust
22 Fund’). The Trust Fund shall consist of such gifts and be-
23 quests as may be made as provided in section 201(i)(1), and
24 such amounts as may be deposited in, or appropriated to, such
25 fund as provided in this part.

26 “(b) APPLICATION OF SMI TRUST FUND PROVISIONS.—
27 The provisions of subsections (b) through (i) of section 1841
28 shall apply to this part and the Trust Fund in the same man-
29 ner as they apply to part B and the Federal Supplementary
30 Medical Insurance Trust Fund, respectively.

31 “COMPENSATION FOR EMPLOYERS COVERING RETIREE

32 MEDICINE COSTS

33 “SEC. 1859G. (a) IN GENERAL.—In the case of an indi-
34 vidual who is eligible to be enrolled under this part and is a
35 participant or beneficiary under a group health plan that pro-
36 vides outpatient prescription medicine coverage to retirees the
37 actuarial value of which is not less than the actuarial value of

1 the coverage provided under this part, the Secretary shall make
2 payments to such plan subject to the provisions of this section.
3 Such payments shall be treated as payments under this part
4 for purposes of sections 1859F and 1859C(e)(2). In applying
5 the previous sentence with respect to section 1859C(e)(2), the
6 amount of the Government contribution referred to in section
7 1844(a)(1)(A) is deemed to be equal to the aggregate amount
8 of the payments made under this section.

9 “(b) REQUIREMENTS.—To receive payment under this sec-
10 tion, a group health plan shall comply with the following re-
11 quirements:

12 “(1) COMPLIANCE WITH REQUIREMENTS.—The group
13 health plan shall comply with the requirements of this Act
14 and other reasonable, necessary, and related requirements
15 that are needed to administer this section, as determined
16 by the Secretary.

17 “(2) ANNUAL ASSURANCES AND NOTICE BEFORE TER-
18 MINATION.—The sponsor of the plan shall—

19 “(A) annually attest, and provide such assurances
20 as the Secretary may require, that the coverage offered
21 under the group health plan meets the requirements of
22 this section and will continue to meet such require-
23 ments for the duration of the sponsor’s participation in
24 the program under this section; and

25 “(B) guarantee that it will give notice to the Sec-
26 retary and covered enrollees—

27 “(i) at least 120 days before terminating its
28 plan, and

29 “(ii) immediately upon determining that the
30 actuarial value of the prescription medicine benefit
31 under the plan falls below the actuarial value re-
32 quired under subsection (a).

33 “(3) BENEFICIARY INFORMATION.—The sponsor of
34 the plan shall report to the Secretary, for each calendar
35 quarter for which it seeks a payment under this section, the
36 names and social security numbers of all enrollees described
37 in subsection (a) covered under such plan during such

1 quarter and the dates (if less than the full quarter) during
2 which each such individual was covered.

3 “(4) AUDITS.—The sponsor or plan seeking payment
4 under this section shall agree to maintain, and to afford
5 the Secretary access to, such records as the Secretary may
6 require for purposes of audits and other oversight activities
7 necessary to ensure the adequacy of prescription medicine
8 coverage, the accuracy of payments made, and such other
9 matters as may be appropriate.

10 “(c) PAYMENT.—

11 “(1) IN GENERAL.—The sponsor of a group health
12 plan that meets the requirements of subsection (b) with re-
13 spect to a quarter in a calendar year shall be entitled to
14 have payment made on a quarterly basis of the amount
15 specified in paragraph (2) for each individual described in
16 subsection (a) who during the quarter is covered under the
17 plan and was not enrolled in the insurance program under
18 this part.

19 “(2) AMOUNT OF PAYMENT.—

20 “(A) IN GENERAL.—The amount of the payment
21 for a quarter shall approximate, for each such covered
22 individual, $\frac{2}{3}$ of the sum of the monthly Government
23 contribution amounts (computed under subparagraph
24 (B)) for each of the 3 months in the quarter.

25 “(B) COMPUTATION OF MONTHLY GOVERNMENT
26 CONTRIBUTION AMOUNT.—For purposes of subpara-
27 graph (A), the monthly Government contribution
28 amount for a month in a year is equal to the amount
29 by which—

30 “(i) $\frac{1}{12}$ of the average per capita aggregate
31 expenditures, as estimated under section
32 1859D(c)(8) for the year involved; exceeds

33 “(ii) the monthly premium rate under section
34 1859D(d) for the month involved.

1 “MEDICARE PRESCRIPTION MEDICINE ADVISORY COMMITTEE
2 “SEC. 1859H. (a) ESTABLISHMENT OF COMMITTEE.—
3 There is established a Medicare Prescription Medicine Advisory
4 Committee (in this section referred to as the ‘Committee’).
5 “(b) FUNCTIONS OF COMMITTEE.—The Committee shall
6 advise the Secretary on policies related to—
7 “(1) the development of guidelines for the implementa-
8 tion and administration of the outpatient prescription medi-
9 cine benefit program under this part; and
10 “(2) the development of—
11 “(A) standards required of pharmacy contractors
12 under section 1859D(c)(5) for determining if a medi-
13 cine is as effective for an enrollee or has a significant
14 adverse effect on an enrollee under this part;
15 “(B) standards for—
16 “(i) defining therapeutic classes;
17 “(ii) adding new therapeutic classes;
18 “(iii) assigning to such classes covered out-
19 patient prescription medicines; and
20 “(iv) identifying breakthrough medicines;
21 “(C) procedures to evaluate the bids submitted by
22 pharmacy contractors under this part;
23 “(D) procedures for negotiations, and standards
24 for entering into contracts, with manufacturers, includ-
25 ing identifying medicines or classes of medicines where
26 Secretarial negotiation is most likely to yield savings
27 under this part significantly above those that which
28 could be achieved by a pharmacy contractor; and
29 “(E) procedures to ensure that pharmacy contrac-
30 tors with a contract under this part are in compliance
31 with the requirements under this part.
32 For purposes of this part, a medicine is a ‘breakthrough medi-
33 cine’ if the Secretary, in consultation with the Committee, de-
34 termines it is a new product that will make a significant and
35 major improvement by reducing physical or mental illness, re-
36 ducing mortality, or reducing disability, and that no other
37 product is available to beneficiaries that achieves similar results

1 for the same condition. The Committee may consider cost-effec-
2 tiveness in establishing standards for defining therapeutic
3 classes and assigning drugs to such classes under subparagraph
4 (B).

5 “(c) STRUCTURE AND MEMBERSHIP OF THE COM-
6 MITTEE.—

7 “(1) STRUCTURE.—The Committee shall be composed
8 of 19 members who shall be appointed by the Secretary.

9 “(2) MEMBERSHIP.—

10 “(A) IN GENERAL.—The members of the Com-
11 mittee shall be chosen on the basis of their integrity,
12 impartiality, and good judgment, and shall be individ-
13 uals who are, by reason of their education, experience,
14 and attainments, exceptionally qualified to perform the
15 duties of members of the Committee.

16 “(B) SPECIFIC MEMBERS.—Of the members ap-
17 pointed under paragraph (1)—

18 “(i) 5 shall be chosen to represent practicing
19 physicians, 2 of whom shall be gerontologists;

20 “(ii) 2 shall be chosen to represent practicing
21 nurse practitioners;

22 “(iii) 4 shall be chosen to represent practicing
23 pharmacists;

24 “(iv) 1 shall be chosen to represent the Cen-
25 ters for Medicare & Medicaid Services;

26 “(v) 4 shall be chosen to represent actuaries,
27 pharmacoeconomists, researchers, and other appro-
28 priate experts;

29 “(vi) 1 shall be chosen to represent emerging
30 medicine technologies;

31 “(vii) 1 shall be chosen to represent the Food
32 and Drug Administration; and

33 “(viii) 1 shall be chosen to represent individ-
34 uals enrolled under this part.

35 “(d) TERMS OF APPOINTMENT.—Each member of the
36 Committee shall serve for a term determined appropriate by the

1 Secretary. The terms of service of the members initially ap-
2 pointed shall begin on January 1, 2004.

3 “(e) CHAIRPERSON.—The Secretary shall designate a
4 member of the Committee as Chairperson. The term as Chair-
5 person shall be for a 1-year period.

6 “(f) COMMITTEE PERSONNEL MATTERS.—

7 “(1) MEMBERS.—

8 “(A) COMPENSATION.—Each member of the Com-
9 mittee who is not an officer or employee of the Federal
10 Government shall be compensated at a rate equal to
11 the daily equivalent of the annual rate of basic pay pre-
12 scribed for level IV of the Executive Schedule under
13 section 5315 of title 5, United States Code, for each
14 day (including travel time) during which such member
15 is engaged in the performance of the duties of the
16 Committee. All members of the Committee who are of-
17 ficers or employees of the United States shall serve
18 without compensation in addition to that received for
19 their services as officers or employees of the United
20 States.

21 “(B) TRAVEL EXPENSES.—The members of the
22 Committee shall be allowed travel expenses, including
23 per diem in lieu of subsistence, at rates authorized for
24 employees of agencies under subchapter I of chapter 57
25 of title 5, United States Code, while away from their
26 homes or regular places of business in the performance
27 of services for the Committee.

28 “(2) STAFF.—The Committee may appoint such per-
29 sonnel as the Committee considers appropriate.

30 “(g) OPERATION OF THE COMMITTEE.—

31 “(1) MEETINGS.—The Committee shall meet at the
32 call of the Chairperson (after consultation with the other
33 members of the Committee) not less often than quarterly
34 to consider a specific agenda of issues, as determined by
35 the Chairperson after such consultation.

36 “(2) QUORUM.—Ten members of the Committee shall
37 constitute a quorum for purposes of conducting business.

1 “(h) FEDERAL ADVISORY COMMITTEE ACT.—Section 14
2 of the Federal Advisory Committee Act (5 U.S.C. App.) shall
3 not apply to the Committee.

4 “(i) TRANSFER OF PERSONNEL, RESOURCES, AND AS-
5 SETS.—For purposes of carrying out its duties, the Secretary
6 and the Committee may provide for the transfer to the Com-
7 mittee of such civil service personnel in the employ of the De-
8 partment of Health and Human Services (including the Centers
9 for Medicare & Medicaid Services), and such resources and as-
10 sets of the Department used in carrying out this title, as the
11 Committee requires.

12 “(j) AUTHORIZATION OF APPROPRIATIONS.—There are
13 authorized to be appropriated such sums as may be necessary
14 to carry out the purposes of this section.”.

15 (b) APPLICATION OF GENERAL EXCLUSIONS FROM COV-
16 ERAGE.—

17 (1) APPLICATION TO PART D.—Section 1862(a) (42
18 U.S.C. 1395y(a)) is amended in the matter preceding para-
19 graph (1) by striking “part A or part B” and inserting
20 “part A, B, or D”.

21 (2) PRESCRIPTION MEDICINES NOT EXCLUDED FROM
22 COVERAGE IF APPROPRIATELY PRESCRIBED.—Section
23 1862(a)(1) (42 U.S.C. 1395y(a)(1)) is amended—

24 (A) in subparagraph (H), by striking “and” at the
25 end;

26 (B) in subparagraph (I), by striking the semicolon
27 at the end and inserting “, and”; and

28 (C) by adding at the end the following new sub-
29 paragraph:

30 “(J) in the case of prescription medicines covered
31 under part D, which are not prescribed in accordance
32 with such part;”.

33 (c) CONFORMING AMENDMENTS.—(1) Part C of title
34 XVIII is amended—

35 (A) in section 1851(a)(2)(B) (42 U.S.C. 1395w-
36 21(a)(2)(B)), by striking “1859(b)(3)” and inserting
37 “1858(b)(3)”;

1 (B) in section 1851(a)(2)(C) (42 U.S.C. 1395w-
2 21(a)(2)(C)), by striking “1859(b)(2)” and inserting
3 “1858(b)(2)”;

4 (C) in section 1852(a)(1) (42 U.S.C. 1395w-
5 22(a)(1)), by striking “1859(b)(3)” and inserting
6 “1858(b)(3)”;

7 (D) in section 1852(a)(3)(B)(ii) (42 U.S.C. 1395w-
8 22(a)(3)(B)(ii)), by striking “1859(b)(2)(B)” and inserting
9 “1858(b)(2)(B)”;

10 (E) in section 1853(a)(1)(A) (42 U.S.C. 1395w-
11 23(a)(1)(A)), by striking “1859(e)(4)” and inserting
12 “1858(e)(4)”;

13 (F) in section 1853(a)(3)(D) (42 U.S.C. 1395w-
14 23(a)(3)(D)), by striking “1859(e)(4)” and inserting
15 “1858(e)(4)”.

16 (2) Section 1171(a)(5)(D) (42 U.S.C. 1320d(a)(5)(D)) is
17 amended by striking “or (C)” and inserting “(C), or (D)”.

18 **SEC. 102. PROVISION OF MEDICARE OUTPATIENT PRE-**
19 **SCRIPTION MEDICINE COVERAGE UNDER**
20 **THE MEDICARE+CHOICE PROGRAM.**

21 (a) REQUIRING AVAILABILITY OF AN ACTUARIALLY
22 EQUIVALENT PRESCRIPTION MEDICINE BENEFIT.—Section
23 1851 (42 U.S.C. 1395w-21) is amended by adding at the end
24 the following new subsection:

25 “(j) AVAILABILITY OF PRESCRIPTION MEDICINE BENE-
26 FITS.—

27 “(1) IN GENERAL.—Notwithstanding any other provi-
28 sion of this part, each Medicare+Choice organization that
29 makes available a Medicare+Choice plan described in sec-
30 tion 1851(a)(2)(A) shall make available such a plan that
31 offers coverage of covered outpatient prescription medicines
32 that is at least actuarially equivalent to the benefits pro-
33 vided under part D. Information respecting such benefits
34 shall be made available in the same manner as information
35 on other benefits provided under this part is made avail-
36 able. Nothing in this paragraph shall be construed as re-

1 quiring the offering of such coverage separate from cov-
2 erage that includes benefits under parts A and B.

3 “(2) TREATMENT OF PRESCRIPTION MEDICINE EN-
4 ROLLEES.—In the case of a Medicare+Choice eligible indi-
5 vidual who is enrolled under part D, the benefits described
6 in paragraph (1) shall be treated in the same manner as
7 benefits described in part B for purposes of coverage and
8 payment and any reference in this part to the Federal Sup-
9 plementary Medical Insurance Trust Fund shall be deemed,
10 with respect to such benefits, to be a reference to the Fed-
11 eral Medicare Prescription Medicine Trust Fund.”.

12 (b) APPLICATION OF QUALITY STANDARDS.—Section
13 1852(e)(2)(A) (42 U.S.C. 1395w-22(e)(2)(A)) is amended—

14 (1) by striking “and” at the end of clause (xi);

15 (2) by striking the period at the end of clause (xii)
16 and inserting “, and”; and

17 (3) by adding at the end the following new clause:

18 “(xiii) comply with the standards, and apply
19 the programs, under section 1859B(b) for covered
20 outpatient prescription medicines under the plan.”.

21 (c) PAYMENT SEPARATE FROM PAYMENT FOR PART A
22 AND B BENEFITS.—Section 1853 (42 U.S.C. 1395w-23) is
23 amended—

24 (1) in subsection (a)(1)(A), by striking “and (i)” and
25 inserting “(i), and (j)”; and

26 (2) by adding at the end the following new subsection:

27 “(j) PAYMENT FOR PRESCRIPTION MEDICINE COVERAGE
28 OPTION.—

29 “(1) IN GENERAL.—In the case of a Medicare+Choice
30 plan that provides prescription medicine benefits described
31 in section 1851(j)(1), the amount of payment otherwise
32 made to the Medicare+Choice organization offering the
33 plan shall be increased by the amount described in para-
34 graph (2). Such payments shall be made in the same man-
35 ner and time as the amount otherwise paid, but such
36 amount shall be payable from the Federal Medicare Pre-
37 scription Medicine Trust Fund.

1 “(2) AMOUNT.—The amount described in this para-
2 graph is the monthly Government contribution amount
3 computed under section 1859G(c)(2)(B), but subject to ad-
4 justment under paragraph (3). Such amount shall be uni-
5 form geographically and shall not vary based on the
6 Medicare+Choice payment area involved.

7 “(3) RISK ADJUSTMENT.—The Secretary shall estab-
8 lish a methodology for the adjustment of the payment
9 amount under this subsection in a manner that takes into
10 account the relative risks for use of outpatient prescription
11 medicines by Medicare+Choice enrollees. Such methodology
12 shall be designed in a manner so that the total payments
13 under this title (including part D) are not changed as a re-
14 sult of the application of such methodology.”.

15 (d) SEPARATE APPLICATION OF ADJUSTED COMMUNITY
16 RATE (ACR).—Section 1854 (42 U.S.C. 1395w–24) is amend-
17 ed by adding at the end the following:

18 “(i) APPLICATION TO PRESCRIPTION MEDICINE COV-
19 ERAGE.—The Secretary shall apply the previous provisions of
20 this section (including the computation of the adjusted commu-
21 nity rate) separately with respect to prescription medicine bene-
22 fits described in section 1851(j)(1).”.

23 (f) CONFORMING AMENDMENTS.—

24 (1) Section 1851 (42 U.S.C. 1395w–21) is amended—

25 (A) in subsection (a)(1)(A), by striking “parts A
26 and B” and inserting “parts A, B, and D”; and

27 (B) in subsection (i) by inserting “(and, if applica-
28 ble, part D)” after “parts A and B”.

29 (2) Section 1852(a)(1)(A) (42 U.S.C. 1395w–
30 22(a)(1)(A)) is amended by inserting “(and under part D
31 to individuals also enrolled under such part)” after “parts
32 A and B”.

33 (3) Section 1852(d)(1) (42 U.S.C. 1395w–22(d)(1)) is
34 amended—

35 (A) by striking “and” at the end of subparagraph
36 (D);

1 (B) by striking the period at the end of subpara-
2 graph (E) and inserting “; and”; and

3 (C) by adding at the end the following:

4 “(F) the plan for part D benefits guarantees cov-
5 erage of any specifically named prescription medicine
6 for an enrollee to the extent that it would be required
7 to be covered under part D.

8 In carrying out subparagraph (F), a Medicare+Choice or-
9 ganization has the same authority to enter into contracts
10 with respect to coverage of preferred medicines as the Sec-
11 retary has under part D, but subject to an independent
12 contractor appeal or other appeal process that would be ap-
13 plicable to determinations by such a pharmacy contractor
14 consistent with section 1859D(c)(5).”.

15 (e) LIMITATION ON COST-SHARING.—Section 1854(e) (42
16 U.S.C. 1395w-24(e)) is amended by adding at the end the fol-
17 lowing new paragraph:

18 “(5) LIMITATION ON COST-SHARING.—In no event
19 may a Medicare+Choice organization include a require-
20 ment that an enrollee pay cost-sharing in excess of the
21 cost-sharing otherwise permitted under part D.”.

22 **SEC. 103. MEDIGAP REVISIONS.**

23 (a) REQUIRED COVERAGE OF COVERED OUTPATIENT
24 PRESCRIPTION MEDICINES.—Section 1882(p)(2)(B) (42
25 U.S.C. 1395ss(p)(2)(B)) is amended by inserting before “and”
26 at the end the following: “including a requirement that an ap-
27 propriate number of policies provide coverage of medicines
28 which complements but does not duplicate the medicine benefits
29 that beneficiaries are otherwise eligible for benefits under part
30 D of this title (with the Secretary and the National Association
31 of Insurance Commissioners determining the appropriate level
32 of medicine benefits that each benefit package must provide
33 and ensuring that policies providing such coverage are afford-
34 able for beneficiaries;”.

35 (b) EFFECTIVE DATE.—The amendment made by sub-
36 section (a) shall take effect on January 1, 2005.

37 (c) TRANSITION PROVISIONS.—

1 (1) IN GENERAL.—If the Secretary of Health and
2 Human Services identifies a State as requiring a change to
3 its statutes or regulations to conform its regulatory pro-
4 gram to the amendments made by this section, the State
5 regulatory program shall not be considered to be out of
6 compliance with the requirements of section 1882 of the
7 Social Security Act due solely to failure to make such
8 change until the date specified in paragraph (4).

9 (2) NAIC STANDARDS.—If, within 9 months after the
10 date of enactment of this Act, the National Association of
11 Insurance Commissioners (in this subsection referred to as
12 the “NAIC”) modifies its NAIC Model Regulation relating
13 to section 1882 of the Social Security Act (referred to in
14 such section as the 1991 NAIC Model Regulation, as sub-
15 sequently modified) to conform to the amendments made
16 by this section, such revised regulation incorporating the
17 modifications shall be considered to be the applicable NAIC
18 model regulation (including the revised NAIC model regula-
19 tion and the 1991 NAIC Model Regulation) for the pur-
20 poses of such section.

21 (3) SECRETARY STANDARDS.—If the NAIC does not
22 make the modifications described in paragraph (2) within
23 the period specified in such paragraph, the Secretary of
24 Health and Human Services shall make the modifications
25 described in such paragraph and such revised regulation in-
26 corporating the modifications shall be considered to be the
27 appropriate regulation for the purposes of such section.

28 (4) DATE SPECIFIED.—

29 (A) IN GENERAL.—Subject to subparagraph (B),
30 the date specified in this paragraph for a State is the
31 earlier of—

32 (i) the date the State changes its statutes or
33 regulations to conform its regulatory program to
34 the changes made by this section; or

35 (ii) 1 year after the date the NAIC or the Sec-
36 retary first makes the modifications under para-
37 graph (2) or (3), respectively.

(B) ADDITIONAL LEGISLATIVE ACTION REQUIRED.—In the case of a State which the Secretary identifies as—

(i) requiring State legislation (other than legislation appropriating funds) to conform its regulatory program to the changes made in this section; but

(ii) having a legislature which is not scheduled to meet in 2003 in a legislative session in which such legislation may be considered;

the date specified in this paragraph is the first day of the first calendar quarter beginning after the close of the first legislative session of the State legislature that begins on or after January 1, 2003. For purposes of the previous sentence, in the case of a State that has a 2-year legislative session, each year of such session shall be deemed to be a separate regular session of the State legislature.

SEC. 104. TRANSITIONAL ASSISTANCE FOR LOW INCOME BENEFICIARIES.

(a) QMB COVERAGE OF PREMIUMS AND COST-SHARING.—Section 1905(p)(3) (42 U.S.C. 1396d(p)(3)) is amended—

(1) in subparagraph (A)—

(A) by striking “and” at the end of clause (i),

(B) by adding “and” at the end of clause (ii), and

(C) by adding at the end the following new clause:

“(iii) premiums under section 1859D(d).”;

(2) in subparagraph (B), by inserting “and section 1859D(c)(3)(B) and 1859D(c)(3)(C)(i)” after “1813”; and

(3) in subparagraph (C), by striking “and section 1833(b)” and inserting “, section 1833(b), and section 1859D(c)(2)”.

(b) EXPANDED SLMB ELIGIBILITY.—Section 1902(a)(10)(E) (42 U.S.C. 1396a(a)(10)(E)) is amended—

(1) by striking “and” at the end of clause (iii);

(2) by adding “and” at the end of clause (iv); and

1 (3) by adding at the end the following new clause:

2 “(v)(I) for making medical assistance available for
3 medicare cost-sharing described in section
4 1905(p)(3)(A)(iii) and medicare cost-sharing described
5 in section 1905(p)(3)(B) and section 1905(p)(3)(C) but
6 only insofar as it relates to benefits provided under
7 part D of title XVIII, subject to section 1905(p)(4), for
8 individuals (other than qualified medicare beneficiaries)
9 who are enrolled under part D of title XVIII and are
10 described in section 1905(p)(1)(B) or would be so de-
11 scribed but for the fact that their income exceeds 100
12 percent, but is less than 150 percent, of the official
13 poverty line (referred to in such section) for a family
14 of the size involved;

15 “(II) subject to section 1905(p)(4), for individuals
16 (other than qualified medicare beneficiaries and individ-
17 uals described in subclause (I)) who are enrolled under
18 part D of title XVIII and would be described in section
19 1905(p)(1)(B) but for the fact that their income ex-
20 ceeds 150 percent, but is less than 175 percent, of the
21 official poverty line (referred to in such section) for a
22 family of the size involved, for making medical assist-
23 ance available for medicare cost-sharing described in
24 section 1905(p)(3)(A)(iii) and medicare cost-sharing
25 described in section 1905(p)(3)(B) and section
26 1905(p)(3)(C) but only insofar as it relates to benefits
27 provided under part D of title XVIII, and the assist-
28 ance for medicare cost-sharing described in section
29 1905(p)(3)(A)(iii) is reduced (on a sliding scale based
30 on income) from 100 percent to 0 percent as the in-
31 come increases from 150 percent to 175 percent of
32 such poverty line;”.

33 (c) FEDERAL FINANCING.—The third sentence of section
34 1905(b) (42 U.S.C. 1396d(b)) is amended by inserting before
35 the period at the end the following: “and with respect to
36 amounts expended that are attributable to section

1 1902(a)(10)(E)(v) (other than for individuals described in sec-
2 tion 1905(p)(1)(B))”.

3 (d) TREATMENT OF TERRITORIES.—

4 (1) IN GENERAL.—Section 1905(p) (42 U.S.C.
5 1396d(p)) is amended—

6 (A) by redesignating paragraphs (5) and (6) as
7 paragraphs (6) and (7), respectively; and

8 (B) by inserting after paragraph (4) the following
9 new paragraph:

10 “(5)(A) In the case of a State, other than the 50 States
11 and the District of Columbia—

12 “(i) the provisions of paragraph (3) insofar as they re-
13 late to section 1859D and the provisions of section
14 1902(a)(10)(E)(v) shall not apply to residents of such
15 State; and

16 “(ii) if the State establishes a plan described in sub-
17 paragraph (B) (for providing medical assistance with re-
18 spect to the provision of prescription medicines to medicare
19 beneficiaries), the amount otherwise determined under sec-
20 tion 1108(f) (as increased under section 1108(g)) for the
21 State shall be increased by the amount specified in sub-
22 paragraph (C).

23 “(B) The plan described in this subparagraph is a plan
24 that—

25 “(i) provides medical assistance with respect to the
26 provision of covered outpatient medicines (as defined in
27 section 1859D(b)) to low-income medicare beneficiaries;
28 and

29 “(ii) assures that additional amounts received by the
30 State that are attributable to the operation of this para-
31 graph are used only for such assistance.

32 “(C)(i) The amount specified in this subparagraph for a
33 State for a year is equal to the product of—

34 “(I) the aggregate amount specified in clause (ii); and

35 “(II) the amount specified in section 1108(g)(1) for
36 that State, divided by the sum of the amounts specified in
37 such section for all such States.

1 “(ii) The aggregate amount specified in this clause for—

2 “(I) 2005, is equal to \$25,000,000; or

3 “(II) a subsequent year, is equal to the aggregate
4 amount specified in this clause for the previous year in-
5 creased by annual percentage increase specified in section
6 1859D(c)(8)(B) for the year involved.

7 “(D) The Secretary shall submit to Congress a report on
8 the application of this paragraph and may include in the report
9 such recommendations as the Secretary deems appropriate.”.

10 (2) CONFORMING AMENDMENT.—Section 1108(f) (42
11 U.S.C. 1308(f)) is amended by inserting “and section
12 1905(p)(5)(A)(ii)” after “Subject to subsection (g)”.

13 (e) APPLICATION OF COST-SHARING.—Section 1902(n)(2)
14 (42 U.S.C. 1396a(n)(2)) is amended by adding at the end the
15 following: “The previous sentence shall not apply to medicare
16 cost-sharing relating to benefits under part D of title XVIII.”.

17 (f) EFFECTIVE DATE.—The amendments made by this
18 section apply to medical assistance for premiums and cost-shar-
19 ing incurred on or after January 1, 2005, with regard to
20 whether regulations to implement such amendments are pro-
21 mulgated by such date.

22 **SEC. 105. EXPANSION OF MEMBERSHIP AND DUTIES OF**
23 **MEDICARE PAYMENT ADVISORY COMMIS-**
24 **SION (MEDPAC).**

25 (a) EXPANSION OF MEMBERSHIP.—

26 (1) IN GENERAL.—Section 1805(c) (42 U.S.C. 1395b–
27 6(c)) is amended—

28 (A) in paragraph (1), by striking “17” and insert-
29 ing “19”; and

30 (B) in paragraph (2)(B), by inserting “experts in
31 the area of pharmacology and prescription medicine
32 benefit programs,” after “other health professionals,”.

33 (2) INITIAL TERMS OF ADDITIONAL MEMBERS.—

34 (A) IN GENERAL.—For purposes of staggering the
35 initial terms of members of the Medicare Payment Ad-
36 visory Commission under section 1805(c)(3) of the So-
37 cial Security Act (42 U.S.C. 1395b–6(c)(3)), the initial

1 terms of the 2 additional members of the Commission
2 provided for by the amendment under paragraph (1)(A)
3 are as follows:

4 (i) One member shall be appointed for 1 year.

5 (ii) One member shall be appointed for 2
6 years.

7 (B) COMMENCEMENT OF TERMS.—Such terms
8 shall begin on January 1, 2003.

9 (b) EXPANSION OF DUTIES.—Section 1805(b)(2) (42
10 U.S.C. 1395b–6(b)(2)) is amended by adding at the end the
11 following new subparagraph:

12 “(D) PRESCRIPTION MEDICINE BENEFIT PRO-
13 GRAM.—Specifically, the Commission shall review, with
14 respect to the prescription medicine benefit program
15 under part D, the following:

16 “(i) The methodologies used for the manage-
17 ment of costs and utilization of prescription medi-
18 cines.

19 “(ii) The prices negotiated and paid, including
20 trends in such prices and applicable discounts and
21 comparisons with prices under section
22 1859E(a)(2)(E).

23 “(iii) The relationship of pharmacy acquisition
24 costs to the prices so negotiated and paid.

25 “(iv) The methodologies used to ensure access
26 to covered outpatient prescription medicines and to
27 ensure quality in the appropriate dispensing and
28 utilization of such medicines.

29 “(v) The impact of the program on promoting
30 the development of breakthrough medicines.”.

**Subtitle B—Affordable
Pharmaceuticals**

**PART I—GREATER ACCESS TO AFFORDABLE
PHARMACEUTICALS**

SEC. 111. ACCELERATED GENERIC DRUG COMPETITION.

(a) IN GENERAL.—Section 505(j)(5) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)) is amended—

(1) in subparagraph (B)(iv), by striking subclause (II)
and inserting the following:

“(II) the earlier of—

“(aa) the date of a final decision of a court in
an action described in clause (iii)(II) (from which
no appeal can or has been taken, other than a peti-
tion to the Supreme Court for a writ of certiorari)
holding the patent that is the subject of the certifi-
cation to be invalid or not infringed; or

“(bb) the date of a settlement order or consent
decree in such an action signed by a Federal judge
that enters a final judgment and includes a finding
that the patent that is the subject of the certifi-
cation is invalid or not infringed;”;

(2) by redesignating subparagraphs (C) and (D) as
subparagraphs (E) and (F), respectively; and

(3) by inserting before subparagraph (E) (as so redesi-
gnated) the following subparagraph:

“(D)(i) The 180-day period described in subparagraph
(B)(iv) shall be forfeited by the previous applicant if—

“(I) the previous applicant fails to market the drug by
the later of the date 60 days after the date on which the
approval of the application for the drug is made effective
under subparagraph (B)(iii) or, if such approval has been
made effective, and if an action has been brought against
the previous applicant for infringement of a patent subject
to a certification under paragraph (2)(A)(vii)(IV), or an ac-
tion has been brought by the previous applicant for a de-
claratory judgment that such a patent is invalid or not in-

1 fringed, the date 60 days after the date of a final decision
2 in such action, if there is no other such action pending by
3 or against the previous applicant; except, however, that ei-
4 ther of such dates may be extended due to extraordinary
5 or unusual circumstances, as determined by the Secretary;

6 “(II) the previous applicant withdraws the application;

7 “(III) the previous applicant amends the certification
8 from a certification under subclause (IV) of paragraph
9 (2)(A)(vii) to a certification under subclause (III) of such
10 paragraph, either voluntarily or as a result of a settlement
11 or defeat in patent litigation;

12 “(IV) the previous applicant fails to obtain tentative
13 approval of the application within 30 months after the date
14 on which the application is filed, unless the failure is
15 caused by—

16 “(aa) a change in the requirements for tentative
17 approval of the application imposed after the date on
18 which the application was filed; or

19 “(bb) other extraordinary or unusual cir-
20 cumstances, as determined by the Secretary;

21 “(V) in a case in which, after the date on which the
22 previous application was submitted under this subsection,
23 new patent information is submitted under subsection
24 (c)(2) for the listed drug for a patent for which certifi-
25 cation or a method of use statement is required under
26 paragraph (2)(A), the previous applicant fails to submit no
27 later than 60 days from the date the applicant receives no-
28 tice from the Secretary under paragraph (7)(A)(iii) of the
29 submission of the new patent information either a certifi-
30 cation described in paragraph (2)(A)(vii)(IV) or a state-
31 ment that the method of use patent does not claim a use
32 for which the applicant is seeking approval under this sub-
33 section in accordance with paragraph (2)(A)(viii); except,
34 however, that such date may be extended due to extraor-
35 dinary or unusual circumstances, as determined by the Sec-
36 retary; or

1 “(VI) the previous applicant is determined by the Sec-
2 retary, after a fair and sufficient hearing and in consulta-
3 tion with the Federal Trade Commission, to have engaged
4 in anticompetitive or collusive conduct, or any other con-
5 duct intended to unfairly monopolize the commercial manu-
6 facturing of the drug of the application.

7 “(ii) If under clause (i) the previous applicant referred to
8 in subparagraph (B)(iv) forfeits the 180-day period described
9 in such subparagraph, such period shall become available to the
10 next applicant submitting an application containing a certifi-
11 cation under paragraph (2)(A)(vii)(IV) if—

12 “(I) no action described in subparagraph (B)(iii)(II)
13 was brought against or by the previous applicant, or such
14 an action was brought but did not result in a final judg-
15 ment that included a finding that the patent involved is in-
16 valid; and

17 “(II) an action described in subparagraph (B)(iii)(II)
18 is brought against or by the next applicant, and such action
19 results in a final judgment that includes a finding that the
20 patent involved is invalid.

21 “(iii) The 180-day period described in subparagraph
22 (B)(iv) shall be available only to—

23 “(I) the previous applicant submitting an application
24 for a drug under this subsection containing a certification
25 described in paragraph (2)(A)(vii)(IV) with respect to any
26 patent; or

27 “(II) under clause (ii), the next applicant submitting
28 an application for a drug under this subsection containing
29 such a certification with respect to any patent;
30 even if an application has been submitted for the drug under
31 this subsection containing such a certification with respect to
32 a different patent.

33 “(iv) The 180-day period described in subparagraph
34 (B)(iv) for an application containing a certification described in
35 paragraph (2)(A)(vii)(IV) shall apply only if an action is
36 brought for infringement of a patent that is the subject of the
37 certification or the applicant brings an action (not later than

1 60 days after the date on which the notice provided under
2 paragraph (2)(B)(ii) was received) against the holder of the ap-
3 proved application for the listed drug.”.

4 (b) EFFECTIVE DATE.—The amendment made by this sec-
5 tion shall be effective only with respect to an application filed
6 under section 505(j) of the Federal Food, Drug, and Cosmetic
7 Act (21 U.S.C. 355(j)) for a listed drug for which no certifi-
8 cation under section 505(j)(2)(A)(vii)(IV) of that Act was made
9 before June 7, 2002.

10 **SEC. 112. PATENT CERTIFICATION.**

11 (a) ABBREVIATED NEW DRUG APPLICATIONS.—Section
12 505(j)(5) of the Federal Food, Drug, and Cosmetic Act (21
13 U.S.C. 355(j)(5)) is amended—

14 (1) in subparagraph (B), by striking clause (iii) and
15 inserting the following:

16 “(iii)(I) If the applicant made a certification described
17 in paragraph (2)(A)(vii)(IV) and—

18 “(aa) no action is brought for infringement of a
19 patent that is the subject of the certification before the
20 expiration of the 45-day period beginning on the date
21 on which the notice provided under paragraph
22 (2)(B)(ii) was received; and

23 “(bb) the applicant does not bring an action for
24 declaratory judgment authorized in subclause (II) be-
25 fore the expiration of the 60-day period beginning on
26 the date on which the notice provided under paragraph
27 (2)(B)(ii) was received;

28 the approval shall be made effective on the expiration of 60
29 days after the date on which the notice provided under
30 paragraph (2)(B)(ii) was received, provided none of the
31 conditions for denial of approval in paragraph (4) apply.

32 “(II) With respect to an applicant who made a certifi-
33 cation described in paragraph (2)(A)(vii)(IV), if an action
34 referred to in item (aa) of subclause (I) is brought before
35 the expiration of the period described in such item, or if
36 the applicant brings an action for declaratory judgment of
37 invalidity or noninfringement of such patent (which action

1 is hereby authorized) before the expiration of the period de-
2 scribed in item (bb) of such subclause, the approval shall,
3 provided none of the conditions for denial of approval in
4 paragraph (4) apply, be made effective in accordance with
5 the following:

6 “(aa) If the action is an action referred to in sub-
7 clause (I)(aa), and neither the holder of the approved
8 application nor the owner of the patent seek a prelimi-
9 nary injunction prohibiting the applicant from engaging
10 in the commercial manufacture or sale (or both) of the
11 drug, the approval shall be made effective on the expi-
12 ration of 60 days after the date on which the notice
13 provided under paragraph (2)(B)(ii) was received.

14 “(bb) If the action is an action referred to in sub-
15 clause (I)(aa), and such a preliminary injunction is
16 sought and the court denies the motion, the approval
17 shall be made effective on the date on which the court
18 denies the injunction.

19 “(cc) If neither item (aa) nor (bb) applies, and the
20 holding of the court in the decision in the action is that
21 the patent is invalid or was not infringed, the approval
22 shall be made effective on the date of the decision of
23 the court.

24 “(dd) If neither item (aa) nor (bb) applies, and
25 the holding of the court in the decision in the action
26 is that the patent was infringed, the approval shall be
27 made effective on such date as the court orders under
28 section 271(e)(4)(A) of title 35, United States Code.”;
29 and

30 (2) by inserting before subparagraph (D) (as added by
31 section 111(a)(3)) the following subparagraph:

32 “(C) With respect to a civil action described in subpara-
33 graph (B)(iii)(II):

34 “(i) Each of the parties shall reasonably cooperate in
35 expediting the action.

36 “(ii) If the notice under paragraph (2)(B)(ii) contains
37 an address for the receipt of expedited notification of such

1 an action, the plaintiff shall, on the date the complaint is
2 filed in the court, simultaneously cause a notification of
3 such action to be delivered to such address by the next
4 business day.

5 “(iii) An action for a declaratory judgment authorized
6 in such subparagraph may not be brought by the applicant
7 until the expiration of 45 days after the date the notice
8 provided under paragraph (2)(B)(ii) was received, except
9 that if information on the patent involved has been pub-
10 lished under subsection (c)(2) for at least one year after
11 the date on which the application under this subsection was
12 filed in relation to the listed drug involved, the applicant
13 may immediately bring such an action for declaratory judg-
14 ment.

15 “(iv) Any such action shall be brought in the judicial
16 district in which the defendant has its principal place of
17 business or a regular and established place of business.”.

18 (b) NEW DRUG APPLICATIONS.—Section 505(c)(3) of the
19 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(c)(3))
20 is amended by striking subparagraph (C) and inserting the fol-
21 lowing:

22 “(C)(i)(I) If the applicant made a certification de-
23 scribed in subsection (b)(2)(A)(iv) and—

24 “(aa) no action is brought for infringement of a
25 patent that is the subject of the certification before the
26 expiration of the 45-day period beginning on the date
27 on which the notice provided under subsection
28 (b)(3)(B) was received; and

29 “(bb) the applicant does not bring an action for
30 declaratory judgment authorized in subclause (II) be-
31 fore the expiration of the 60-day period beginning on
32 the date on which the notice provided under subsection
33 (b)(3)(B) was received;

34 the approval shall be made effective on the expiration of 60
35 days after the date on which the notice provided under sub-
36 section (b)(3)(B) was received, provided that none of the
37 conditions for refusal of approval in subsection (d) apply.

1 “(II) With respect to an applicant who made a certifi-
2 cation described in subsection (b)(2)(A)(iv), if an action re-
3 ferred to in item (aa) of subclause (I) is brought before the
4 expiration of the period described in such item, or if the
5 applicant brings an action for declaratory judgment of in-
6 validity or noninfringement of such patent (which action is
7 hereby authorized) before the expiration of the period de-
8 scribed in item (bb) of such subclause, the approval shall,
9 provided none of the conditions for refusal of approval in
10 subsection (d) apply, be made effective in accordance with
11 the following:

12 “(aa) If the action is an action referred to in sub-
13 clause (I)(aa), and neither the holder of the approved
14 application nor the owner of the patent seek a prelimi-
15 nary injunction prohibiting the applicant from engaging
16 in the commercial manufacture or sale (or both) of the
17 drug, the approval shall be made effective on the expi-
18 ration of 60 days after the date on which the notice
19 provided under subsection (b)(3)(B) was received.

20 “(bb) If the action is an action referred to in sub-
21 clause (I)(aa), and such a preliminary injunction is
22 sought and the court denies the motion, the approval
23 shall be made effective on the date on which the court
24 denies the injunction.

25 “(cc) If neither item (aa) nor (bb) applies, and the
26 holding of the court in the decision in the action is that
27 the patent is invalid or was not infringed, the approval
28 shall be made effective on the date of the decision of
29 the court.

30 “(dd) If neither item (aa) nor (bb) applies, and
31 the holding of the court in the decision in the action
32 is that the patent was infringed, the approval shall be
33 made effective on such date as the court orders under
34 section 271(e)(4)(A) of title 35, United States Code.

35 “(ii) With respect to a civil action described in clause
36 (i)(II):

1 “(I) Each of the parties shall reasonably cooperate
2 in expediting the action.

3 “(II) If the notice under subsection (b)(3)(B) con-
4 tains an address for the receipt of expedited notifica-
5 tion of such an action, the plaintiff shall, on the date
6 the complaint is filed in the court, simultaneously cause
7 a notification of such action to be delivered to such ad-
8 dress by the next business day.

9 “(III) An action for a declaratory judgment au-
10 thorized in such clause may not be brought by the ap-
11 plicant until the expiration of 45 days after the date
12 the notice provided under subsection (b)(3)(B) was re-
13 ceived, except that if information on the patent involved
14 has been published under paragraph (2) for at least
15 one year after the date on which the application was
16 filed in relation to the drug involved, the applicant may
17 immediately bring such an action for declaratory judg-
18 ment.

19 “(IV) Any such action shall be brought in the ju-
20 dicial district in which the defendant has its principal
21 place of business or a regular and established place of
22 business.”.

23 (c) EFFECTIVE DATE.—The amendments made by this
24 section shall not apply to an application submitted under sec-
25 tion 505(b)(1) or 505(j) of the Federal Food, Drug, and Cos-
26 metic Act (21 U.S.C. 355) before June 7, 2002.

27 **SEC. 113. ADDITIONAL USES.**

28 Section 505(j) of the Federal Food, Drug, and Cosmetic
29 Act (21 U.S.C. 355(j)) is amended by adding at the end the
30 following paragraph:”

31 “(10)(A) A drug for which an application has been sub-
32 mitted or approved under this subsection shall not be consid-
33 ered ineligible for approval under this subsection or misbranded
34 under section 502 on the basis that the labeling of the drug
35 omits a use or any other aspect of labeling when the omitted
36 use or other aspect is protected by patent or by exclusivity
37 under clause (iii) or (iv) of paragraph (5)(D).

1 “(B) Notwithstanding clauses (iii) and (iv) of paragraph
2 (5)(D), the Secretary may require that the labeling of a drug
3 approved under this subsection that omits a use or other aspect
4 of labeling as described in subparagraph (A) include—

5 “(i) any statement that the Secretary considers nec-
6 essary for the safe use of the drug, such as appropriate
7 contraindications, warnings, or precautions; and

8 “(ii) a statement that, because of marketing exclu-
9 sivity for a manufacturer, the drug is not labeled for the
10 use.”.

11 **PART II—NOTIFICATION OF AGREEMENTS AF-**
12 **FECTING THE SALE OR MARKETING OF GE-**
13 **NERIC DRUGS**

14 **SEC. 121. DEFINITIONS.**

15 In this part:

16 (1) AGREEMENT.—The term “agreement” means an
17 agreement under section 1 of the Sherman Act (15 U.S.C.
18 1) or section 5 of the Federal Trade Commission Act (15
19 U.S.C. 45).

20 (2) ANTITRUST LAWS.—The term “antitrust laws” has
21 the same meaning as in section 1 of the Clayton Act (15
22 U.S.C. 12), except that such term includes section 5 of the
23 Federal Trade Commission Act (15 U.S.C. 45) to the ex-
24 tent that such section applies to unfair methods of competi-
25 tion.

26 (3) ANDA.—The term “ANDA” means an Abbre-
27 viated New Drug Application, as defined under section
28 505(j) of the Federal Food, Drug and Cosmetic Act.

29 (4) BRAND NAME DRUG COMPANY.—The term “brand
30 name drug company” means a person engaged in the man-
31 ufacture or marketing of a drug approved under section
32 505(b) of the Federal Food, Drug and Cosmetic Act.

33 (5) COMMISSION.—The term “Commission” means the
34 Federal Trade Commission.

35 (6) FDA.—The term “FDA” means the United States
36 Food and Drug Administration.

1 (7) GENERIC DRUG.—The term “generic drug” means
2 a product that is the subject of an ANDA.

3 (8) GENERIC DRUG APPLICANT.—The term “generic
4 drug applicant” means a person who has filed or received
5 approval for an ANDA under section 505(j) of the Federal
6 Food, Drug and Cosmetic Act.

7 (9) SECRETARY.—The term “Secretary” means the
8 Secretary of Health and Human Services.

9 **SEC. 122. NOTIFICATION OF AGREEMENTS AFFECTING**
10 **THE SALE OR MARKETING OF GENERIC**
11 **DRUGS.**

12 A brand name drug company and a generic drug applicant
13 that enter into an agreement regarding the sale or manufacture
14 of a generic drug that the Secretary has determined is the
15 therapeutic equivalent of a brand name drug that is manufac-
16 tured or marketed by that brand name drug company, or for
17 which the generic drug applicant seeks such a determination of
18 therapeutic equivalence, and which agreement could have the
19 effect of limiting the research, development, manufacture, mar-
20 keting, or selling of a generic drug that has been or could be
21 approved for sale by the FDA pursuant to an ANDA, shall file
22 with the Commission and the Secretary the text of the agree-
23 ment, an explanation of the purpose and scope of the agree-
24 ment, and an explanation of whether the agreement could
25 delay, restrain, limit, or in any way interfere with the produc-
26 tion, manufacture, or sale of the generic version of the drug in
27 question.

28 **SEC. 123. FILING DEADLINES.**

29 Any notice, agreement, or other material required to be
30 filed under section 122 shall be filed with the Commission and
31 the Secretary not later than 10 business days after the date the
32 agreement is executed.

33 **SEC. 124. ENFORCEMENT.**

34 (a) CIVIL FINE.—Any person, or any officer, director, or
35 partner thereof, who fails to comply with any provision of this
36 part shall be liable for a civil penalty of not more than \$20,000
37 for each day during which such person is in violation of this

1 part. Such penalty may be recovered in a civil action brought
2 by the United States, or brought by the Commission in accord-
3 ance with the procedures established in section 16(a)(1) of the
4 Federal Trade Commission Act (15 U.S.C. 56(a)).

5 (b) COMPLIANCE AND EQUITABLE RELIEF.—If any per-
6 son, or any officer, director, partner, agent, or employee there-
7 of, fails to comply with the notification requirement under sec-
8 tion 122 of this part, the United States district court may
9 order compliance, and may grant such other equitable relief as
10 the court in its discretion determines necessary or appropriate,
11 upon application of the Commission or the Assistant Attorney
12 General.

13 **SEC. 125. RULEMAKING.**

14 The Commission, in consultation with the Secretary, and
15 with the concurrence of the Assistant Attorney General and by
16 rule in accordance with section 553 of title 5, United States
17 Code, consistent with the purposes of this part—

18 (1) may require that the notice described in section
19 122 of this part be in such form and contain such docu-
20 mentary material and information relevant to the agree-
21 ment as is necessary and appropriate to enable the Com-
22 mission and the Assistant Attorney General to determine
23 whether such agreement may violate the antitrust laws;

24 (2) may define the terms used in this part;

25 (3) may exempt classes of persons or agreements from
26 the requirements of this part; and

27 (4) may prescribe such other rules as may be nec-
28 essary and appropriate to carry out the purposes of this
29 part.

30 **SEC. 126. EFFECTIVE DATES.**

31 This part shall take effect 90 days after the date of enact-
32 ment of this Act.

1 **TITLE II—MEDICARE+CHOICE RE-**
2 **VITALIZATION AND**
3 **MEDICARE+CHOICE COMPETI-**
4 **TION PROGRAM**

5 **SEC. 201. MEDICARE+CHOICE IMPROVEMENTS.**

6 (a) EQUALIZING PAYMENTS BETWEEN FEE-FOR-SERVICE
7 AND MEDICARE+CHOICE.—

8 (1) IN GENERAL.—Section 1853(c)(1) (42 U.S.C.
9 1395w-23(c)(1)) is amended by adding at the end the fol-
10 lowing:

11 “(D) BASED ON 100 PERCENT OF FEE-FOR-SERV-
12 ICE COSTS.—

13 “(i) IN GENERAL.—For 2003 and 2004, the
14 adjusted average per capita cost for the year in-
15 volved, determined under section 1876(a)(4) for the
16 Medicare+Choice payment area for services cov-
17 ered under parts A and B for individuals entitled
18 to benefits under part A and enrolled under part
19 B who are not enrolled in a Medicare+Choice plan
20 under this part for the year, but adjusted to ex-
21 clude costs attributable to payments under section
22 1886(h).

23 “(ii) INCLUSION OF COSTS OF VA AND DOD
24 MILITARY FACILITY SERVICES TO MEDICARE-ELIGI-
25 BLE BENEFICIARIES.—In determining the adjusted
26 average per capita cost under clause (i) for a year,
27 such cost shall be adjusted to include the Sec-
28 retary’s estimate, on a per capita basis, of the
29 amount of additional payments that would have
30 been made in the area involved under this title if
31 individuals entitled to benefits under this title had
32 not received services from facilities of the Depart-
33 ment of Veterans Affairs or the Department of De-
34 fense.”.

1 (2) CONFORMING AMENDMENT.—Such section is fur-
2 ther amended, in the matter before subparagraph (A), by
3 striking “or (C)” and inserting “(C), or (D)”.

4 (b) REVISION OF BLEND.—

5 (1) REVISION OF NATIONAL AVERAGE USED IN CAL-
6 CULATION OF BLEND.—Section 1853(c)(4)(B)(i)(II) (42
7 U.S.C. 1395w–23(c)(4)(B)(i)(II)) is amended by inserting
8 “who (with respect to determinations for 2003 and for
9 2004) are enrolled in a Medicare+Choice plan” after “the
10 average number of medicare beneficiaries”.

11 (2) CHANGE IN BUDGET NEUTRALITY.—Section
12 1853(c) (42 U.S.C. 1395w–23(c)) is amended—

13 (A) in paragraph (1)(A), by inserting “(for a year
14 before 2003)” after “multiplied”; and

15 (B) in paragraph (5), by inserting “(before 2003)”
16 after “for each year”.

17 (c) REVISION IN MINIMUM PERCENTAGE INCREASE FOR
18 2003 AND 2004.—Section 1853(c)(1)(C) (42 U.S.C. 1395w–
19 23(c)(1)(C)) is amended by striking clause (iv) and inserting
20 the following:

21 “(iv) For 2002, 102 percent of the annual
22 Medicare+Choice capitation rate under this para-
23 graph for the area for 2001.

24 “(v) For 2003 and 2004, 103 percent of the
25 annual Medicare+Choice capitation rate under this
26 paragraph for the area for the previous year.

27 “(iv) For 2005 and each succeeding year, 102
28 percent of the annual Medicare+Choice capitation
29 rate under this paragraph for the area for the pre-
30 vious year.”.

31 (d) INCLUSION OF COSTS OF DOD AND VA MILITARY FA-
32 CILITY SERVICES TO MEDICARE-ELIGIBLE BENEFICIARIES IN
33 CALCULATION OF MEDICARE+CHOICE PAYMENT RATES.—
34 Section 1853(c)(3) (42 U.S.C. 1395w–23(c)(3)) is amended—

35 (1) in subparagraph (A), by striking “subparagraph
36 (B)” and inserting “subparagraphs (B) and (E)”, and

(2) by adding at the end the following new subparagraph:

“(E) INCLUSION OF COSTS OF DOD AND VA MILITARY FACILITY SERVICES TO MEDICARE-ELIGIBLE BENEFICIARIES.—In determining the area-specific Medicare+Choice capitation rate under subparagraph (A) for a year (beginning with 2003), the annual per capita rate of payment for 1997 determined under section 1876(a)(1)(C) shall be adjusted to include in the rate the Secretary’s estimate, on a per capita basis, of the amount of additional payments that would have been made in the area involved under this title if individuals entitled to benefits under this title had not received services from facilities of the Department of Defense or the Department of Veterans Affairs.”.

(e) ANNOUNCEMENT OF REVISED MEDICARE+CHOICE PAYMENT RATES.—Within 2 weeks after the date of the enactment of this Act, the Secretary shall determine, and shall announce (in a manner intended to provide notice to interested parties) Medicare+Choice capitation rates under section 1853 of the Social Security Act (42 U.S.C. 1395w–23) for 2003, revised in accordance with the provisions of this section.

(f) MEDPAC STUDY OF AAPCC.—

(1) STUDY.—The Medicare Payment Advisory Commission shall conduct a study that assesses the method used for determining the adjusted average per capita cost (AAPCC) under section 1876(a)(4) of the Social Security Act (42 U.S.C. 1395mm(a)(4)). Such study shall examine—

(A) the bases for variation in such costs between different areas, including differences in input prices, utilization, and practice patterns;

(B) the appropriate geographic area for payment under the Medicare+Choice program under part C of title XVIII of such Act; and

(C) the accuracy of risk adjustment methods in reflecting differences in costs of providing care to dif-

1 ferent groups of beneficiaries served under such pro-
2 gram.

3 (2) REPORT.—Not later than 9 months after the date
4 of the enactment of this Act, the Commission shall submit
5 to Congress a report on the study conducted under para-
6 graph (1). Such report shall include recommendations re-
7 garding changes in the methods for computing the adjusted
8 average per capita cost among different areas.

9 (g) APPLYING LIMITATIONS ON BALANCE BILLING TO
10 MEDICARE MSAS.—Section 1852(k)(1) (42 U.S.C. 1395w-
11 22(k)(1)) is amended by inserting “or with an organization of-
12 fering a MSA plan” after “section 1851(a)(2)(A)”.

13 (h) REPORT ON IMPACT OF INCREASED FINANCIAL AS-
14 SISTANCE TO MEDICARE+CHOICE PLANS.—Not later than
15 July 1, 2003, the Secretary shall submit to Congress a report
16 that describes the impact of additional financing provided
17 under this Act and other Acts (including the Medicare, Med-
18 icaid, and SCHIP Balanced Budget Refinement Act of 1999
19 and BIPA) on the availability of Medicare+Choice plans in dif-
20 ferent areas and its impact on lowering premiums and increas-
21 ing benefits under such plans.

22 **SEC. 202. MAKING PERMANENT CHANGE IN**
23 **MEDICARE+CHOICE REPORTING DEADLINES**
24 **AND ANNUAL, COORDINATED ELECTION PE-**
25 **RIOD.**

26 (a) CHANGE IN REPORTING DEADLINE.—Section
27 1854(a)(1) (42 U.S.C. 1395w-24(a)(1)), as amended by sec-
28 tion 532(b)(1) of the Public Health Security and Bioterrorism
29 Preparedness and Response Act of 2002, is amended by strik-
30 ing “2002, 2003, and 2004 (or July 1 of each other year)” and
31 inserting “2002 and each subsequent year (or July 1 of each
32 year before 2002)”.

33 (b) DELAY IN ANNUAL, COORDINATED ELECTION PE-
34 RIOD.—Section 1851(e)(3)(B) (42 U.S.C. 1395w-21(e)(3)(B)),
35 as amended by section 532(c)(1)(A) of the Public Health Secu-
36 rity and Bioterrorism Preparedness and Response Act of 2002,
37 is amended by striking “and after 2005, the month of Novem-

1 ber before such year and with respect to 2003, 2004, and
2 2005” and inserting “, the month of November before such
3 year and with respect to 2003 and any subsequent year”.

4 (c) ANNUAL ANNOUNCEMENT OF PAYMENT RATES.—Sec-
5 tion 1853(b)(1) (42 U.S.C. 1395w-23(b)(1)), as amended by
6 section 532(d)(1) of the Public Health Security and Bioter-
7 rorism Preparedness and Response Act of 2002, is amended by
8 striking “and after 2005 not later than March 1 before the cal-
9 endar year concerned and for 2004 and 2005” and inserting
10 “not later than March 1 before the calendar year concerned
11 and for 2004 and each subsequent year”.

12 (d) REQUIRING PROVISION OF AVAILABLE INFORMATION
13 COMPARING PLAN OPTIONS.—The first sentence of section
14 1851(d)(2)(A)(ii) (42 U.S.C. 1395w-21(d)(2)(A)(ii)) is amend-
15 ed by inserting before the period the following: “to the extent
16 such information is available at the time of preparation of ma-
17 terials for the mailing”.

18 **SEC. 203. SPECIALIZED MEDICARE+CHOICE PLANS FOR**
19 **SPECIAL NEEDS BENEFICIARIES.**

20 (a) TREATMENT AS COORDINATED CARE PLAN.—Section
21 1851(a)(2)(A) (42 U.S.C. 1395w-21(a)(2)(A)) is amended by
22 adding at the end the following new sentence: “Specialized
23 Medicare+Choice plans for special needs beneficiaries (as de-
24 fined in section 1859(b)(4)) may be any type of coordinated
25 care plan.”.

26 (b) SPECIALIZED MEDICARE+CHOICE PLAN FOR SPECIAL
27 NEEDS BENEFICIARIES DEFINED.—Section 1859(b) (42
28 U.S.C. 1395w-29(b)) is amended by adding at the end the fol-
29 lowing new paragraph:

30 “(4) SPECIALIZED MEDICARE+CHOICE PLANS FOR
31 SPECIAL NEEDS BENEFICIARIES.—

32 “(A) IN GENERAL.—The term ‘specialized
33 Medicare+Choice plan for special needs beneficiaries’
34 means a Medicare+Choice plan that exclusively serves
35 special needs beneficiaries (as defined in subparagraph
36 (B)).

1 “(B) SPECIAL NEEDS BENEFICIARY.—The term
2 ‘special needs beneficiary’ means a Medicare+Choice
3 eligible individual who—

4 “(i) is institutionalized (as defined by the Sec-
5 retary);

6 “(ii) is entitled to medical assistance under a
7 State plan under title XIX; or

8 “(iii) meets such requirements as the Sec-
9 retary may determine would benefit from enroll-
10 ment in such a specialized Medicare+Choice plan
11 described in subparagraph (A) for individuals with
12 severe or disabling chronic conditions.”.

13 (c) RESTRICTION ON ENROLLMENT PERMITTED.—Section
14 1859 (42 U.S.C. 1395w–29) is amended by adding at the end
15 the following new subsection:

16 “(f) RESTRICTION ON ENROLLMENT FOR SPECIALIZED
17 MEDICARE+CHOICE PLANS FOR SPECIAL NEEDS BENE-
18 FICIARIES.—In the case of a specialized Medicare+Choice plan
19 (as defined in subsection (b)(4)), notwithstanding any other
20 provision of this part and in accordance with regulations of the
21 Secretary and for periods before January 1, 2007, the plan
22 may restrict the enrollment of individuals under the plan to in-
23 dividuals who are within one or more classes of special needs
24 beneficiaries.”.

25 (d) REPORT TO CONGRESS.—Not later than December 31,
26 2005, the Secretary shall submit to Congress a report that as-
27 sesses the impact of specialized Medicare+Choice plans for spe-
28 cial needs beneficiaries on the cost and quality of services pro-
29 vided to enrollees. Such report shall include an assessment of
30 the costs and savings to the medicare program as a result of
31 amendments made by subsections (a), (b), and (c).

32 (e) EFFECTIVE DATES.—

33 (1) IN GENERAL.—The amendments made by sub-
34 sections (a), (b), and (c) shall take effect upon the date of
35 the enactment of this Act.

36 (2) DEADLINE FOR ISSUANCE OF REQUIREMENTS FOR
37 SPECIAL NEEDS BENEFICIARIES; TRANSITION.—No later

1 than 6 months after the date of the enactment of this Act,
2 the Secretary of Health and Human Services shall issue
3 final regulations to establish requirements for special needs
4 beneficiaries under section 1859(b)(4)(B)(iii) of the Social
5 Security Act, as added by subsection (b).

6 **SEC. 204. EXTENSION OF REASONABLE COST AND SHMO**
7 **CONTRACTS.**

8 (a) REASONABLE COST CONTRACTS.—

9 (1) IN GENERAL.—Section 1876(h)(5)(C) (42 U.S.C.
10 1395mm(h)(5)(C)) is amended—

11 (A) by inserting “(i)” after “(C)”;

12 (B) by inserting before the period the following: “,
13 except (subject to clause (ii)) in the case of a contract
14 for an area which is not covered in the service area of
15 1 or more coordinated care Medicare+Choice plans
16 under part C”; and

17 (C) by adding at the end the following new clause:

18 “(ii) In the case in which—

19 “(I) a reasonable cost reimbursement contract includes
20 an area in its service area as of a date that is after Decem-
21 ber 31, 2003;

22 “(II) such area is no longer included in such service
23 area after such date by reason of the operation of clause
24 (i) because of the inclusion of such area within the service
25 area of a Medicare+Choice plan; and

26 “(III) all Medicare+Choice plans subsequently termi-
27 nate coverage in such area;

28 such reasonable cost reimbursement contract may be extended
29 and renewed to cover such area (so long as it is not included
30 in the service area of any Medicare+Choice plan).”.

31 (2) STUDY.—The Secretary shall conduct a study of
32 an appropriate transition for plans offered under reason-
33 able cost contracts under section 1876 of the Social Secu-
34 rity Act on and after January 1, 2005. Such a transition
35 may take into account whether there are one or more co-
36 ordinated care Medicare+Choice plans being offered in the
37 areas involved. Not later than February 1, 2004, the Sec-

1 retary shall submit to Congress a report on such study and
2 shall include recommendations regarding any changes in
3 the amendment made by paragraph (1) as the Secretary
4 determines to be appropriate.

5 (b) EXTENSION OF SOCIAL HEALTH MAINTENANCE OR-
6 GANIZATION (SHMO) DEMONSTRATION PROJECT.—

7 (1) IN GENERAL.—Section 4018(b)(1) of the Omnibus
8 Budget Reconciliation Act of 1987 is amended by striking
9 “the date that is 30 months after the date that the Sec-
10 retary submits to Congress the report described in section
11 4014(c) of the Balanced Budget Act of 1997” and insert-
12 ing “December 31, 2004”.

13 (2) SHMOS OFFERING MEDICARE+CHOICE PLANS.—
14 Nothing in such section 4018 shall be construed as pre-
15 venting a social health maintenance organization from of-
16 fering a Medicare+Choice plan under part C of title XVIII
17 of the Social Security Act.

18 **SEC. 205. CONTINUOUS OPEN ENROLLMENT AND**
19 **DISENROLLMENT.**

20 (a) IN GENERAL.—Section 1851(e)(2) (42 U.S.C. 1395w-
21 21(e)(2)) is amended to read as follows:

22 “(2) CONTINUOUS OPEN ENROLLMENT AND
23 DISENROLLMENT.—Subject to paragraph (5), a
24 Medicare+Choice eligible individual may change the elec-
25 tion under subsection (a)(1) at any time.”.

26 (b) CONFORMING AMENDMENTS.—

27 (1) MEDICARE+CHOICE.—Section 1851(e) (42 U.S.C.
28 1395w-21(e)) is amended—

29 (A) in paragraph (4)—

30 (i) by striking “Effective as of January 1,
31 2002, an” and inserting “An”;

32 (ii) by striking “other than during an annual,
33 coordinated election period”;

34 (iii) by inserting “in a special election period
35 for such purpose” after “make a new election
36 under this section”; and

37 (iv) by striking the second sentence; and

1 (B) in paragraphs (5)(B) and (6)(A), by striking
2 “the first sentence of”.

3 (2) PERMITTING ENROLLMENT IN MEDIGAP WHEN
4 M+C PLANS REDUCE BENEFITS OR WHEN PROVIDER
5 LEAVES A M+C PLAN.—

6 (A) IN GENERAL.—Clause (ii) of section
7 1882(s)(3)(B) (42 U.S.C. 1395ss(s)(3)(B)) is
8 amended—

9 (i) by inserting “(I)” after “(ii)”;

10 (ii) by striking “under the first sentence of”
11 each place it appears and inserting “during a spe-
12 cial election period provided for under”;

13 (iii) by inserting “the circumstances described
14 in subclause (II) are present or” before “there are
15 circumstances”; and

16 (iv) by adding at the end the following new
17 subclause:

18 “(II) The circumstances described in this subclause
19 are, with respect to an individual enrolled in a
20 Medicare+Choice plan, a reduction in benefits (including
21 an increase in cost-sharing) offered under the
22 Medicare+Choice plan from the previous year or a provider
23 of services or physician who serves the individual no longer
24 participating in the plan (other than because of good cause
25 relating to quality of care under the plan).”.

26 (B) CONFORMING AMENDMENT.—Clause (iii) of
27 such section is amended—

28 (i) by inserting “the circumstances described
29 in clause (ii)(II) are met or” after “policy described
30 in subsection (t), and”; and

31 (ii) by striking “under the first sentence of”
32 and inserting “during a special election period pro-
33 vided for under”.

34 (c) EFFECTIVE DATE.—The amendments made by this
35 section shall take effect on January 1, 2003, and shall apply
36 to reductions in benefits and changes in provider participation
37 occurring on or after such date.

1 **SEC. 206. LIMITATION ON MEDICARE+CHOICE COST-**
2 **SHARING.**

3 (a) IN GENERAL.—Section 1852(a) (42 U.S.C. 1395w–
4 22(a)) is amended by adding at the end the following new para-
5 graph:

6 “(6) LIMITATION ON COST-SHARING.—

7 “(A) IN GENERAL.—Subject to subparagraph (B),
8 in no case shall the cost-sharing with respect to an
9 item or service under a Medicare+Choice plan exceed
10 the cost-sharing otherwise applicable under parts A and
11 B to an individual who is not enrolled in a
12 Medicare+Choice plan under this part.

13 “(B) PERMITTING FLAT COPAYMENTS.—Subpara-
14 graph (A) shall not be construed as preventing the ap-
15 plication of flat dollar copayment amounts (in place of
16 a percentage coinsurance), such as a fixed copayment
17 for a doctor’s visit, so long as such amounts are rea-
18 sonable and appropriate and do not adversely affect ac-
19 cess to items and services (as determined by the Sec-
20 retary).”.

21 (b) EFFECTIVE DATE.—The amendment made by sub-
22 section (a) shall apply as of January 1, 2003.

23 **SEC. 207. EXTENSION OF MUNICIPAL HEALTH SERVICE**
24 **DEMONSTRATION PROJECTS.**

25 The last sentence of section 9215(a) of the Consolidated
26 Omnibus Budget Reconciliation Act of 1985 (42 U.S.C.
27 1395b–1 note), as previously amended, is amended by striking
28 “December 31, 2004, but only with respect to” and all that fol-
29 lows and inserting “December 31, 2009, but only with respect
30 to individuals who reside in the city in which the project is op-
31 erated and so long as the total number of individuals partici-
32 pating in the project does not exceed the number of such indi-
33 viduals participating as of January 1, 1996.”.

**TITLE III—RURAL HEALTH CARE
IMPROVEMENTS**

**SEC. 301. REFERENCE TO FULL MARKET BASKET IN-
CREASE FOR SOLE COMMUNITY HOSPITALS.**

For provision eliminating any reduction from full market basket in the update for inpatient hospital services for sole community hospitals, see section 401.

**SEC. 302. ENHANCED DISPROPORTIONATE SHARE HOS-
PITAL (DSH) TREATMENT FOR RURAL HOS-
PITALS AND URBAN HOSPITALS WITH
FEWER THAN 100 BEDS.**

(a) BLENDING OF PAYMENT AMOUNTS.—

(1) IN GENERAL.—Section 1886(d)(5)(F) (42 U.S.C. 1395ww(d)(5)(F)) is amended by adding at the end the following new clause:

“(xiv)(I) In the case of discharges in a fiscal year beginning on or after October 1, 2002, subject to subclause (II), there shall be substituted for the disproportionate share adjustment percentage otherwise determined under clause (iv) (other than subclause (I)) or under clause (viii), (x), (xi), (xii), or (xiii), the old blend proportion (specified under subclause (III)) of the disproportionate share adjustment percentage otherwise determined under the respective clause and 100 percent minus such old blend proportion of the disproportionate share adjustment percentage determined under clause (vii) (relating to large, urban hospitals).

“(II) Under subclause (I), the disproportionate share adjustment percentage shall not exceed 10 percent for a hospital that is not classified as a rural referral center under subparagraph (C).

“(III) For purposes of subclause (I), the old blend proportion for fiscal year 2003 is $66\frac{2}{3}$ percent, for fiscal year 2004 is $33\frac{1}{3}$ percent subsequent year, and for each fiscal year beginning with 2005 is 0 percent.”.

(2) CONFORMING AMENDMENTS.—Section 1886(d)(5)(F) (42 U.S.C. 1395ww(d)(5)(F)) is amended—

1 (A) in each of subclauses (II), (III), (IV), (V), and
2 (VI) of clause (iv), by inserting “subject to clause (xiv)
3 and” before “for discharges occurring”;

4 (B) in clause (viii), by striking “The formula” and
5 inserting “Subject to clause (xiv), the formula”; and

6 (C) in each of clauses (x), (xi), (xii), and (xiii), by
7 striking “For purposes” and inserting “Subject to
8 clause (xiv), for purposes”.

9 (b) EFFECTIVE DATE.—The amendments made by this
10 section shall apply with respect to discharges occurring on or
11 after October 1, 2002.

12 **SEC. 303. 2-YEAR PHASED-IN INCREASE IN THE STAND-**
13 **ARDIZED AMOUNT IN RURAL AND SMALL**
14 **URBAN AREAS TO ACHIEVE A SINGLE, UNI-**
15 **FORM STANDARDIZED AMOUNT.**

16 Section 1886(d)(3)(A)(iv) (42 U.S.C.
17 1395ww(d)(3)(A)(iv)) is amended—

18 (1) by striking “(iv) For discharges” and inserting
19 “(iv)(I) Subject to the succeeding provisions of this clause,
20 for discharges”; and

21 (2) by adding at the end the following new subclauses:

22 “(II) For discharges occurring during fiscal year
23 2003, the average standardized amount for hospitals lo-
24 cated other than in a large urban area shall be increased
25 by ½ of the difference between the average standardized
26 amount determined under subclause (I) for hospitals lo-
27 cated in large urban areas for such fiscal year and such
28 amount determined (without regard to this subclause) for
29 other hospitals for such fiscal year.

30 “(III) For discharges occurring in a fiscal year begin-
31 ning with fiscal year 2004, the Secretary shall compute an
32 average standardized amount for hospitals located in any
33 area within the United States and within each region equal
34 to the average standardized amount computed for the pre-
35 vious fiscal year under this subparagraph for hospitals lo-
36 cated in a large urban area (or, beginning with fiscal year
37 2005, for hospitals located in any area) increased by the

1 applicable percentage increase under subsection
2 (b)(3)(B)(i).”.

3 **SEC. 304. MORE FREQUENT UPDATE IN WEIGHTS USED**
4 **IN HOSPITAL MARKET BASKET.**

5 (a) MORE FREQUENT UPDATES IN WEIGHTS.—After re-
6 vising the weights used in the hospital market basket under
7 section 1886(b)(3)(B)(iii) of the Social Security Act (42 U.S.C.
8 1395ww(b)(3)(B)(iii)) to reflect the most current data avail-
9 able, the Secretary shall establish a frequency for revising such
10 weights in such market basket to reflect the most current data
11 available more frequently than once every 5 years.

12 (b) REPORT.—Not later than October 1, 2003, the Sec-
13 retary shall submit a report to Congress on the frequency es-
14 tablished under subsection (a), including an explanation of the
15 reasons for, and options considered, in determining such fre-
16 quency.

17 **SEC. 305. IMPROVEMENTS TO CRITICAL ACCESS HOS-**
18 **PITAL PROGRAM.**

19 (a) REINSTATEMENT OF PERIODIC INTERIM PAYMENT
20 (PIP).—Section 1815(e)(2) (42 U.S.C. 1395g(e)(2)) is
21 amended—

22 (1) by striking “and” at the end of subparagraph (C);

23 (2) by adding “and” at the end of subparagraph (D);

24 and

25 (3) by inserting after subparagraph (D) the following
26 new subparagraph:

27 “(E) inpatient critical access hospital services;”.

28 (b) CONDITION FOR APPLICATION OF SPECIAL PHYSICIAN
29 PAYMENT ADJUSTMENT.—Section 1834(g)(2) (42 U.S.C.
30 1395m(g)(2)) is amended by adding after and below subpara-
31 graph (B) the following:

32 “The Secretary may not require, as a condition for apply-
33 ing subparagraph (B) with respect to a critical access hos-
34 pital, that each physician providing professional services in
35 the hospital must assign billing rights with respect to such
36 services, except that such subparagraph shall not apply to

1 those physicians who have not assigned such billing
2 rights.”.

3 (c) FLEXIBILITY IN BED LIMITATION FOR HOSPITALS
4 WITH STRONG SEASONAL CENSUS FLUCTUATIONS.—Section
5 1820 (42 U.S.C. 1395i–4) is amended—

6 (1) in subsection (c)(2)(B)(iii), by inserting “subject
7 to paragraph (3)” after “(iii) provides”;

8 (2) by adding at the end of subsection (c) the fol-
9 lowing new paragraph:

10 “(3) INCREASE IN MAXIMUM NUMBER OF BEDS FOR
11 HOSPITALS WITH STRONG SEASONAL CENSUS FLUCTUA-
12 TIONS.—

13 “(A) IN GENERAL.—In the case of a hospital that
14 demonstrates that it meets the standards established
15 under subparagraph (B), the bed limitations otherwise
16 applicable under paragraph (2)(B)(iii) and subsection
17 (f) shall be increased by 5 beds.

18 “(B) STANDARDS.—The Secretary shall specify
19 standards for determining whether a critical access hos-
20 pital has sufficiently strong seasonal variations in pa-
21 tient admissions to justify the increase in bed limitation
22 provided under subparagraph (A).”; and

23 (3) in subsection (f), by adding at the end the fol-
24 lowing new sentence: “The limitations in numbers of beds
25 under the first sentence are subject to adjustment under
26 subsection (c)(3).”.

27 (d) 5-YEAR EXTENSION OF THE AUTHORIZATION FOR AP-
28 PROPRIATIONS FOR GRANT PROGRAM.—Section 1820(j) (42
29 U.S.C. 1395i–4(j)) is amended by striking “through 2002” and
30 inserting “through 2007”.

31 (e) PROHIBITION OF RETROACTIVE RECOUPMENT.—The
32 Secretary shall not recoup (or otherwise seek to recover) over-
33 payments made for outpatient critical access hospital services
34 under part B of title XVIII of the Social Security Act, for serv-
35 ices furnished in cost reporting periods that began before Octo-
36 ber 1, 2002, insofar as such overpayments are attributable to
37 payment being based on 80 percent of reasonable costs (instead

1 of 100 percent of reasonable costs minus 20 percent of
2 charges).

3 (f) EFFECTIVE DATES.—

4 (1) REINSTATEMENT OF PIP.—The amendments made
5 by subsection (a) shall apply to payments made on or after
6 January 1, 2003.

7 (2) PHYSICIAN PAYMENT ADJUSTMENT CONDITION.—
8 The amendment made by subsection (b) shall be effective
9 as if included in the enactment of section 403(d) of the
10 Medicare, Medicaid, and SCHIP Balanced Budget Refine-
11 ment Act of 1999 (113 Stat. 1501A–371).

12 (3) FLEXIBILITY IN BED LIMITATION.—The amend-
13 ments made by subsection (c) shall apply to designations
14 made on or after January 1, 2003, but shall not apply to
15 critical access hospitals that were designated as of such
16 date.

17 **SEC. 306. EXTENSION OF TEMPORARY INCREASE FOR**
18 **HOME HEALTH SERVICES FURNISHED IN A**
19 **RURAL AREA.**

20 (a) IN GENERAL.—Section 508(a) of BIPA (114 Stat.
21 2763A–533) is amended—

22 (1) by striking “24-MONTH INCREASE BEGINNING
23 APRIL 1, 2001” and inserting “IN GENERAL”; and

24 (2) by striking “April 1, 2003” and inserting “Janu-
25 ary 1, 2005”.

26 (b) CONFORMING AMENDMENT.—Section 547(e)(2) of
27 BIPA (114 Stat. 2763A–553) is amended by striking “the pe-
28 riod beginning on April 1, 2001, and ending on September 30,
29 2002,” and inserting “a period under such section”.

30 **SEC. 307. REFERENCE TO 10 PERCENT INCREASE IN**
31 **PAYMENT FOR HOSPICE CARE FURNISHED**
32 **IN A FRONTIER AREA AND RURAL HOSPICE**
33 **DEMONSTRATION PROJECT.**

34 For—

35 (1) provision of 10 percent increase in payment for
36 hospice care furnished in a frontier area, see section 422;
37 and

1 (2) provision of a rural hospice demonstration project,
2 see section 423.

3 **SEC. 308. REFERENCE TO PRIORITY FOR HOSPITALS LO-**
4 **CATED IN RURAL OR SMALL URBAN AREAS**
5 **IN REDISTRIBUTION OF UNUSED GRADUATE**
6 **MEDICAL EDUCATION RESIDENCIES.**

7 For provision providing priority for hospitals located in
8 rural or small urban areas in redistribution of unused graduate
9 medical education residencies, see section 611.

10 **SEC. 309. GAO STUDY OF GEOGRAPHIC DIFFERENCES IN**
11 **PAYMENTS FOR PHYSICIANS' SERVICES.**

12 (a) STUDY.—The Comptroller General of the United
13 States shall conduct a study of differences in payment amounts
14 under the physician fee schedule under section 1848 of the So-
15 cial Security Act (42 U.S.C. 1395w-4) for physicians' services
16 in different geographic areas. Such study shall include—

17 (1) an assessment of the validity of the geographic ad-
18 justment factors used for each component of the fee sched-
19 ule;

20 (2) an evaluation of the measures used for such ad-
21 justment, including the frequency of revisions; and

22 (3) an evaluation of the methods used to determine
23 professional liability insurance costs used in computing the
24 malpractice component, including a review of increases in
25 professional liability insurance premiums and variation in
26 such increases by State and physician specialty and meth-
27 ods used to update the geographic cost of practice index
28 and relative weights for the malpractice component.

29 (b) REPORT.—Not later than 1 year after the date of the
30 enactment of this Act, the Comptroller General shall submit to
31 Congress a report on the study conducted under subsection (a).
32 The report shall include recommendations regarding the use of
33 more current data in computing geographic cost of practice in-
34 dices as well as the use of data directly representative of physi-
35 cians' costs (rather than proxy measures of such costs).

SEC. 310. PROVIDING SAFE HARBOR FOR CERTAIN COLLABORATIVE EFFORTS THAT BENEFIT MEDICALLY UNDERSERVED POPULATIONS.

(a) IN GENERAL.—Section 1128B(b)(3) (42 U.S.C. 1320a–7(b)(3)), as amended by section 101(b)(2), is amended—

(1) in subparagraph (F), by striking “and” after the semicolon at the end;

(2) in subparagraph (G), by striking the period at the end and inserting “; and”; and

(3) by adding at the end the following new subparagraph:

“(H) any remuneration between a public or non-profit private health center entity described under clause (i) or (ii) of section 1905(l)(2)(B) and any individual or entity providing goods, items, services, donations or loans, or a combination thereof, to such health center entity pursuant to a contract, lease, grant, loan, or other agreement, if such agreement contributes to the ability of the health center entity to maintain or increase the availability, or enhance the quality, of services provided to a medically underserved population served by the health center entity.”.

(b) RULEMAKING FOR EXCEPTION FOR HEALTH CENTER ENTITY ARRANGEMENTS.—

(1) ESTABLISHMENT.—

(A) IN GENERAL.—The Secretary of Health and Human Services (in this subsection referred to as the “Secretary”) shall establish, on an expedited basis, standards relating to the exception described in section 1128B(b)(3)(H) of the Social Security Act, as added by subsection (a), for health center entity arrangements to the antikickback penalties.

(B) FACTORS TO CONSIDER.—The Secretary shall consider the following factors, among others, in establishing standards relating to the exception for health center entity arrangements under subparagraph (A):

1 (i) Whether the arrangement between the
2 health center entity and the other party results in
3 savings of Federal grant funds or increased reve-
4 nues to the health center entity.

5 (ii) Whether the arrangement between the
6 health center entity and the other party restricts or
7 limits a patient's freedom of choice.

8 (iii) Whether the arrangement between the
9 health center entity and the other party protects a
10 health care professional's independent medical
11 judgment regarding medically appropriate treat-
12 ment.

13 The Secretary may also include other standards and
14 criteria that are consistent with the intent of Congress
15 in enacting the exception established under this section.

16 (2) INTERIM FINAL EFFECT.—No later than 180 days
17 after the date of enactment of this Act, the Secretary shall
18 publish a rule in the Federal Register consistent with the
19 factors under paragraph (1)(B). Such rule shall be effective
20 and final immediately on an interim basis, subject to such
21 change and revision, after public notice and opportunity
22 (for a period of not more than 60 days) for public com-
23 ment, as is consistent with this subsection.

24 **SEC. 311. RELIEF FOR CERTAIN NON-TEACHING HOS-**
25 **PITALS.**

26 (a) IN GENERAL.—In the case of a non-teaching hospital
27 that meets the condition of subsection (b), for its cost reporting
28 period beginning in each of fiscal years 2003, 2004, and 2005
29 the amount of payment made to the hospital under section
30 1886(d) of the Social Security Act for discharges occurring
31 during such fiscal year only shall be increased as though the
32 applicable percentage increase (otherwise applicable to dis-
33 charges occurring during such fiscal year under section
34 1886(b)(3)(B)(i) of the Social Security Act (42 U.S.C.
35 1395ww(b)(3)(B)(i)) had been increased by 5 percentage
36 points. The previous sentence shall be applied for each such fis-
37 cal year separately without regard to its application in a pre-

1 vious fiscal year and shall not affect payment for discharges for
2 any hospital occurring during a fiscal year after fiscal year
3 2005.

4 (b) CONDITION.—A non-teaching hospital meets the condi-
5 tion of this paragraph if—

6 (1) it is located in a rural area and the amount of the
7 aggregate payments under subsection (d) of such section
8 for non-teaching hospitals located in rural areas in the
9 State for their cost reporting periods beginning during fis-
10 cal year 1999 is less than the aggregate allowable operating
11 costs of inpatient hospital services (as defined in section
12 1886(a)(4) of such Act) for all such hospitals in such areas
13 in such State with respect to such cost reporting periods;
14 or

15 (2) it is located in an urban area and the amount of
16 the aggregate payments under subsection (d) of such sec-
17 tion for non-teaching hospitals located in urban areas in
18 the State for their cost reporting periods beginning during
19 fiscal year 1999 is less than 103 percent of the aggregate
20 allowable operating costs of inpatient hospital services (as
21 defined in section 1886(a)(4) of such Act) for all such hos-
22 pitals in such areas in such State with respect to such cost
23 reporting periods.

24 The amounts under paragraphs (1) and (2) shall be determined
25 by the Secretary of Health and Human Services based on data
26 of the Medicare Payment Advisory Commission.

27 (c) DEFINITIONS.—For purposes of this section:

28 (1) NON-TEACHING HOSPITAL.—The term “non-teach-
29 ing hospital” means, for a cost reporting period, a sub-
30 section (d) hospital (as defined in section 1886(d)(1)(B) of
31 the Social Security Act, 42 U.S.C. 1395ww(d)(1)(B))) that
32 is not receiving any additional payment under section
33 1886(d)(5)(B) of such Act (42 U.S.C. 1395ww(d)(5)(B))
34 or a payment under section 1886(h) of such Act (42 U.S.C.
35 1395ww(h)) for discharges occurring during the period.

1 (2) RURAL; URBAN.—The terms “rural” and “urban”
2 have the meanings given such terms for purposes of section
3 1886(d) of the Social Security Act (42 U.S.C. 1395ww(d)).

4 **TITLE IV—PROVISIONS RELATING**
5 **TO PART A**
6 **Subtitle A—Inpatient Hospital**
7 **Services**

8 **SEC. 401. REVISION OF ACUTE CARE HOSPITAL PAY-**
9 **MENT UPDATES.**

10 Subclause (XVIII) of section 1886(b)(3)(B)(i) (42 U.S.C.
11 1395ww(b)(3)(B)(i)) is amended to read as follows:

12 “(XVIII) for fiscal year 2003, the market basket per-
13 centage increase for sole community hospitals and such in-
14 crease minus 0.25 percentage points for other hospitals,
15 and”.

16 **SEC. 402. FREEZE IN LEVEL OF ADJUSTMENT FOR INDI-**
17 **RECT COSTS OF MEDICAL EDUCATION (IME)**
18 **THROUGH FISCAL YEAR 2007.**

19 Section 1886(d)(5)(B)(ii) (42 U.S.C. 1395ww(d)(5)(B)(ii))
20 is amended—

21 (1) in subclause (VI), by inserting “and each suc-
22 ceeding fiscal year through fiscal year 2007” after “2002”;
23 and

24 (2) in subclause (VII), by striking “2002” and insert-
25 ing “2007”.

26 **SEC. 403. RECOGNITION OF NEW MEDICAL TECH-**
27 **NOLOGIES UNDER INPATIENT HOSPITAL**
28 **PPS.**

29 (a) IMPROVING TIMELINESS OF DATA COLLECTION.—Sec-
30 tion 1886(d)(5)(K) (42 U.S.C. 1395ww(d)(5)(K)) is amended
31 by adding at the end the following new clause:

32 “(vii) Under the mechanism under this subparagraph, the
33 Secretary shall provide for the addition of new diagnosis and
34 procedure codes in April 1 of each year, but the addition of
35 such codes shall not require the Secretary to adjust the pay-
36 ment (or diagnosis-related group classification) under this sub-
37 section until the fiscal year that begins after such date.”.

1 (b) ELIGIBILITY STANDARD.—

2 (1) MINIMUM PERIOD FOR RECOGNITION OF NEW
3 TECHNOLOGIES.—Section 1886(d)(5)(K)(vi) (42 U.S.C.
4 1395ww(d)(5)(K)(vi)) is amended—

5 (A) by inserting “(I)” after “(vi)”; and

6 (B) by adding at the end the following new sub-
7 clause:

8 “(II) Under such criteria, a service or technology shall not
9 be denied treatment as a new service or technology on the basis
10 of the period of time in which the service or technology has
11 been in use if such period ends before the end of the 2-to-3-
12 year period that begins on the effective date of implementation
13 of a code under ICD–9–CM (or a successor coding method-
14 ology) that enables the identification of a significant sample of
15 specific discharges in which the service or technology has been
16 used.”.

17 (2) ADJUSTMENT OF THRESHOLD.—Section
18 1886(d)(5)(K)(ii)(I) (42 U.S.C. 1395ww(d)(5)(K)(ii)(I)) is
19 amended by inserting “(applying a threshold specified by
20 the Secretary that is the lesser of 50 percent of the na-
21 tional average standardized amount for operating costs of
22 inpatient hospital services for all hospitals and all diag-
23 nosis-related groups or one standard deviation for the diag-
24 nosis-related group involved)” after “is inadequate”.

25 (3) CRITERION FOR SUBSTANTIAL IMPROVEMENT.—
26 Section 1886(d)(5)(K)(vi) (42 U.S.C.
27 1395ww(d)(5)(K)(vi)), as amended by paragraph (1), is
28 further amended by adding at the end the following sub-
29 clause:

30 “(III) The Secretary shall by regulation provide for fur-
31 ther clarification of the criteria applied to determine whether
32 a new service or technology represents an advance in medical
33 technology that substantially improves the diagnosis or treat-
34 ment of beneficiaries. Under such criteria, in determining
35 whether a new service or technology represents an advance in
36 medical technology that substantially improves the diagnosis or
37 treatment of beneficiaries, the Secretary shall deem a service

1 or technology as meeting such requirement if the service or
2 technology is a drug or biological that is designated under sec-
3 tion 506 or 526 of the Federal Food, Drug, and Cosmetic Act,
4 approved under section 314.510 or 601.41 of title 21, Code of
5 Federal Regulations, or designated for priority review when the
6 marketing application for such drug or biological was filed or
7 is a medical device for which an exemption has been granted
8 under section 520(m) of such Act, or for which priority review
9 has been provided under section 515(d)(5) of such Act.”.

10 (4) PROCESS FOR PUBLIC INPUT.—Section
11 1886(d)(5)(K) (42 U.S.C. 1395ww(d)(5)(K)), as amended
12 by paragraph (1), is amended—

13 (A) in clause (i), by adding at the end the fol-
14 lowing: “Such mechanism shall be modified to meet the
15 requirements of clause (viii).”; and

16 (B) by adding at the end the following new clause:

17 “(viii) The mechanism established pursuant to clause (i)
18 shall be adjusted to provide, before publication of a proposed
19 rule, for public input regarding whether a new service or tech-
20 nology not described in the second sentence of clause (vi)(III)
21 represents an advance in medical technology that substantially
22 improves the diagnosis or treatment of beneficiaries as follows:

23 “(I) The Secretary shall make public and periodically
24 update a list of all the services and technologies for which
25 an application for additional payment under this subpara-
26 graph is pending.

27 “(II) The Secretary shall accept comments, rec-
28 ommendations, and data from the public regarding whether
29 the service or technology represents a substantial improve-
30 ment.

31 “(III) The Secretary shall provide for a meeting at
32 which organizations representing hospitals, physicians,
33 medicare beneficiaries, manufacturers, and any other inter-
34 ested party may present comments, recommendations, and
35 data to the clinical staff of the Centers for Medicare &
36 Medicaid Services before publication of a notice of proposed

1 rulemaking regarding whether service or technology rep-
2 resents a substantial improvement.”.

3 (c) PREFERENCE FOR USE OF DRG ADJUSTMENT.—Sec-
4 tion 1886(d)(5)(K) (42 U.S.C. 1395ww(d)(5)(K)) is further
5 amended by adding at the end the following new clause:

6 “(ix) Before establishing any add-on payment under this
7 subparagraph with respect to a new technology, the Secretary
8 shall seek to identify one or more diagnosis-related groups as-
9 sociated with such technology, based on similar clinical or ana-
10 tomical characteristics and the cost of the technology. Within
11 such groups the Secretary shall assign an eligible new tech-
12 nology into a diagnosis-related group where the average costs
13 of care most closely approximate the costs of care of using the
14 new technology. In such case, no add-on payment under this
15 subparagraph shall be made with respect to such new tech-
16 nology and this clause shall not affect the application of para-
17 graph (4)(C)(iii).”.

18 (d) IMPROVEMENT IN PAYMENT FOR NEW TECH-
19 NOLOGY.—Section 1886(d)(5)(K)(ii)(III) (42 U.S.C.
20 1395ww(d)(5)(K)(ii)(III)) is amended by inserting after “the
21 estimated average cost of such service or technology” the fol-
22 lowing: “(based on the marginal rate applied to costs under
23 subparagraph (A))”.

24 (e) EFFECTIVE DATE.—

25 (1) IN GENERAL.—The Secretary shall implement the
26 amendments made by this section so that they apply to
27 classification for fiscal years beginning with fiscal year
28 2004.

29 (2) RECONSIDERATIONS OF APPLICATIONS FOR FISCAL
30 YEAR 2003 THAT ARE DENIED.—In the case of an applica-
31 tion for a classification of a medical service or technology
32 as a new medical service or technology under section
33 1886(d)(5)(K) of the Social Security Act (42 U.S.C.
34 1395ww(d)(5)(K)) that was filed for fiscal year 2003 and
35 that is denied—

1 (A) the Secretary shall automatically reconsider
2 the application as an application for fiscal year 2004
3 under the amendments made by this section; and

4 (B) the maximum time period otherwise permitted
5 for such classification of the service or technology shall
6 be extended by 12 months.

7 **SEC. 404. PHASE-IN OF FEDERAL RATE FOR HOSPITALS**
8 **IN PUERTO RICO.**

9 Section 1886(d)(9) (42 U.S.C. 1395ww(d)(9)) is
10 amended—

11 (1) in subparagraph (A)—

12 (A) in clause (i), by striking “for discharges begin-
13 ning on or after October 1, 1997, 50 percent (and for
14 discharges between October 1, 1987, and September
15 30, 1997, 75 percent)” and inserting “the applicable
16 Puerto Rico percentage (specified in subparagraph
17 (E))”; and

18 (B) in clause (ii), by striking “for discharges be-
19 ginning in a fiscal year beginning on or after October
20 1, 1997, 50 percent (and for discharges between Octo-
21 ber 1, 1987, and September 30, 1997, 25 percent)”
22 and inserting “the applicable Federal percentage (spec-
23 ified in subparagraph (E))”; and

24 (2) by adding at the end the following new subpara-
25 graph:

26 “(E) For purposes of subparagraph (A), for discharges
27 occurring—

28 “(i) between October 1, 1987, and September 30,
29 1997, the applicable Puerto Rico percentage is 75 percent
30 and the applicable Federal percentage is 25 percent;

31 “(ii) on or after October 1, 1997, and before October
32 1, 2003, the applicable Puerto Rico percentage is 50 per-
33 cent and the applicable Federal percentage is 50 percent;

34 “(iii) during fiscal year 2004, the applicable Puerto
35 Rico percentage is 45 percent and the applicable Federal
36 percentage is 55 percent;

1 “(iv) during fiscal year 2005, the applicable Puerto
2 Rico percentage is 40 percent and the applicable Federal
3 percentage is 60 percent;

4 “(v) during fiscal year 2006, the applicable Puerto
5 Rico percentage is 35 percent and the applicable Federal
6 percentage is 65 percent;

7 “(vi) during fiscal year 2007, the applicable Puerto
8 Rico percentage is 30 percent and the applicable Federal
9 percentage is 70 percent; and

10 “(vii) on or after October 1, 2007, the applicable
11 Puerto Rico percentage is 25 percent and the applicable
12 Federal percentage is 75 percent.”.

13 **SEC. 405. REFERENCE TO PROVISION RELATING TO EN-**
14 **HANCED DISPROPORTIONATE SHARE HOS-**
15 **PITAL (DSH) PAYMENTS FOR RURAL HOS-**
16 **PITALS AND URBAN HOSPITALS WITH**
17 **FEWER THAN 100 BEDS.**

18 For provision enhancing disproportionate share hospital
19 (DSH) treatment for rural hospitals and urban hospitals with
20 fewer than 100 beds, see section 302.

21 **SEC. 406. REFERENCE TO PROVISION RELATING TO 2-**
22 **YEAR PHASED-IN INCREASE IN THE STAND-**
23 **ARDIZED AMOUNT IN RURAL AND SMALL**
24 **URBAN AREAS TO ACHIEVE A SINGLE, UNI-**
25 **FORM STANDARDIZED AMOUNT.**

26 For provision phasing in over a 2-year period an increase
27 in the standardized amount for rural and small urban areas to
28 achieve a single, uniform, standardized amount, see section
29 303.

30 **SEC. 407. REFERENCE TO PROVISION FOR MORE FRE-**
31 **QUENT UPDATES IN THE WEIGHTS USED IN**
32 **HOSPITAL MARKET BASKET.**

33 For provision providing for more frequent updates in the
34 weights used in hospital market basket, see section 304.

35 **SEC. 408. REFERENCE TO PROVISION MAKING IMPROVE-**
36 **MENTS TO CRITICAL ACCESS HOSPITAL PRO-**
37 **GRAM.**

38 For provision providing making improvements to critical
39 access hospital program, see section 305.

1 **Subtitle B—Skilled Nursing Facility**
2 **Services**

3 **SEC. 411. PAYMENT FOR COVERED SKILLED NURSING**
4 **FACILITY SERVICES.**

5 (a) 5-YEAR EXTENSION OF TEMPORARY INCREASE IN
6 NURSING COMPONENT OF PPS FEDERAL RATE.—Section
7 312(a) of BIPA is amended by striking “, and before October
8 1, 2002” and inserting “and before October 1, 2007”.

9 (b) ADJUSTMENT TO RUGS FOR AIDS RESIDENTS.—

10 (1) IN GENERAL.—Paragraph (12) of section 1888(e)
11 (42 U.S.C. 1395yy(e)) is amended to read as follows:

12 “(12) ADJUSTMENT FOR RESIDENTS WITH AIDS.—

13 “(A) IN GENERAL.—Subject to subparagraph (B),
14 in the case of a resident of a skilled nursing facility
15 who is afflicted with acquired immune deficiency syn-
16 drome (AIDS), the per diem amount of payment other-
17 wise applicable shall be increased by 128 percent to re-
18 flect increased costs associated with such residents.

19 “(B) SUNSET.—Subparagraph (A) shall not apply
20 on and after such date as the Secretary certifies that
21 there is an appropriate adjustment in the case mix
22 under paragraph (4)(G)(i) to compensate for the in-
23 creased costs associated with residents described in
24 such subparagraph.”.

25 (2) EFFECTIVE DATE.—The amendment made by
26 paragraph (1) shall apply to services furnished on or after
27 October 1, 2003.

28 **Subtitle C—Hospice**

29 **SEC. 421. COVERAGE OF HOSPICE CONSULTATION SERV-**
30 **ICES.**

31 (a) COVERAGE OF HOSPICE CONSULTATION SERVICES.—
32 Section 1812(a) (42 U.S.C. 1395d(a)) is amended—

33 (1) by striking “and” at the end of paragraph (3);

34 (2) by striking the period at the end of paragraph (4)
35 and inserting “; and”; and

1 (3) by inserting after paragraph (4) the following new
2 paragraph:

3 “(5) for individuals who are terminally ill, have not
4 made an election under subsection (d)(1), and have not
5 previously received services under this paragraph, services
6 that are furnished by a physician who is the medical direc-
7 tor or an employee of a hospice program and that consist
8 of—

9 “(A) an evaluation of the individual’s need for
10 pain and symptom management;

11 “(B) counseling the individual with respect to end-
12 of-life issues and care options; and

13 “(C) advising the individual regarding advanced
14 care planning.”.

15 (b) PAYMENT.—Section 1814(i) (42 U.S.C. 1395f(i)) is
16 amended by adding at the end the following new paragraph:

17 “(4) The amount paid to a hospice program with respect
18 to the services under section 1812(a)(5) for which payment
19 may be made under this part shall be equal to an amount
20 equivalent to the amount established for an office or other out-
21 patient visit for evaluation and management associated with
22 presenting problems of moderate severity under the fee sched-
23 ule established under section 1848(b), other than the portion
24 of such amount attributable to the practice expense compo-
25 nent.”.

26 (c) CONFORMING AMENDMENT.—Section
27 1861(dd)(2)(A)(i) (42 U.S.C. 1395x(dd)(2)(A)(i)) is amended
28 by inserting before the comma at the end the following: “and
29 services described in section 1812(a)(5)”.

30 (d) EFFECTIVE DATE.—The amendments made by this
31 section shall apply to services provided by a hospice program
32 on or after January 1, 2004.

1 **SEC. 422. 10 PERCENT INCREASE IN PAYMENT FOR HOS-**
2 **PICE CARE FURNISHED IN A FRONTIER**
3 **AREA.**

4 (a) IN GENERAL.—Section 1814(i)(1) (42 U.S.C.
5 1395f(i)(1)) is amended by adding at the end the following new
6 subparagraph:

7 “(D) With respect to hospice care furnished in a frontier
8 area on or after January 1, 2003, and before January 1, 2008,
9 the payment rates otherwise established for such care shall be
10 increased by 10 percent. For purposes of this subparagraph,
11 the term ‘frontier area’ means a county in which the population
12 density is less than 7 persons per square mile.”.

13 (b) REPORT ON COSTS.—Not later than January 1, 2007,
14 the Comptroller General of the United States shall submit to
15 Congress a report on the costs of furnishing hospice care in
16 frontier areas. Such report shall include recommendations re-
17 garding the appropriateness of extending, and modifying, the
18 payment increase provided under the amendment made by sub-
19 section (a).

20 **SEC. 423. RURAL HOSPICE DEMONSTRATION PROJECT.**

21 (a) IN GENERAL.—The Secretary shall conduct a dem-
22 onstration project for the delivery of hospice care to medicare
23 beneficiaries in rural areas. Under the project medicare bene-
24 ficiaries who are unable to receive hospice care in the home for
25 lack of an appropriate caregiver are provided such care in a fa-
26 cility of 20 or fewer beds which offers, within its walls, the full
27 range of services provided by hospice programs under section
28 1861(dd) of the Social Security Act (42 U.S.C. 1395x(dd)).

29 (b) SCOPE OF PROJECT.—The Secretary shall conduct the
30 project under this section with respect to no more than 3 hos-
31 pice programs over a period of not longer than 5 years each.

32 (c) COMPLIANCE WITH CONDITIONS.—Under the dem-
33 onstration project—

34 (1) the hospice program shall comply with otherwise
35 applicable requirements, except that it shall not be required
36 to offer services outside of the home or to meet the require-

1 ments of section 1861(dd)(2)(A)(iii) of the Social Security
2 Act; and

3 (2) payments for hospice care shall be made at the
4 rates otherwise applicable to such care under title XVIII of
5 such Act.

6 The Secretary may require the program to comply with such
7 additional quality assurance standards for its provision of serv-
8 ices in its facility as the Secretary deems appropriate.

9 (d) REPORT.—Upon completion of the project, the Sec-
10 retary shall submit a report to Congress on the project and
11 shall include in the report recommendations regarding exten-
12 sion of such project to hospice programs serving rural areas.

13 **Subtitle D—Other Provisions**

14 **SEC. 431. DEMONSTRATION PROJECT FOR USE OF RE-** 15 **COVERY AUDIT CONTRACTORS.**

16 (a) IN GENERAL.—The Secretary of Health and Human
17 Services shall conduct a demonstration project under this sec-
18 tion (in this section referred to as the “project”) to dem-
19 onstrate the use of recovery audit contractors under the Medi-
20 care Integrity Program in identifying and recouping overpay-
21 ments under the medicare program for services for which pay-
22 ment is made under part A of title XVIII of the Social Security
23 Act. Under the project—

24 (1) payment may be made to such a contractor on a
25 contingent basis;

26 (2) a percentage of the amount recovered may be re-
27 tained by the Secretary and shall be available to the pro-
28 gram management account of the Centers for Medicare &
29 Medicaid Services; and

30 (3) the Secretary shall examine the efficacy of such
31 use with respect to duplicative payments, accuracy of cod-
32 ing, and other payment policies in which inaccurate pay-
33 ments arise.

34 (b) SCOPE AND DURATION.—The project shall cover at
35 least 2 States and at least 3 contractors and shall last for not
36 longer than 3 years.

1 (c) WAIVER.—The Secretary of Health and Human Serv-
2 ices shall waive such provisions of title XVIII of the Social Se-
3 curity Act as may be necessary to provide for payment for serv-
4 ices under the project in accordance with subsection (a).

5 (d) QUALIFICATIONS OF CONTRACTORS.—

6 (1) IN GENERAL.—The Secretary shall enter into a re-
7 covery audit contract under this section with an entity only
8 if the entity has staff that has knowledge of and experience
9 with the payment rules and regulations under the medicare
10 program or the entity has or will contract with another en-
11 tity that has such knowledgeable and experienced staff.

12 (2) INELIGIBILITY OF CERTAIN CONTRACTORS.—The
13 Secretary may not enter into a recovery audit contract
14 under this section with an entity to the extent that the en-
15 tity is a fiscal intermediary under section 1816 of the So-
16 cial Security Act (42 U.S.C. 1395h), a carrier under sec-
17 tion 1842 of such Act (42 U.S.C. 1395u), or a Medicare
18 Administrative Contractor under section 1874A of such
19 Act, or any other entity that carries out the type of activi-
20 ties with respect to providers of services under part A that
21 would constitute a conflict of interest, as determined by the
22 Secretary.

23 (3) PREFERENCE FOR ENTITIES WITH DEM-
24 ONSTRATED PROFICIENCY WITH PRIVATE INSURERS.—In
25 awarding contracts to recovery audit contractors under this
26 section, the Secretary shall give preference to those entities
27 that the Secretary determines have demonstrated pro-
28 ficiency in recovery audits with private insurers or under
29 the medicaid program under title XIX of such Act.

30 (e) REPORT.—The Secretary of Health and Human Serv-
31 ices shall submit to Congress a report on the project not later
32 than 6 months after the date of its completion. Such reports
33 shall include information on the impact of the project on sav-
34 ings to the medicare program and recommendations on the
35 cost-effectiveness of extending or expanding the project.

**TITLE V—PROVISIONS RELATING
TO PART B
Subtitle A—Physicians’ Services**

**SEC. 501. REVISION OF UPDATES FOR PHYSICIANS’
SERVICES.**

(a) UPDATE FOR 2003 THROUGH 2006.—

(1) IN GENERAL.—Section 1848(d) (42 U.S.C. 1395w-4(d)) is amended by adding at the end the following new paragraphs:

“(5) UPDATE FOR 2003.—The update to the single conversion factor established in paragraph (1)(C) for 2003 is 2 percent.

“(6) SPECIAL RULES FOR UPDATE FOR 2004, 2005, AND 2006.—The following rules apply in determining the update adjustment factors under paragraph (4)(B) for 2004, 2005, and 2006:

“(A) USE OF 2002 DATA IN DETERMINING ALLOWABLE COSTS.—

“(i) The reference in clause (ii)(I) of such paragraph to April 1, 1996, is deemed to be a reference to January 1, 2002.

“(ii) The allowed expenditures for 2002 is deemed to be equal to the actual expenditures for physicians’ services furnished during 2002, as estimated by the Secretary.

“(B) 1 PERCENTAGE POINT INCREASE IN GDP UNDER SGR.—The annual average percentage growth in real gross domestic product per capita under subsection (f)(2)(C) for each of 2003, 2004, 2005, and 2006 is deemed to be increased by 1 percentage point.”.

(2) CONFORMING AMENDMENT.—Paragraph (4)(B) of such section is amended, in the matter before clause (i), by inserting “and paragraph (6)” after “subparagraph (D)”.

(3) NOT TREATED AS CHANGE IN LAW AND REGULATION IN SUSTAINABLE GROWTH RATE DETERMINATION.—

1 The amendments made by this subsection shall not be
2 treated as a change in law for purposes of applying section
3 1848(f)(2)(D) of the Social Security Act (42 U.S.C.
4 1395w-4(f)(2)(D)).

5 (b) USE OF 10-YEAR ROLLING AVERAGE IN COMPUTING
6 GROSS DOMESTIC PRODUCT.—

7 (1) IN GENERAL.—Section 1848(f)(2)(C) (42 U.S.C.
8 1395w-4(f)(2)(C)) is amended—

9 (A) by striking “projected” and inserting “annual
10 average”; and

11 (B) by striking “from the previous applicable pe-
12 riod to the applicable period involved” and inserting
13 “during the 10-year period ending with the applicable
14 period involved”.

15 (2) EFFECTIVE DATE.—The amendment made by
16 paragraph (1) shall apply to computations of the sustain-
17 able growth rate for years beginning with 2002.

18 (c) ELIMINATION OF TRANSITIONAL ADJUSTMENT.—Sec-
19 tion 1848(d)(4)(F) (42 U.S.C. 1395w-4(d)(4)(F)) is amended
20 by striking “subparagraph (A)” and all that follows and insert-
21 ing “subparagraph (A), for each of 2001 and 2002, of -0.2
22 percent.”

23 **SEC. 502. STUDIES ON ACCESS TO PHYSICIANS’ SERV-**
24 **ICES.**

25 (a) GAO STUDY ON BENEFICIARY ACCESS TO PHYSI-
26 CIANS’ SERVICES.—

27 (1) STUDY.—The Comptroller General of the United
28 States shall conduct a study on access of medicare bene-
29 ficiaries to physicians’ services under the medicare pro-
30 gram. The study shall include—

31 (A) an assessment of the use by beneficiaries of
32 such services through an analysis of claims submitted
33 by physicians for such services under part B of the
34 medicare program;

35 (B) an examination of changes in the use by bene-
36 ficiaries of physicians’ services over time;

1 (C) an examination of the extent to which physi-
2 cians are not accepting new medicare beneficiaries as
3 patients.

4 (2) REPORT.—Not later than 18 months after the
5 date of the enactment of this Act, the Comptroller General
6 shall submit to Congress a report on the study conducted
7 under paragraph (1). The report shall include a determina-
8 tion whether—

9 (A) data from claims submitted by physicians
10 under part B of the medicare program indicate poten-
11 tial access problems for medicare beneficiaries in cer-
12 tain geographic areas; and

13 (B) access by medicare beneficiaries to physicians'
14 services may have improved, remained constant, or de-
15 teriorated over time.

16 (b) STUDY AND REPORT ON SUPPLY OF PHYSICIANS.—

17 (1) STUDY.—The Secretary shall request the Institute
18 of Medicine of the National Academy of Sciences to con-
19 duct a study on the adequacy of the supply of physicians
20 (including specialists) in the United States and the factors
21 that affect such supply.

22 (2) REPORT TO CONGRESS.—Not later than 2 years
23 after the date of enactment of this section, the Secretary
24 shall submit to Congress a report on the results of the
25 study described in paragraph (1), including any rec-
26 ommendations for legislation.

27 **SEC. 503. MEDPAC REPORT ON PAYMENT FOR PHYSI-**
28 **CIAANS' SERVICES.**

29 Not later than 1 year after the date of the enactment of
30 this Act, the Medicare Payment Advisory Commission shall
31 submit to Congress a report on the effect of refinements to the
32 practice expense component of payments for physicians' serv-
33 ices in the case of services for which there are no physician
34 work relative value units, after the transition to a full resource-
35 based payment system in 2002, under section 1848 of the So-
36 cial Security Act (42 U.S.C. 1395w-4). Such report shall ex-
37 amine the following matters by physician specialty:

1 (1) The effect of such refinements on payment for
2 physicians' services.

3 (2) The interaction of the practice expense component
4 with other components of and adjustments to payment for
5 physicians' services under such section.

6 (3) The appropriateness of the amount of compensa-
7 tion by reason of such refinements.

8 (4) The effect of such refinements on access to care
9 by medicare beneficiaries to physicians' services.

10 (5) The effect of such refinements on physician par-
11 ticipation under the medicare program.

12 **SEC. 504. 1-YEAR EXTENSION OF TREATMENT OF CER-**
13 **TAIN PHYSICIAN PATHOLOGY SERVICES**
14 **UNDER MEDICARE.**

15 Section 542(c) of BIPA is amended by striking "2-year
16 period" and inserting "3-year period".

17 **SEC. 505. PHYSICIAN FEE SCHEDULE WAGE INDEX REVI-**
18 **SION.**

19 (a) IN GENERAL.—Notwithstanding any other provision of
20 law, for purposes of payment under the physician fee schedule
21 under section 1848 of the Social Security Act (42 U.S.C.
22 1395w-4) for physicians' services furnished during 2004, in no
23 case may the work geographic index otherwise calculated under
24 section 1848(e)(1)(A)(iii) of such Act (42 U.S.C. 1395w-
25 4(e)(1)(A)(iii)) be less than 0.985.

26 (b) EXEMPTION FROM LIMITATION ON ANNUAL ADJUST-
27 MENTS.—The increase in expenditures attributable to sub-
28 section (a) during 2004 shall not be taken into account in ap-
29 plying section 1848(c)(2)(B)(ii)(II) of such Act (42 U.S.C.
30 1395w-4(c)(2)(B)(ii)(II)) for that year.

31 (c) GAO REPORT.—

32 (1) STUDY.—The Comptroller General of the United
33 States shall conduct a study to evaluate the following:

34 (A) The economic basis of the current method-
35 ology for geographic adjustment of the work component
36 of the physician payment rate under the physician fee

1 schedule under section 1848 of the Social Security Act
2 (42 U.S.C. 1395w-4).

3 (B) Whether the adjustment under subsection (a)
4 should be continued, and whether there is an economic
5 basis for the continuation of such adjustment, in those
6 areas in which the adjustment applies.

7 (C) The effect of the methodology on physician lo-
8 cation and retention in areas affected by such adjust-
9 ment.

10 (D) The differences in recruitment costs and re-
11 tention rates for physicians, including specialists, be-
12 tween large urban areas and other areas.

13 (E) The mobility of physicians, including special-
14 ists, over the last decade.

15 (F) The effect of raising the floor of the geo-
16 graphic index to a value of 1.0 for adjustment of the
17 work component.

18 (2) REPORT.—The Comptroller General shall submit
19 to Congress a report on the study conducted under para-
20 graph (1) by not later than 1 year after the date of the
21 enactment of this Act.

22 **Subtitle B—Other Services**

23 **SEC. 511. COMPETITIVE ACQUISITION OF CERTAIN** 24 **ITEMS AND SERVICES.**

25 (a) IN GENERAL.—Section 1847 (42 U.S.C. 1395w-3) is
26 amended to read as follows:

27 “COMPETITIVE ACQUISITION OF CERTAIN ITEMS AND SERVICES

28 “SEC. 1847. (a) ESTABLISHMENT OF COMPETITIVE AC-
29 quisition Programs.—

30 “(1) IMPLEMENTATION OF PROGRAMS.—

31 “(A) IN GENERAL.—The Secretary shall establish
32 and implement programs under which, beginning in
33 2008, competitive acquisition areas are established
34 throughout the United States for contract award pur-
35 poses for the furnishing under this part of competi-
36 tively priced items and services (described in paragraph

1 (2)) for which payment is made under this part. Such
2 areas may differ for different items and services.

3 “(B) PHASED-IN IMPLEMENTATION.—The pro-
4 grams shall be phased-in among competitive acquisition
5 areas over a period of not longer than 3 years in a
6 manner so that the competition under the programs oc-
7 curs in—

8 “(i) at least $\frac{1}{3}$ of such areas in 2008; and

9 “(ii) at least $\frac{2}{3}$ of such areas in 2009.

10 “(C) WAIVER OF CERTAIN PROVISIONS.—In car-
11 rying out the programs, the Secretary may waive such
12 provisions of the Federal Acquisition Regulation as are
13 necessary for the efficient implementation of this sec-
14 tion, other than provisions relating to confidentiality of
15 information and such other provisions as the Secretary
16 determines appropriate.

17 “(2) ITEMS AND SERVICES DESCRIBED.—The items
18 and services referred to in paragraph (1) are the following:

19 “(A) DURABLE MEDICAL EQUIPMENT AND INHA-
20 LATION DRUGS USED IN CONNECTION WITH DURABLE
21 MEDICAL EQUIPMENT.—Covered items (as defined in
22 section 1834(a)(13)) for which payment is otherwise
23 made under section 1834(a), other than items used in
24 infusion, and inhalation drugs used in conjunction with
25 durable medical equipment.

26 “(B) OFF-THE-SHELF ORTHOTICS.—Orthotics (de-
27 scribed in section 1861(s)(9)) for which payment is
28 otherwise made under section 1834(h) which require
29 minimal self-adjustment for appropriate use and does
30 not require expertise in trimming, bending, molding,
31 assembling, or customizing to fit to the patient.

32 “(3) EXEMPTION AUTHORITY.—In carrying out the
33 programs under this section, the Secretary may exempt—

34 “(A) areas that are not competitive due to low
35 population density; and

1 “(B) items and services for which the application
2 of competitive acquisition is not likely to result in sig-
3 nificant savings.

4 “(b) PROGRAM REQUIREMENTS.—

5 “(1) IN GENERAL.—The Secretary shall conduct a
6 competition among entities supplying items and services de-
7 scribed in subsection (a)(2) for each competitive acquisition
8 area in which the program is implemented under subsection
9 (a) with respect to such items and services.

10 “(2) CONDITIONS FOR AWARDED CONTRACT.—

11 “(A) IN GENERAL.—The Secretary may not award
12 a contract to any entity under the competition con-
13 ducted in an competitive acquisition area pursuant to
14 paragraph (1) to furnish such items or services unless
15 the Secretary finds all of the following:

16 “(i) The entity meets quality and financial
17 standards specified by the Secretary or developed
18 by accreditation entities or organizations recognized
19 by the Secretary.

20 “(ii) The total amounts to be paid under the
21 contract (including costs associated with the ad-
22 ministration of the contract) are expected to be less
23 than the total amounts that would otherwise be
24 paid.

25 “(iii) Beneficiary access to a choice of multiple
26 suppliers in the area is maintained.

27 “(iv) Beneficiary liability is limited to the ap-
28 plicable percentage of contract award price.

29 “(B) QUALITY STANDARDS.—The quality stand-
30 ards specified under subparagraph (A)(i) shall not be
31 less than the quality standards that would otherwise
32 apply if this section did not apply and shall include
33 consumer services standards. The Secretary shall con-
34 sult with an expert outside advisory panel composed of
35 an appropriate selection of representatives of physi-
36 cians, practitioners, and suppliers to review (and advise
37 the Secretary concerning) such quality standards.

102

1 “(3) CONTENTS OF CONTRACT.—

2 “(A) IN GENERAL.—A contract entered into with
3 an entity under the competition conducted pursuant to
4 paragraph (1) is subject to terms and conditions that
5 the Secretary may specify.

6 “(B) TERM OF CONTRACTS.—The Secretary shall
7 rebid contracts under this section not less often than
8 once every 3 years.

9 “(4) LIMIT ON NUMBER OF CONTRACTORS.—

10 “(A) IN GENERAL.—The Secretary may limit the
11 number of contractors in a competitive acquisition area
12 to the number needed to meet projected demand for
13 items and services covered under the contracts. In
14 awarding contracts, the Secretary shall take into ac-
15 count the ability of bidding entities to furnish items or
16 services in sufficient quantities to meet the anticipated
17 needs of beneficiaries for such items or services in the
18 geographic area covered under the contract on a timely
19 basis.

20 “(B) MULTIPLE WINNERS.—The Secretary shall
21 award contracts to more than one entity submitting a
22 bid in each area for an item or service.

23 “(5) PARTICIPATING CONTRACTORS.—Payment shall
24 not be made for items and services described in subsection
25 (a)(2) furnished by a contractor and for which competition
26 is conducted under this section unless—

27 “(A) the contractor has submitted a bid for such
28 items and services under this section; and

29 “(B) the Secretary has awarded a contract to the
30 contractor for such items and services under this sec-
31 tion.

32 “(6) AUTHORITY TO CONTRACT FOR EDUCATION, OUT-
33 REACH AND COMPLAINT SERVICES.—The Secretary may
34 enter into a contract with an appropriate entity to address
35 complaints from beneficiaries who receive items and serv-
36 ices from an entity with a contract under this section and

1 to conduct appropriate education of and outreach to such
2 beneficiaries with respect to the program.

3 “(c) ANNUAL REPORTS.—The Secretary shall submit to
4 Congress an annual management report on the programs under
5 this section. Each such report shall include information on sav-
6 ings, reductions in cost-sharing, access to items and services,
7 and beneficiary satisfaction.

8 “(d) DEMONSTRATION PROJECT FOR CLINICAL LABORA-
9 TORY SERVICES.—

10 “(1) IN GENERAL.—The Secretary shall, beginning in
11 2008, conduct a demonstration project on the application
12 of competitive acquisition under this section to clinical di-
13 agnostic laboratory tests—

14 “(A) for which payment is otherwise made under
15 section 1833(h) or 1834(d)(1) (relating to colorectal
16 cancer screening tests); and

17 “(B) which are furnished without a face-to-face
18 encounter between the individual and the hospital or
19 physician ordering the tests.

20 “(2) TERMS AND CONDITIONS.—Such project shall be
21 under the same conditions as are applicable to items and
22 services described in subsection (a)(2).

23 “(3) REPORT.—The Secretary shall submit to
24 Congress—

25 “(A) an initial report on the project not later than
26 December 31, 2009; and

27 “(B) such progress and final reports on the
28 project after such date as the Secretary determines ap-
29 propriate.”.

30 (b) CONTINUATION OF CERTAIN DEMONSTRATION
31 PROJECTS.—Notwithstanding the amendment made by sub-
32 section (a), with respect to demonstration projects implemented
33 by the Secretary under section 1847 of the Social Security Act
34 (42 U.S.C. 1395w–3) (relating to the establishment of competi-
35 tive acquisition areas) that was in effect on the day before the
36 date of the enactment of this Act, each such demonstration

1 project may continue under the same terms and conditions ap-
2 plicable under that section as in effect on that date.

3 (c) REPORT ON DIFFERENCES IN PAYMENT FOR LABORA-
4 TORY SERVICES.—Not later than 18 months after the date of
5 the enactment of this Act, the Comptroller General of the
6 United States shall submit to Congress a report that analyzes
7 differences in reimbursement between public and private payors
8 for clinical diagnostic laboratory services.

9 (d) MEDPAC REPORT ON IMPACT OF DEMONSTRATION
10 PROJECTS ON BENEFICIARY ACCESS TO SERVICES.—Not later
11 than 1 year after the date of the enactment of this Act, the
12 Medicare Payment Advisory Commission shall submit to Con-
13 gress a report that analyzes the impact of demonstration
14 projects carried out under section 1847 of the Social Security
15 Act, as in effect on June 1, 2002, on access by medicare bene-
16 ficiaries to durable medical equipment for which payment was
17 made under the demonstration project.

18 **SEC. 512. PAYMENT FOR AMBULANCE SERVICES.**

19 (a) PHASE-IN PROVIDING FLOOR USING BLEND OF FEE
20 SCHEDULE AND REGIONAL FEE SCHEDULES.—Section 1834(l)
21 (42 U.S.C. 1395m(l)) is amended—

22 (1) in paragraph (2)(E), by inserting “consistent with
23 paragraph (10)” after “in an efficient and fair manner”;

24 (2) by redesignating the paragraph (8) added by sec-
25 tion 221(a) of BIPA as paragraph (9); and

26 (3) by adding at the end the following new paragraph:

27 “(10) PHASE-IN PROVIDING FLOOR USING BLEND OF
28 FEE SCHEDULE AND REGIONAL FEE SCHEDULES.—In car-
29 rying out the phase-in under paragraph (2)(E) for each
30 level of service furnished in a year before January 1, 2007,
31 the portion of the payment amount that is based on the fee
32 schedule shall not be less than the following blended rate
33 of the fee schedule under paragraph (1) and of a regional
34 fee schedule for the region involved:

35 “(A) For 2003, the blended rate shall be based 20
36 percent on the fee schedule under paragraph (1) and
37 80 percent on the regional fee schedule.

1 “(B) For 2004, the blended rate shall be based 40
2 percent on the fee schedule under paragraph (1) and
3 60 percent on the regional fee schedule.

4 “(C) For 2005, the blended rate shall be based 60
5 percent on the fee schedule under paragraph (1) and
6 40 percent on the regional fee schedule.

7 “(D) For 2006, the blended rate shall be based 80
8 percent on the fee schedule under paragraph (1) and
9 20 percent on the regional fee schedule.

10 For purposes of this paragraph, the Secretary shall estab-
11 lish a regional fee schedule for each of the 9 Census divi-
12 sions using the methodology (used in establishing the fee
13 schedule under paragraph (1)) to calculate a regional con-
14 version factor and a regional mileage payment rate and
15 using the same payment adjustments and the same relative
16 value units as used in the fee schedule under such para-
17 graph.”.

18 (b) ADJUSTMENT IN PAYMENT FOR CERTAIN LONG
19 TRIPS.—Section 1834(l), as amended by subsection (a), is fur-
20 ther amended by adding at the end the following new para-
21 graph:

22 “(11) ADJUSTMENT IN PAYMENT FOR CERTAIN LONG
23 TRIPS.—In the case of ground ambulance services fur-
24 nished on or after January 1, 2003, and before January 1,
25 2008, regardless of where the transportation originates, the
26 fee schedule established under this subsection shall provide
27 that, with respect to the payment rate for mileage for a
28 trip above 50 miles the per mile rate otherwise established
29 shall be increased by $\frac{1}{4}$ of the payment per mile otherwise
30 applicable to such miles.”.

31 (c) EFFECTIVE DATE.—The amendments made by this
32 section shall apply to ambulance services furnished on or after
33 January 1, 2003.

**SEC. 513. 5-YEAR EXTENSION OF MORATORIUM ON
THERAPY CAPS; PROVISIONS RELATING TO
REPORTS.**

(a) 5-YEAR EXTENSION OF MORATORIUM ON THERAPY CAPS.—Section 1833(g)(4) (42 U.S.C. 1395l(g)(4)) is amended by striking “and 2002” and inserting “2002, 2003, 2004, 2005, 2006, and 2007”.

(b) PROMPT SUBMISSION OF OVERDUE REPORTS ON PAYMENT AND UTILIZATION OF OUTPATIENT THERAPY SERVICES.—Not later than December 31, 2002, the Secretary shall submit to Congress the reports required under section 4541(d)(2) of the Balanced Budget Act of 1997 (relating to alternatives to a single annual dollar cap on outpatient therapy) and under section 221(d) of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (relating to utilization patterns for outpatient therapy).

(c) IDENTIFICATION OF CONDITIONS AND DISEASES JUSTIFYING WAIVER OF THERAPY CAP.—

(1) STUDY.—The Secretary shall request the Institute of Medicine of the National Academy of Sciences to identify conditions or diseases that should justify conducting an assessment of the need to waive the therapy caps under section 1833(g)(4) of the Social Security Act (42 U.S.C. 1395l(g)(4)).

(2) REPORTS TO CONGRESS.—Not later than July 1, 2003, the Secretary shall submit to Congress a preliminary report on the conditions and diseases identified under paragraph (1) and not later than September 1, 2003, a final report on the conditions and diseases so identified.

(d) GAO STUDY OF PATIENT ACCESS TO PHYSICAL THERAPIST SERVICES.—

(1) STUDY.—The Comptroller General of the United States shall conduct a study on access to physical therapist services in States authorizing such services without a physician referral and in States that require such a physician referral. The study shall—

(A) examine the use of and referral patterns for physical therapist services for patients age 50 and older in States that authorize such services without a physician referral and in States that require such a physician referral;

(B) examine the use of and referral patterns for physical therapist services for patients who are medicare beneficiaries;

(C) examine the potential effect of prohibiting a physician from referring patients to physical therapy services owned by the physician and provided in the physician's office;

(D) examine the delivery of physical therapists' services within the facilities of Department of Defense; and

(E) analyze the potential impact on medicare beneficiaries and on expenditures under the medicare program of eliminating the need for a physician referral and physician certification for physical therapist services under the medicare program.

(2) REPORT.—The Comptroller General shall submit to Congress a report on the study conducted under paragraph (1) by not later than 1 year after the date of the enactment of this Act.

SEC. 514. ACCELERATED IMPLEMENTATION OF 20 PERCENT COINSURANCE FOR HOSPITAL OUTPATIENT DEPARTMENT (OPD) SERVICES; OTHER OPD PROVISIONS.

(a) ACCELERATED IMPLEMENTATION OF COINSURANCE REDUCTIONS.—Section 1833(t)(8)(C)(ii) (42 U.S.C. 1395l(t)(8)(C)(ii)) is amended by striking subclauses (III) through (V) and inserting the following:

“(III) For procedures performed in 2004, 45 percent.

“(IV) For procedures performed in 2005, 40 percent.

1 “(V) For procedures performed in 2006,
2 2007, 2008 and 2009, 35 percent.

3 “(VI) For procedures performed in 2010,
4 30 percent.

5 “(VII) For procedures performed in 2011,
6 25 percent.

7 “(VIII) For procedures performed in 2012
8 and thereafter, 20 percent.”.

9 (b) TREATMENT OF TEMPERATURE MONITORED
10 CRYOABLATION.—

11 (1) IN GENERAL.—Section 1833(t)(6)(A)(ii) (42
12 U.S.C. 1395l(t)(6)(A)(ii)) is amended by striking “or tem-
13 perature monitored cryoablation”.

14 (2) EFFECTIVE DATE.—The amendment made by
15 paragraph (1) applies to payment for services furnished on
16 or after January 1, 2003.

17 **SEC. 515. COVERAGE OF AN INITIAL PREVENTIVE PHYS-**
18 **ICAL EXAMINATION.**

19 (a) COVERAGE.—Section 1861(s)(2) (42 U.S.C.
20 1395x(s)(2)), is amended—

21 (1) in subparagraph (U), by striking “and” at the
22 end;

23 (2) in subparagraph (V), by inserting “and” at the
24 end; and

25 (3) by adding at the end the following new subpara-
26 graph:

27 “(W) an initial preventive physical examination (as
28 defined in subsection (ww));”.

29 (b) SERVICES DESCRIBED.—Section 1861 (42 U.S.C.
30 1395x) is amended by adding at the end the following new sub-
31 section:

32 “Initial Preventive Physical Examination

33 “(ww) The term ‘initial preventive physical examination’
34 means physicians’ services consisting of a physical examination
35 with the goal of health promotion and disease detection and in-
36 cludes items and services specified by the Secretary in regula-
37 tions.”.

1 (c) WAIVER OF DEDUCTIBLE AND COINSURANCE.—

2 (1) DEDUCTIBLE.—The first sentence of section
3 1833(b) (42 U.S.C. 1395l(b)) is amended—

4 (A) by striking “and” before “(6)”, and

5 (B) by inserting before the period at the end the
6 following: “, and (7) such deductible shall not apply
7 with respect to an initial preventive physical examina-
8 tion (as defined in section 1861(wv))”.

9 (2) COINSURANCE.—Section 1833(a)(1) (42 U.S.C.
10 1395l(a)(1)) is amended—

11 (A) in clause (N), by inserting “(or 100 percent
12 in the case of an initial preventive physical examina-
13 tion, as defined in section 1861(wv))” after “80 per-
14 cent”; and

15 (B) in clause (O), by inserting “(or 100 percent
16 in the case of an initial preventive physical examina-
17 tion, as defined in section 1861(wv))” after “80 per-
18 cent”.

19 (d) PAYMENT AS PHYSICIANS’ SERVICES.—Section
20 1848(j)(3) (42 U.S.C. 1395w-4(j)(3)) is amended by inserting
21 “(2)(W),” after “(2)(S),”.

22 (e) OTHER CONFORMING AMENDMENTS.—Section 1862(a)
23 (42 U.S.C. 1395y(a)) is amended—

24 (1) in paragraph (1)—

25 (A) by striking “and” at the end of subparagraph
26 (H);

27 (B) by striking the semicolon at the end of sub-
28 paragraph (I) and inserting “, and”; and

29 (C) by adding at the end the following new sub-
30 paragraph:

31 “(J) in the case of an initial preventive physical exam-
32 ination, which is performed not later than 6 months after
33 the date the individual’s first coverage period begins under
34 part B;” and

35 (2) in paragraph (7), by striking “or (H)” and insert-
36 ing “(H), or (J)”.

1 (f) EFFECTIVE DATE.—The amendments made by this
2 section shall apply to services furnished on or after January 1,
3 2004, but only for individuals whose coverage period begins on
4 or after such date.

5 **SEC. 516. RENAL DIALYSIS SERVICES.**

6 (a) REPORT ON DIFFERENCES IN COSTS IN DIFFERENT
7 SETTINGS.—Not later than 1 year after the date of the enact-
8 ment of this Act, the Comptroller General of the United States
9 shall submit to Congress a report containing—

10 (1) an analysis of the differences in costs of providing
11 renal dialysis services under the medicare program in home
12 settings and in facility settings;

13 (2) an assessment of the percentage of overhead costs
14 in home settings and in facility settings; and

15 (3) an evaluation of whether the charges for home di-
16 alysis supplies and equipment are reasonable and nec-
17 essary.

18 (b) RESTORING COMPOSITE RATE EXCEPTIONS FOR PEDI-
19 ATRIC FACILITIES.—

20 (1) IN GENERAL.—Section 422(a)(2) of BIPA is
21 amended—

22 (A) in subparagraph (A), by striking “and (C)”
23 and inserting “, (C), and (D)”;

24 (B) in subparagraph (B), by striking “In the
25 case” and inserting “Subject to subparagraph (D), in
26 the case”; and

27 (C) by adding at the end the following new sub-
28 paragraph:

29 “(D) INAPPLICABILITY TO PEDIATRIC FACILI-
30 TIES.—Subparagraphs (A) and (B) shall not apply, as
31 of October 1, 2002, to pediatric facilities that do not
32 have an exception rate described in subparagraph (C)
33 in effect on such date. For purposes of this subpara-
34 graph, the term ‘pediatric facility’ means a renal facil-
35 ity at least 50 percent of whose patients are individuals
36 under 18 years of age.”.

1 (2) CONFORMING AMENDMENT.—The fourth sentence
2 of section 1881(b)(7) (42 U.S.C. 1395rr(b)(7)) is amended
3 by striking “The Secretary” and inserting “Subject to sec-
4 tion 422(a)(2) of the Medicare, Medicaid, and SCHIP Ben-
5 efits Improvement and Protection Act of 2000, the Sec-
6 retary”.

7 (c) INCREASE IN RENAL DIALYSIS COMPOSITE RATE FOR
8 SERVICES FURNISHED IN 2004.—Notwithstanding any other
9 provision of law, with respect to payment under part B of title
10 XVIII of the Social Security Act for renal dialysis services fur-
11 nished in 2004, the composite payment rate otherwise estab-
12 lished under section 1881(b)(7) of such Act (42 U.S.C.
13 1395rr(b)(7)) shall be increased by 1.2 percent.

14 **SEC. 517. IMPROVED PAYMENT FOR CERTAIN MAMMOG-**
15 **RAPHY SERVICES.**

16 (a) EXCLUSION FROM OPD FEE SCHEDULE.—Section
17 1833(t)(1)(B)(iv) (42 U.S.C. 1395l(t)(1)(B)(iv)) is amended by
18 inserting before the period at the end the following: “and does
19 not include screening mammography (as defined in section
20 1861(jj)) and unilateral and bilateral diagnostic mammog-
21 raphy”.

22 (b) ADJUSTMENT TO TECHNICAL COMPONENT.—For diag-
23 nostic mammography performed on or after January 1, 2004,
24 for which payment is made under the physician fee schedule
25 under section 1848 of the Social Security Act (42 U.S.C.
26 1395w–4), the Secretary, based on the most recent cost data
27 available, shall provide for an appropriate adjustment in the
28 payment amount for the technical component of the diagnostic
29 mammography.

30 (c) EFFECTIVE DATE.—The amendment made by sub-
31 section (a) shall apply to mammography performed on or after
32 January 1, 2004.

33 **SEC. 518. WAIVER OF PART B LATE ENROLLMENT PEN-**
34 **ALTY FOR CERTAIN MILITARY RETIREES;**
35 **SPECIAL ENROLLMENT PERIOD.**

36 (a) WAIVER OF PENALTY.—

1 (1) IN GENERAL.—Section 1839(b) (42 U.S.C.
2 1395r(b)) is amended by adding at the end the following
3 new sentence: “No increase in the premium shall be ef-
4 fected for a month in the case of an individual who is 65
5 years of age or older, who enrolls under this part during
6 2001, 2002, or 2003, and who demonstrates to the Sec-
7 retary before December 31, 2003, that the individual is a
8 covered beneficiary (as defined in section 1072(5) of title
9 10, United States Code). The Secretary of Health and
10 Human Services shall consult with the Secretary of De-
11 fense in identifying individuals described in the previous
12 sentence.”.

13 (2) EFFECTIVE DATE.—The amendment made by
14 paragraph (1) shall apply to premiums for months begin-
15 ning with January 2003. The Secretary of Health and
16 Human Services shall establish a method for providing re-
17 bates of premium penalties paid for months on or after
18 January 2003 for which a penalty does not apply under
19 such amendment but for which a penalty was previously
20 collected.

21 (b) MEDICARE PART B SPECIAL ENROLLMENT PERIOD.—

22 (1) IN GENERAL.—In the case of any individual who,
23 as of the date of the enactment of this Act, is 65 years of
24 age or older, is eligible to enroll but is not enrolled under
25 part B of title XVIII of the Social Security Act, and is a
26 covered beneficiary (as defined in section 1072(5) of title
27 10, United States Code), the Secretary of Health and
28 Human Services shall provide for a special enrollment pe-
29 riod during which the individual may enroll under such
30 part. Such period shall begin as soon as possible after the
31 date of the enactment of this Act and shall end on Decem-
32 ber 31, 2003.

33 (2) COVERAGE PERIOD.—In the case of an individual
34 who enrolls during the special enrollment period provided
35 under paragraph (1), the coverage period under part B of
36 title XVIII of the Social Security Act shall begin on the

1 first day of the month following the month in which the in-
2 dividual enrolls.

3 **SEC. 519. COVERAGE OF CHOLESTEROL AND BLOOD**
4 **LIPID SCREENING.**

5 (a) COVERAGE.—Section 1861(s)(2) (42 U.S.C.
6 1395x(s)(2)), as amended by section 515(a), is amended—

7 (1) in subparagraph (V), by striking “and” at the end;

8 (2) in subparagraph (W), by inserting “and” at the
9 end; and

10 (3) by adding at the end the following new subpara-
11 graph:

12 “(X) cholesterol and other blood lipid screening
13 tests (as defined in subsection (xx));”.

14 (b) SERVICES DESCRIBED.—Section 1861 (42 U.S.C.
15 1395x), as amended by section 515(b), is amended by adding
16 at the end the following new subsection:

17 “Cholesterol and Other Blood Lipid Screening Test

18 “(xx)(1) The term ‘cholesterol and other blood lipid
19 screening test’ means diagnostic testing of cholesterol and other
20 lipid levels of the blood for the purpose of early detection of
21 abnormal cholesterol and other lipid levels.

22 “(2) The Secretary shall establish standards, in consulta-
23 tion with appropriate organizations, regarding the frequency
24 and type of cholesterol and other blood lipid screening tests, ex-
25 cept that such frequency may not be more often than once
26 every 2 years.”.

27 (c) FREQUENCY.—Section 1862(a)(1) (42 U.S.C.
28 1395y(a)(1)), as amended by section 515(e), is amended

29 (1) by striking “and” at the end of subparagraph (I);

30 (2) by striking the semicolon at the end of subpara-
31 graph (J) and inserting “; and”; and

32 (3) by adding at the end the following new subpara-
33 graph:

34 “(K) in the case of a cholesterol and other blood lipid
35 screening test (as defined in section 1861(xx)(1)), which is
36 performed more frequently than is covered under section
37 1861(xx)(2).”.

(d) EFFECTIVE DATE.—The amendments made by this section shall apply to tests furnished on or after January 1, 2004.

**TITLE VI—PROVISIONS RELATING
TO PARTS A AND B
Subtitle A—Home Health Services**

**SEC. 601. ELIMINATION OF 15 PERCENT REDUCTION IN
PAYMENT RATES UNDER THE PROSPECTIVE
PAYMENT SYSTEM.**

(a) IN GENERAL.—Section 1895(b)(3)(A) (42 U.S.C. 1395fff(b)(3)(A)) is amended to read as follows:

“(A) INITIAL BASIS.—Under such system the Secretary shall provide for computation of a standard prospective payment amount (or amounts) as follows:

“(i) Such amount (or amounts) shall initially be based on the most current audited cost report data available to the Secretary and shall be computed in a manner so that the total amounts payable under the system for fiscal year 2001 shall be equal to the total amount that would have been made if the system had not been in effect and if section 1861(v)(1)(L)(ix) had not been enacted.

“(ii) For fiscal year 2002 and for the first quarter of fiscal year 2003, such amount (or amounts) shall be equal to the amount (or amounts) determined under this paragraph for the previous fiscal year, updated under subparagraph (B).

“(iii) For 2003, such amount (or amounts) shall be equal to the amount (or amounts) determined under this paragraph for fiscal year 2002, updated under subparagraph (B) for 2003.

“(iv) For 2004 and each subsequent year, such amount (or amounts) shall be equal to the amount (or amounts) determined under this paragraph for the previous year, updated under subparagraph (B).

1 Each such amount shall be standardized in a manner
2 that eliminates the effect of variations in relative case
3 mix and area wage adjustments among different home
4 health agencies in a budget neutral manner consistent
5 with the case mix and wage level adjustments provided
6 under paragraph (4)(A). Under the system, the Sec-
7 retary may recognize regional differences or differences
8 based upon whether or not the services or agency are
9 in an urbanized area.”.

10 (b) EFFECTIVE DATE.—The amendment made by sub-
11 section (a) shall take effect as if included in the amendments
12 made by section 501 of the Medicare, Medicaid, and SCHIP
13 Benefits Improvement and Protection Act of 2000 (as enacted
14 into law by section 1(a)(6) of Public Law 106–554).

15 **SEC. 602. UPDATE IN HOME HEALTH SERVICES.**

16 (a) CHANGE TO CALENDAR YEAR UPDATE.—

17 (1) IN GENERAL.—Section 1895(b) (42 U.S.C.
18 1395fff(b)(3)) is amended—

19 (A) in paragraph (3)(B)(i)—

20 (i) by striking “each fiscal year (beginning
21 with fiscal year 2002)” and inserting “fiscal year
22 2002 and for each subsequent year (beginning with
23 2003)”; and

24 (ii) by inserting “or year” after “the fiscal
25 year”;

26 (B) in paragraph (3)(B)(ii)—

27 (i) in subclause (II), by striking “fiscal year”
28 and inserting “year” and by redesignating such
29 subclause as subclause (III); and

30 (ii) in subclause (I), by striking “each of fiscal
31 years 2002 and 2003” and inserting the following:
32 “fiscal year 2002, the home health market basket
33 percentage increase (as defined in clause (iii))
34 minus 1.1 percentage points;

35 “(II) 2003”;

36 (C) in paragraph (3)(B)(iii), by inserting “or
37 year” after “fiscal year” each place it appears;

- 1 (D) in paragraph (3)(B)(iv)—
2 (i) by inserting “or year” after “fiscal year”
3 each place it appears; and
4 (ii) by inserting “or years” after “fiscal
5 years”; and
6 (E) in paragraph (5), by inserting “or year” after
7 “fiscal year”.

8 (2) TRANSITION RULE.—The standard prospective
9 payment amount (or amounts) under section 1895(b)(3) of
10 the Social Security Act for the calendar quarter beginning
11 on October 1, 2002, shall be such amount (or amounts) for
12 the previous calendar quarter.

13 (b) CHANGES IN UPDATES FOR 2003, 2004, AND 2005.—
14 Section 1895(b)(3)(B)(ii) (42 U.S.C. 1395fff(b)(3)(B)(ii)), as
15 amended by subsection (a)(1)(B), is amended—

16 (1) in subclause (II), by striking “the home health
17 market basket percentage increase (as defined in clause
18 (iii)) minus 1.1 percentage points” and inserting “2.0 per-
19 centage points”;

20 (2) by striking “or” at the end of subclause (II);

21 (3) by redesignating subclause (III) as subclause (V);
22 and

23 (4) by inserting after subclause (II) the following new
24 subclause:

25 “(III) 2004, 1.1 percentage points;

26 “(IV) 2005, 2.7 percentage points; or”.

27 (c) PAYMENT ADJUSTMENT.—

28 (1) IN GENERAL.—Section 1895(b)(5) (42 U.S.C.
29 1395fff(b)(5)) is amended by striking “5 percent” and in-
30 serting “3 percent”.

31 (2) EFFECTIVE DATE.—The amendment made by
32 paragraph (1) shall apply to years beginning with 2003.

**SEC. 603. OASIS TASK FORCE; SUSPENSION OF CERTAIN
OASIS DATA COLLECTION REQUIREMENTS
PENDING TASK FORCE SUBMITTAL OF RE-
PORT.**

(a) ESTABLISHMENT.—The Secretary of Health and Human Services shall establish and appoint a task force (to be known as the “OASIS Task Force”) to examine the data collection and reporting requirements under OASIS. For purposes of this section, the term “OASIS” means the Outcome and Assessment Information Set required by reason of section 4602(e) of Balanced Budget Act of 1997 (42 U.S.C. 1395fff note).

(b) COMPOSITION.—The OASIS Task Force shall be composed of the following:

(1) Staff of the Centers for Medicare & Medicaid Services with expertise in post-acute care.

(2) Representatives of home health agencies.

(3) Health care professionals and research and health care quality experts outside the Federal Government with expertise in post-acute care.

(4) Advocates for individuals requiring home health services.

(c) DUTIES.—

(1) REVIEW AND RECOMMENDATIONS.—The OASIS Task Force shall review and make recommendations to the Secretary regarding changes in OASIS to improve and simplify data collection for purposes of—

(A) assessing the quality of home health services;
and

(B) providing consistency in classification of patients into home health resource groups (HHRGs) for payment under section 1895 of the Social Security Act (42 U.S.C. 1395fff).

(2) SPECIFIC ITEMS.—In conducting the review under paragraph (1), the OASIS Task Force shall specifically examine—

(A) the 41 outcome measures currently in use;

1 (B) the timing and frequency of data collection;
2 and

3 (C) the collection of information on comorbidities
4 and clinical indicators.

5 (3) REPORT.—The OASIS Task Force shall submit a
6 report to the Secretary containing its findings and rec-
7 ommendations for changes in OASIS by not later than 18
8 months after the date of the enactment of this Act.

9 (d) SUNSET.—The OASIS Task Force shall terminate 60
10 days after the date on which the report is submitted under sub-
11 section (c)(2).

12 (e) NONAPPLICATION OF FACA.—The provisions of the
13 Federal Advisory Committee Act shall not apply to the OASIS
14 Task Force.

15 (f) SUSPENSION OF OASIS REQUIREMENT FOR COLLEC-
16 TION OF DATA ON NON-MEDICARE AND NON-MEDICAID PA-
17 TIENTS PENDING TASK FORCE REPORT.—

18 (1) IN GENERAL.—During the period described in
19 paragraph (2), the Secretary of Health and Human Serv-
20 ices may not require, under section 4602(e) of the Bal-
21 anced Budget Act of 1997 or otherwise under OASIS, a
22 home health agency to gather or submit information that
23 relates to an individual who is not eligible for benefits
24 under either title XVIII or title XIX of the Social Security
25 Act.

26 (2) PERIOD OF SUSPENSION.—The period described in
27 this paragraph—

28 (A) begins on January 1, 2003, and

29 (B) ends on the last day of the 2nd month begin-
30 ning after the date the report is submitted under sub-
31 section (c)(2).

32 **SEC. 604. MEDPAC STUDY ON MEDICARE MARGINS OF**
33 **HOME HEALTH AGENCIES.**

34 (a) STUDY.—The Medicare Payment Advisory Commission
35 shall conduct a study of payment margins of home health agen-
36 cies under the home health prospective payment system under
37 section 1895 of the Social Security Act (42 U.S.C. 1395fff).

1 Such study shall examine whether systematic differences in
2 payment margins are related to differences in case mix (as
3 measured by home health resource groups (HHRGs)) among
4 such agencies. The study shall use the partial or full-year cost
5 reports filed by home health agencies.

6 (b) REPORT.—Not later than 2 years after the date of the
7 enactment of this Act, the Commission shall submit to Con-
8 gress a report on the study under subsection (a).

9 **Subtitle B—Direct Graduate Medical** 10 **Education**

11 **SEC. 611. REDISTRIBUTION OF UNUSED RESIDENT POSI-** 12 **TIONS.**

13 (a) IN GENERAL.—Section 1886(h)(4) (42 U.S.C.
14 1395ww(h)(4)) is amended—

15 (1) in subparagraph (F)(i), by inserting “subject to
16 subparagraph (I),” after “October 1, 1997,”;

17 (2) in subparagraph (H)(i), by inserting “subject to
18 subparagraph (I),” after “subparagraphs (F) and (G),”;
19 and

20 (3) by adding at the end the following new subpara-
21 graph:

22 “(I) REDISTRIBUTION OF UNUSED RESIDENT PO-
23 SITIONS.—

24 “(i) REDUCTION IN LIMIT BASED ON UNUSED
25 POSITIONS.—

26 “(I) IN GENERAL.—If a hospital’s resident
27 level (as defined in clause (iii)(I)) is less than
28 the otherwise applicable resident limit (as de-
29 fined in clause (iii)(II)) for each of the ref-
30 erence periods (as defined in subclause (II)),
31 effective for cost reporting periods beginning on
32 or after January 1, 2003, the otherwise appli-
33 cable resident limit shall be reduced by 75 per-
34 cent of the difference between such limit and
35 the reference resident level specified in sub-
36 clause (III) (or subclause (IV) if applicable).

“(II) REFERENCE PERIODS DEFINED.—In this clause, the term ‘reference periods’ means, for a hospital, the 3 most recent consecutive cost reporting periods of the hospital for which cost reports have been settled (or, if not, submitted) on or before September 30, 2001.

“(III) REFERENCE RESIDENT LEVEL.—Subject to subclause (IV), the reference resident level specified in this subclause for a hospital is the highest resident level for the hospital during any of the reference periods.

“(IV) ADJUSTMENT PROCESS.—Upon the timely request of a hospital, the Secretary may adjust the reference resident level for a hospital to be the resident level for the hospital for the cost reporting period that includes July 1, 2002.

“(ii) REDISTRIBUTION.—

“(I) IN GENERAL.—The Secretary is authorized to increase the otherwise applicable resident limits for hospitals by an aggregate number estimated by the Secretary that does not exceed the aggregate reduction in such limits attributable to clause (i) (without taking into account any adjustment under subclause (IV) of such clause).

“(II) EFFECTIVE DATE.—No increase under subclause (I) shall be permitted or taken into account for a hospital for any portion of a cost reporting period that occurs before July 1, 2003, or before the date of the hospital’s application for an increase under this clause. No such increase shall be permitted for a hospital unless the hospital has applied to the Secretary for such increase by December 31, 2004.

“(III) CONSIDERATIONS IN REDISTRIBUTION.—In determining for which hospitals the

1 increase in the otherwise applicable resident
2 limit is provided under subclause (I), the Sec-
3 retary shall take into account the need for such
4 an increase by specialty and location involved,
5 consistent with subclause (IV).

6 “(IV) PRIORITY FOR RURAL AND SMALL
7 URBAN AREAS.—In determining for which hos-
8 pitals and residency training programs an in-
9 crease in the otherwise applicable resident limit
10 is provided under subclause (I), the Secretary
11 shall first distribute the increase to programs
12 of hospitals located in rural areas or in urban
13 areas that are not large urban areas (as de-
14 fined for purposes of subsection (d)) on a first-
15 come-first-served basis (as determined by the
16 Secretary) based on a demonstration that the
17 hospital will fill the positions made available
18 under this clause and not to exceed an increase
19 of 25 full-time equivalent positions with respect
20 to any hospital.

21 “(V) APPLICATION OF LOCALITY AD-
22 JUSTED NATIONAL AVERAGE PER RESIDENT
23 AMOUNT.—With respect to additional residency
24 positions in a hospital attributable to the in-
25 crease provided under this clause, notwith-
26 standing any other provision of this subsection,
27 the approved FTE resident amount is deemed
28 to be equal to the locality adjusted national av-
29 erage per resident amount computed under
30 subparagraph (E) for that hospital.

31 “(VI) CONSTRUCTION.—Nothing in this
32 clause shall be construed as permitting the re-
33 distribution of reductions in residency positions
34 attributable to voluntary reduction programs
35 under paragraph (6) or as affecting the ability
36 of a hospital to establish new medical residency
37 training programs under subparagraph (H).

1 “(iii) RESIDENT LEVEL AND LIMIT DE-
2 FINED.—In this subparagraph:

3 “(I) RESIDENT LEVEL.—The term ‘resi-
4 dent level’ means, with respect to a hospital,
5 the total number of full-time equivalent resi-
6 dents, before the application of weighting fac-
7 tors (as determined under this paragraph), in
8 the fields of allopathic and osteopathic medi-
9 cine for the hospital.

10 “(II) OTHERWISE APPLICABLE RESIDENT
11 LIMIT.—The term ‘otherwise applicable resi-
12 dent limit’ means, with respect to a hospital,
13 the limit otherwise applicable under subpara-
14 graphs (F)(i) and (H) on the resident level for
15 the hospital determined without regard to this
16 subparagraph.”.

17 (b) NO APPLICATION OF INCREASE TO IME.—Section
18 1886(d)(5)(B)(v) (42 U.S.C. 1395ww(d)(5)(B)(v)) is amended
19 by adding at the end the following: “The provisions of clause
20 (i) of subparagraph (I) of subsection (h)(4) shall apply with re-
21 spect to the first sentence of this clause in the same manner
22 as it applies with respect to subparagraph (F) of such sub-
23 section, but the provisions of clause (ii) of such subparagraph
24 shall not apply.”.

25 (c) REPORT ON EXTENSION OF APPLICATIONS UNDER
26 REDISTRIBUTION PROGRAM.—Not later than July 1, 2004, the
27 Secretary shall submit to Congress a report containing rec-
28 ommendations regarding whether to extend the deadline for ap-
29 plications for an increase in resident limits under section
30 1886(h)(4)(I)(ii)(II) of the Social Security Act (as added by
31 subsection (a)).

**SEC. 612. INCREASING FOR 5 YEARS TO 100 PERCENT OF
THE LOCALITY ADJUSTED NATIONAL AVERAGE PER RESIDENT AMOUNT THE PAYMENT
FLOOR FOR DIRECT GRADUATE MEDICAL
EDUCATION PAYMENTS UNDER THE MEDICARE PROGRAM.**

Section 1886(h)(2)(D)(iii) (42 U.S.C. 1395ww(h)(2)(D)(iii)), as amended by section 511 of BIPA, is amended—

(1) by striking “and” after “70 percent,”; and

(2) by inserting after “85 percent,” the following:

“and for cost reporting periods beginning during the period beginning on October 1, 2002, and ending on September 31, 2007, shall not be less than 100 percent.”.

Subtitle C—Other Provisions

SEC. 621. MODIFICATIONS TO MEDICARE PAYMENT ADVISORY COMMISSION (MEDPAC).

(a) EXAMINATION OF BUDGET CONSEQUENCES.—Section 1805(b) (42 U.S.C. 1395b–6(b)) is amended by adding at the end the following new paragraph:

“(8) EXAMINATION OF BUDGET CONSEQUENCES.—Before making any recommendations, the Commission shall examine the budget consequences of such recommendations, directly or through consultation with appropriate expert entities.”.

(b) CONSIDERATION OF EFFICIENT PROVISION OF SERVICES.—Section 1805(b)(2)(B)(i) (42 U.S.C. 1395b–6(b)(2)(B)(i)) is amended by inserting “the efficient provision of” after “expenditures for”.

(c) ADDITIONAL REPORTS.—

(1) DATA NEEDS AND SOURCES.—The Medicare Payment Advisory Commission shall conduct a study, and submit a report to Congress by not later than June 1, 2003, on the need for current data, and sources of current data available, to determine the solvency and financial circumstances of hospitals and other medicare providers of services. The Commission shall examine data on uncompen-

1 sated care, as well as the share of uncompensated care ac-
2 counted for by the expenses for treating illegal aliens.

3 (2) USE OF TAX-RELATED RETURNS.—Using return
4 information provided under Form 990 of the Internal Rev-
5 enue Service, the Commission shall submit to Congress, by
6 not later than June 1, 2003, a report on the following:

7 (A) Investments and capital financing of hospitals
8 participating under the medicare program and related
9 foundations.

10 (B) Access to capital financing for private and for
11 not-for-profit hospitals.

12 **SEC. 622. DEMONSTRATION PROJECT FOR DISEASE**
13 **MANAGEMENT FOR CERTAIN MEDICARE**
14 **BENEFICIARIES WITH DIABETES.**

15 (a) IN GENERAL.—The Secretary of Health and Human
16 Services shall conduct a demonstration project under this sec-
17 tion (in this section referred to as the “project”) to dem-
18 onstrate the impact on costs and health outcomes of applying
19 disease management to certain medicare beneficiaries with di-
20 agnosed diabetes. In no case may the number of participants
21 in the project exceed 30,000 at any time.

22 (b) VOLUNTARY PARTICIPATION.—

23 (1) ELIGIBILITY.—Medicare beneficiaries are eligible
24 to participate in the project only if—

25 (a) they are Hispanic, as determined by the Sec-
26 retary;

27 (A) they meet specific medical criteria dem-
28 onstrating the appropriate diagnosis and the advanced
29 nature of their disease;

30 (B) their physicians approve of participation in the
31 project; and

32 (C) they are not enrolled in a Medicare+Choice
33 plan.

34 (2) BENEFITS.—A medicare beneficiary who is en-
35 rolled in the project shall be eligible—

36 (A) for disease management services related to
37 their diabetes; and

1 (B) for payment for all costs for prescription
2 drugs without regard to whether or not they relate to
3 the diabetes, except that the project may provide for
4 modest cost-sharing with respect to prescription drug
5 coverage.

6 (c) CONTRACTS WITH DISEASE MANAGEMENT ORGANIZA-
7 TIONS.—

8 (1) IN GENERAL.—The Secretary of Health and
9 Human Services shall carry out the project through con-
10 tracts with up to three disease management organizations.
11 The Secretary shall not enter into such a contract with an
12 organization unless the organization demonstrates that it
13 can produce improved health outcomes and reduce aggre-
14 gate medicare expenditures consistent with paragraph (2).

15 (2) CONTRACT PROVISIONS.—Under such contracts—

16 (A) such an organization shall be required to pro-
17 vide for prescription drug coverage described in sub-
18 section (b)(2)(B);

19 (B) such an organization shall be paid a fee nego-
20 tiated and established by the Secretary in a manner so
21 that (taking into account savings in expenditures under
22 parts A and B of the medicare program under title
23 XVIII of the Social Security Act) there will be no net
24 increase, and to the extent practicable, there will be a
25 net reduction in expenditures under the medicare pro-
26 gram as a result of the project; and

27 (C) such an organization shall guarantee, through
28 an appropriate arrangement with a reinsurance com-
29 pany or otherwise, the prohibition on net increases in
30 expenditures described in subparagraph (B).

31 (3) PAYMENTS.—Payments to such organizations shall
32 be made in appropriate proportion from the Trust Funds
33 established under title XVIII of the Social Security Act.

34 (4) WORKING GROUP.—The Secretary shall establish
35 within the Department of Health and Human Services a
36 working group consisting of employees of the Department
37 to carry out the following:

1 (A) To oversee the project.

2 (B) To establish policy and criteria for medicare
3 disease management programs within the Department,
4 including the establishment of policy and criteria for
5 such programs.

6 (C) To identify targeted medical conditions and
7 targeted individuals.

8 (D) To select areas in which such programs are
9 carried out.

10 (E) To monitor health outcomes under such pro-
11 grams.

12 (F) To measure the effectiveness of such programs
13 in meeting any budget neutrality requirements.

14 (G) Otherwise to serve as a central focal point
15 within the Department for dissemination of information
16 on medicare disease management programs.

17 (d) APPLICATION OF MEDIGAP PROTECTIONS TO DEM-
18 ONSTRATION PROJECT ENROLLEES.—(1) Subject to paragraph
19 (2), the provisions of section 1882(s)(3) (other than clauses (i)
20 through (iv) of subparagraph (B)) and 1882(s)(4) of the Social
21 Security Act shall apply to enrollment (and termination of en-
22 rollment) in the demonstration project under this section, in
23 the same manner as they apply to enrollment (and termination
24 of enrollment) with a Medicare+Choice organization in a
25 Medicare+Choice plan.

26 (2) In applying paragraph (1)—

27 (A) any reference in clause (v) or (vi) of section
28 1882(s)(3)(B) of such Act to 12 months is deemed a ref-
29 erence to the period of the demonstration project; and

30 (B) the notification required under section
31 1882(s)(3)(D) of such Act shall be provided in a manner
32 specified by the Secretary of Health and Human Services.

33 (e) DURATION.—The project shall last for not longer than
34 3 years.

35 (f) WAIVER.—The Secretary of Health and Human Serv-
36 ices shall waive such provisions of title XVIII of the Social Se-

1 security Act as may be necessary to provide for payment for serv-
2 ices under the project in accordance with subsection (c)(3).

3 (g) REPORT.—The Secretary of Health and Human Serv-
4 ices shall submit to Congress an interim report on the project
5 not later than 2 years after the date it is first implemented and
6 a final report on the project not later than 6 months after the
7 date of its completion. Such reports shall include information
8 on the impact of the project on costs and health outcomes and
9 recommendations on the cost-effectiveness of extending or ex-
10 panding the project.

11 (h) GAO STUDY ON DISEASE MANAGEMENT PRO-
12 GRAMS.—The Comptroller General of the United States shall
13 conduct a study that compares disease management programs
14 under title XVIII of the Social Security Act with such pro-
15 grams conducted in the private sector, including the prevalence
16 of such programs and programs for case management. The
17 study shall identify the cost-effectiveness of such programs and
18 any savings achieved by such programs. The Comptroller Gen-
19 eral shall submit a report on such study to Congress by not
20 later than 18 months after the date of the enactment of this
21 Act.

22 **SEC. 623. DEMONSTRATION PROJECT FOR MEDICAL**
23 **ADULT DAY CARE SERVICES.**

24 (a) ESTABLISHMENT.—Subject to the succeeding provi-
25 sions of this section, the Secretary of Health and Human Serv-
26 ices shall establish a demonstration project (in this section re-
27 ferred to as the “demonstration project”) under which the Sec-
28 retary shall, as part of a plan of an episode of care for home
29 health services established for a medicare beneficiary, permit a
30 medical adult day care facility or a home health agency, di-
31 rectly or under arrangements with a medical adult day care fa-
32 cility, to provide medical adult day care services as a substitute
33 for a portion of home health services that would otherwise be
34 provided in the beneficiary’s home.

35 (b) PAYMENT.—

36 (1) IN GENERAL.—The amount of payment for an epi-
37 sode of care for home health services, a portion of which

1 consists of substitute medical adult day care services, under
2 the demonstration project shall be made at a rate equal to
3 95 percent of the amount that would otherwise apply for
4 such home health services under section 1895 of the Social
5 Security Act (42 u.s.c. 1395fff). In no case may a a med-
6 ical adult day care facility or home health agency, or a
7 medical adult day care facility under arrangements with a
8 home health agency, separately charge a beneficiary for
9 medical adult day care services furnished under the plan of
10 care.

11 (2) BUDGET NEUTRALITY FOR DEMONSTRATION
12 PROJECT.—Notwithstanding any other provision of law, the
13 Secretary shall provide for an appropriate reduction in the
14 aggregate amount of additional payments made under sec-
15 tion 1895 of the Social Security Act (42 U.S.C. 1395fff)
16 to reflect any increase in amounts expended from the Trust
17 Funds as a result of the demonstration project conducted
18 under this section.

19 (c) DEMONSTRATION PROJECT SITES.—The project estab-
20 lished under this section shall be conducted in not more than
21 5 sites in States selected by the Secretary that license or certify
22 providers of services that furnish medical adult day care serv-
23 ices.

24 (d) DURATION.—The Secretary shall conduct the dem-
25 onstration project for a period of 3 years.

26 (e) VOLUNTARY PARTICIPATION.—Participation of medi-
27 care beneficiaries in the demonstration project shall be vol-
28 untary. The total number of such beneficiaries that may par-
29 ticipate in the project at any given time may not exceed
30 15,000.

31 (f) PREFERENCE IN SELECTING AGENCIES.—In selecting
32 medical adult day care facilities and home health agencies to
33 participate under the demonstration project, the Secretary shall
34 give preference to those facilities and agencies that—

35 (1) are currently licensed or certified to furnish med-
36 ical adult day care services; and

1 (2) have furnished medical adult day care services to
2 medicare beneficiaries for a continuous 2-year period before
3 the beginning of the demonstration project.

4 (g) WAIVER AUTHORITY.—The Secretary may waive such
5 requirements of title XVIII of the Social Security Act as may
6 be necessary for the purposes of carrying out the demonstra-
7 tion project, other than waiving the requirement that an indi-
8 vidual be homebound in order to be eligible for benefits for
9 home health services.

10 (h) EVALUATION AND REPORT.—The Secretary shall con-
11 duct an evaluation of the clinical and cost effectiveness of the
12 demonstration project. Not later 30 months after the com-
13 mencement of the project, the Secretary shall submit to Con-
14 gress a report on the evaluation, and shall include in the report
15 the following:

16 (1) An analysis of the patient outcomes and costs of
17 furnishing care to the medicare beneficiaries participating
18 in the project as compared to such outcomes and costs to
19 beneficiaries receiving only home health services for the
20 same health conditions.

21 (2) Such recommendations regarding the extension,
22 expansion, or termination of the project as the Secretary
23 determines appropriate.

24 (i) DEFINITIONS.—In this section:

25 (1) HOME HEALTH AGENCY.—The term “home health
26 agency” has the meaning given such term in section
27 1861(o) of the Social Security Act (42 U.S.C. 1395x(o)).

28 (2) MEDICAL ADULT DAY CARE FACILITY.—The term
29 “medical adult day care facility” means a facility that—

30 (A) has been licensed or certified by a State to
31 furnish medical adult day care services in the State for
32 a continuous 2-year period;

33 (B) is engaged in providing skilled nursing serv-
34 ices and other therapeutic services directly or under ar-
35 rangement with a home health agency;

36 (C) meets such standards established by the Sec-
37 retary to assure quality of care and such other require-

1 ments as the Secretary finds necessary in the interest
2 of the health and safety of individuals who are fur-
3 nished services in the facility; and

4 (D) provides medical adult day care services.

5 (3) MEDICAL ADULT DAY CARE SERVICES.—The term
6 “medical adult day care services” means—

7 (A) home health service items and services de-
8 scribed in paragraphs (1) through (7) of section
9 1861(m) furnished in a medical adult day care facility;

10 (B) a program of supervised activities furnished in
11 a group setting in the facility that—

12 (i) meet such criteria as the Secretary deter-
13 mines appropriate; and

14 (ii) is designed to promote physical and mental
15 health of the individuals; and

16 (C) such other services as the Secretary may
17 specify.

18 (4) MEDICARE BENEFICIARY.—The term “medicare
19 beneficiary” means an individual entitled to benefits under
20 part A of this title, enrolled under part B of this title, or
21 both.

22 **SEC. 624. PUBLICATION ON FINAL WRITTEN GUIDANCE**
23 **CONCERNING PROHIBITIONS AGAINST DIS-**
24 **CRIMINATION BY NATIONAL ORIGIN WITH**
25 **RESPECT TO HEALTH CARE SERVICES.**

26 Not later than January 1, 2003, the Secretary shall issue
27 final written guidance concerning the application of the prohibi-
28 tion in title VI of the Civil Rights Act of 1964 against national
29 origin discrimination as it affects persons with limited English
30 proficiency with respect to access to health care services under
31 the medicare program.

32 **TITLE VII—MEDICAID AND OTHER**
33 **HEALTH PROVISIONS**
34 **Subtitle A—Medicaid Provisions**

35 **SEC. 701. DSH PROVISIONS.**

36 (a) CONTINUATION OF MEDICAID DSH ALLOTMENT AD-
37 JUSTMENTS UNDER BIPA2000.—

1 (1) IN GENERAL.—Section 1923(f) (42 U.S.C. 1396r–
2 4(f))—

3 (A) in paragraph (2)—

4 (i) in the heading, by striking “THROUGH
5 2002” and inserting “THROUGH 2000”;

6 (ii) by striking “ending with fiscal year 2002”
7 and inserting “ending with fiscal year 2000”; and

8 (iii) in the table in such paragraph, by striking
9 the columns labeled “FY 01” and “FY02”;

10 (B) in paragraph (3)(A), by striking “paragraph
11 (2)” and inserting “paragraph (4)”; and

12 (C) in paragraph (4), as added by section
13 701(a)(1) of BIPA—

14 (i) by striking “FOR FISCAL YEARS 2001 AND
15 2002” in the heading;

16 (ii) in subparagraph (A), by striking “Not-
17 withstanding paragraph (2), the” and inserting
18 “The”;

19 (iii) in subparagraph (C)—

20 (I) by striking “NO APPLICATION” and in-
21 serting “APPLICATION”; and

22 (II) by striking “without regard to” and
23 inserting “taking into account”.

24 (2) INCREASE IN MEDICAID DSH ALLOTMENT FOR THE
25 DISTRICT OF COLUMBIA.—

26 (A) IN GENERAL.—Effective for DSH allotments
27 beginning with fiscal year 2002, the item in the table
28 contained in section 1923(f)(2) of the Social Security
29 Act (42 U.S.C. 1396r–4(f)(2)) for the District of Co-
30 lumbia for the DSH allotment for FY 00 (fiscal year
31 2000) is amended by striking “32” and inserting “49”.

32 (B) CONSTRUCTION.—Nothing in subparagraph
33 (A) shall be construed as preventing the application of
34 section 1923(f)(4) of the Social Security Act (as
35 amended by subsection (a)) to the District of Columbia
36 for fiscal year 2002 and subsequent fiscal years.

(b) INCREASE IN FLOOR FOR TREATMENT AS AN EXTREMELY LOW DSH STATE TO 3 PERCENT IN FISCAL YEAR 2002.—

(1) INCREASE IN DSH FLOOR.—Section 1923(f)(5) (42 U.S.C. 1396r-4(f)(5)) is amended—

(A) by striking “fiscal year 1999” and inserting “fiscal year 2001”;

(B) by striking “August 31, 2000” and inserting “August 31, 2002”;

(C) by striking “1 percent” each place it appears and inserting “3 percent”; and

(D) by striking “fiscal year 2001” and inserting “fiscal year 2003”.

(2) EFFECTIVE DATE.—The amendments made by paragraph (1) take effect on October 1, 2002, and apply to DSH allotments under title XIX of the Social Security Act for fiscal year 2003 and each fiscal year thereafter.

SEC. 702. 1-YEAR EXTENSION OF Q-I1 PROGRAM.

Section 1902(a)(10)(E)(iv) (42 U.S.C. 1396a(a)(10)(E)(iv)) is amended by striking “2002” and inserting “2003”.

Subtitle B—Internet Pharmacies

SEC. 711. INTERNET SALES OF PRESCRIPTION DRUGS.

(a) IN GENERAL.—Chapter 5 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by inserting after section 503A the following section:

“SEC. 503B. INTERNET SALES OF PRESCRIPTION DRUGS.

“(a) REQUIREMENTS REGARDING INFORMATION ON INTERNET SITE.—

“(1) IN GENERAL.—A person may not dispense a prescription drug pursuant to a sale of the drug by such person if—

“(A) the purchaser of the drug submitted the purchase order for the drug, or conducted any other part of the sales transaction for the drug, through an Internet site; and

1 “(B) such site, or any other Internet site used by
2 such person for purposes of sales of a prescription
3 drug, fails to meet each of the requirements specified
4 in paragraph (2) (other than a site or pages on a site
5 that are not intended to be accessed by purchasers or
6 prospective purchasers).

7 “(2) REQUIREMENTS.—With respect to an Internet
8 site, the requirements referred to in subparagraph (B) of
9 paragraph (1) for a person to whom such paragraph ap-
10 plies are as follows:

11 “(A) Each page of the site shall include either the
12 following information or a link to a page that provides
13 the following information:

14 “(i) The name of such person; the address of
15 the principal place of business of the person with
16 respect to sales of prescription drugs through the
17 Internet; and the telephone number for such place
18 of business.

19 “(ii) Each State in which the person is author-
20 ized by law to dispense prescription drugs.

21 “(iii) The name of each individual who serves
22 as a pharmacist for purposes of the site, and each
23 State in which the individual is authorized by law
24 to dispense prescription drugs.

25 “(iv) If the person provides for medical con-
26 sultations through the site for purposes of pro-
27 viding prescriptions, the name of each individual
28 who provides such consultations; each State in
29 which the individual is licensed or otherwise au-
30 thorized by law to provide such consultations; and
31 the type or types of health professions for which
32 the individual holds such licenses or other author-
33 izations.

34 “(B) A link to which paragraph (1) applies shall
35 be clearly visible on the page involved, shall not be of
36 a size smaller than other links on the page (if any),

1 and shall include in the caption for the link the words
2 ‘licensing and contact information’.

3 “(b) INTERNET SALES WITHOUT APPROPRIATE MEDICAL
4 RELATIONSHIPS.—

5 “(1) IN GENERAL.—A person may not dispense a pre-
6 scription drug, or arrange the dispensing of such a drug,
7 pursuant to a sale of the drug if—

8 “(A) for purposes of such sale, the purchaser com-
9 municated with the person through the Internet;

10 “(B) the patient for whom the drug was purchased
11 did not, when such communications began, have a pre-
12 scription for the drug;

13 “(C) pursuant to such communications, the person
14 provided for the involvement of a practitioner and the
15 practitioner issued a prescription for the drug that was
16 purchased;

17 “(D) the person knew, or had reason to know, that
18 the practitioner did not, when issuing the prescription,
19 have a qualifying medical relationship with the patient;
20 and

21 “(E)(i) the person received payment for the drug
22 from the purchaser; or

23 “(ii) in the case of arranging the dispensing of the
24 drug, the person received payment for doing so from
25 the person who dispensed the drug.

26 For purposes of subparagraph (E), payment is received if
27 money or other valuable consideration is received.

28 “(2) QUALIFYING MEDICAL RELATIONSHIP.—

29 “(A) IN GENERAL.—With respect to issuing a pre-
30 scription for a drug for a patient, a practitioner has a
31 qualifying medical relationship with the patient for pur-
32 poses of this section if at least one in-person medical
33 evaluation of the patient has been conducted by the
34 practitioner. This subparagraph and subparagraph (B)
35 may not be construed as having any applicability be-
36 yond this section.

1 “(B) IN-PERSON MEDICAL EVALUATION.—A med-
2 ical evaluation by a practitioner is an in-person medical
3 evaluation for purposes of this section if the practi-
4 tioner is in the physical presence of the patient as part
5 of conducting the evaluation, without regard to whether
6 portions of the evaluation are conducted by other
7 health professionals.

8 “(c) ACTIONS BY STATES.—

9 “(1) IN GENERAL.—Whenever an attorney general of
10 any State has reason to believe that the interests of the
11 residents of that State have been or are being threatened
12 or adversely affected because any person has engaged or is
13 engaging in a pattern or practice that violates section
14 301(l), the State may bring a civil action on behalf of its
15 residents in an appropriate district court of the United
16 States to enjoin such practice, to enforce compliance with
17 such section (including a nationwide injunction), to obtain
18 damages, restitution, or other compensation on behalf of
19 residents of such State, to obtain reasonable attorneys fees
20 and costs if the State prevails in the civil action, or to ob-
21 tain such further and other relief as the court may deem
22 appropriate.

23 “(2) NOTICE.—The State shall serve prior written no-
24 tice of any civil action under paragraph (1) or (5)(B) upon
25 the Secretary and provide the Secretary with a copy of its
26 complaint, except that if it is not feasible for the State to
27 provide such prior notice, the State shall serve such notice
28 immediately upon instituting such action. Upon receiving a
29 notice respecting a civil action, the Secretary shall have the
30 right—

31 “(A) to intervene in such action;

32 “(B) upon so intervening, to be heard on all mat-
33 ters arising therein; and

34 “(C) to file petitions for appeal.

35 “(3) CONSTRUCTION.—For purposes of bringing any
36 civil action under paragraph (1), nothing in this chapter
37 shall prevent an attorney general of a State from exercising

1 the powers conferred on the attorney general by the laws
2 of such State to conduct investigations or to administer
3 oaths or affirmations or to compel the attendance of wit-
4 nesses or the production of documentary and other evi-
5 dence.

6 “(4) VENUE; SERVICE OF PROCESS.—Any civil action
7 brought under paragraph (1) in a district court of the
8 United States may be brought in the district in which the
9 defendant is found, is an inhabitant, or transacts business
10 or wherever venue is proper under section 1391 of title 28,
11 United States Code. Process in such an action may be
12 served in any district in which the defendant is an inhab-
13 itant or in which the defendant may be found.

14 “(5) ACTIONS BY OTHER STATE OFFICIALS.—

15 “(A) Nothing contained in this section shall pro-
16 hibit an authorized State official from proceeding in
17 State court on the basis of an alleged violation of any
18 civil or criminal statute of such State.

19 “(B) In addition to actions brought by an attorney
20 general of a State under paragraph (1), such an action
21 may be brought by officers of such State who are au-
22 thorized by the State to bring actions in such State on
23 behalf of its residents.

24 “(d) DEFINITIONS.—

25 “(1) INTERNET-RELATED DEFINITIONS.—For pur-
26 poses of this section:

27 “(A) The term ‘Internet’ means collectively the
28 myriad of computer and telecommunications facilities,
29 including equipment and operating software, which
30 comprise the interconnected world-wide network of net-
31 works that employ the transmission control protocol/
32 internet protocol, or any predecessor or successor pro-
33 tocols to such protocol, to communicate information of
34 all kinds by wire or radio.

35 “(B) The term ‘link’, with respect to the Internet,
36 means one or more letters, words, numbers, symbols, or
37 graphic items that appear on a page of an Internet site

1 for the purpose of serving, when activated, as a method
2 for executing an electronic command—

3 “(i) to move from viewing one portion of a
4 page on such site to another portion of the page;

5 “(ii) to move from viewing one page on such
6 site to another page on such site; or

7 “(iii) to move from viewing a page on one
8 Internet site to a page on another Internet site.

9 “(C) The term ‘page’, with respect to the Internet,
10 means a document or other file accessed at an Internet
11 site.

12 “(D)(i) The terms ‘site’ and ‘address’, with re-
13 spect to the Internet, mean a specific location on the
14 Internet that is determined by Internet Protocol num-
15 bers. Such term includes the domain name, if any.

16 “(ii) The term ‘domain name’ means a method of
17 representing an Internet address without direct ref-
18 erence to the Internet Protocol numbers for the ad-
19 dress, including methods that use designations such as
20 ‘.com’, ‘.edu’, ‘.gov’, ‘.net’, or ‘.org’.

21 “(iii) The term ‘Internet Protocol numbers’ in-
22 cludes any successor protocol for determining a specific
23 location on the Internet.

24 “(2) OTHER DEFINITIONS.—For purposes of this sec-
25 tion:

26 “(A) The term ‘practitioner’, with respect to the
27 issuance of a prescription for a drug for a patient,
28 means—

29 “(i) an individual authorized by law to admin-
30 ister the drug; or

31 “(ii) an individual who is not so authorized
32 but represents himself or herself as an individual
33 who is so authorized.

34 “(B) The term ‘prescription drug’ means a drug
35 that is subject to section 503(b).

1 “(C) The term ‘qualifying medical relationship’,
2 with respect to a practitioner and a patient, has the
3 meaning indicated for such term in subsection (b).”.

4 (b) INCLUSION AS PROHIBITED ACT.—Section 301 of the
5 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is
6 amended by inserting after paragraph (k) the following:

7 “(l) The dispensing of a prescription drug in violation of
8 section 503B, or arranging for the dispensing of such a drug
9 in violation of such section.”.

10 **SEC. 712. INTERNET SALES OF PRESCRIPTION DRUGS;**
11 **CONSIDERATION BY SECRETARY OF PRAC-**
12 **TICES AND PROCEDURES FOR CERTIFI-**
13 **CATION OF LEGITIMATE BUSINESSES.**

14 In carrying out section 503B of the Federal Food, Drug,
15 and Cosmetic Act (as added by section 711 of this Act), the
16 Secretary of Health and Human Services shall take into consid-
17 eration the practices and procedures of public or private enti-
18 ties that certify that businesses selling prescription drugs
19 through Internet sites are legitimate businesses, including prac-
20 tices and procedures regarding disclosure formats and verifica-
21 tion programs.

22 **SEC. 713. EFFECTIVE DATE.**

23 The amendments made by section 711 take effect upon
24 the expiration of the 60-day period beginning on the date of
25 the enactment of this Act, without regard to whether a final
26 rule to implement such amendments has been promulgated by
27 the Secretary of Health and Human Services under section
28 701(a) of the Federal Food, Drug, and Cosmetic Act. The pre-
29 ceding sentence may not be construed as affecting the authority
30 of such Secretary to promulgate such a final rule.

31 **Subtitle C—Treatment of Rare**
32 **Diseases**

33 **SEC. 721. NIH OFFICE OF RARE DISEASES AT NATIONAL**
34 **INSTITUTES OF HEALTH.**

35 Title IV of the Public Health Service Act (42 U.S.C. 281
36 et seq.), as amended by Public Law 107–84, is amended by in-
37 serting after section 404E the following:

1 “OFFICE OF RARE DISEASES

2 “SEC. 404F. (a) ESTABLISHMENT.—There is established
3 within the Office of the Director of NIH an office to be known
4 as the Office of Rare Diseases (in this section referred to as
5 the ‘Office’), which shall be headed by a Director (in this sec-
6 tion referred to as the ‘Director’), appointed by the Director of
7 NIH.

8 “(b) DUTIES.—

9 “(1) IN GENERAL.—The Director of the Office shall
10 carry out the following:

11 “(A) The Director shall recommend an agenda for
12 conducting and supporting research on rare diseases
13 through the national research institutes and centers.
14 The agenda shall provide for a broad range of research
15 and education activities, including scientific workshops
16 and symposia to identify research opportunities for rare
17 diseases.

18 “(B) The Director shall, with respect to rare dis-
19 eases, promote coordination and cooperation among the
20 national research institutes and centers and entities
21 whose research is supported by such institutes.

22 “(C) The Director, in collaboration with the direc-
23 tors of the other relevant institutes and centers of the
24 National Institutes of Health, may enter into coopera-
25 tive agreements with and make grants for regional cen-
26 ters of excellence on rare diseases in accordance with
27 section 404G.

28 “(D) The Director shall promote the sufficient al-
29 location of the resources of the National Institutes of
30 Health for conducting and supporting research on rare
31 diseases.

32 “(E) The Director shall promote and encourage
33 the establishment of a centralized clearinghouse for
34 rare and genetic disease information that will provide
35 understandable information about these diseases to the
36 public, medical professionals, patients and families.

1 “(F) The Director shall biennially prepare a re-
2 port that describes the research and education activities
3 on rare diseases being conducted or supported through
4 the national research institutes and centers, and that
5 identifies particular projects or types of projects that
6 should in the future be conducted or supported by the
7 national research institutes and centers or other enti-
8 ties in the field of research on rare diseases.

9 “(G) The Director shall prepare the NIH Direc-
10 tor’s annual report to Congress on rare disease re-
11 search conducted by or supported through the national
12 research institutes and centers.

13 “(2) PRINCIPAL ADVISOR REGARDING ORPHAN DIS-
14 EASES.—With respect to rare diseases, the Director shall
15 serve as the principal advisor to the Director of NIH and
16 shall provide advice to other relevant agencies. The Direc-
17 tor shall provide liaison with national and international pa-
18 tient, health and scientific organizations concerned with
19 rare diseases.

20 “(c) DEFINITION.—For purposes of this section, the term
21 ‘rare disease’ means any disease or condition that affects less
22 than 200,000 persons in the United States.

23 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the pur-
24 pose of carrying out this section, there are authorized to be ap-
25 propriated such sums as already have been appropriated for fis-
26 cal year 2002, and \$4,000,000 for each of the fiscal years 2003
27 through 2006.”.

28 **SEC. 722. RARE DISEASE REGIONAL CENTERS OF EXCEL-**
29 **LENCE.**

30 Title IV of the Public Health Service Act (42 U.S.C. 281
31 et seq.), as amended by section 721, is further amended by in-
32 serting after section 404F the following:

33 “RARE DISEASE REGIONAL CENTERS OF EXCELLENCE

34 “SEC. 404G. (a) COOPERATIVE AGREEMENTS AND
35 GRANTS.—

36 “(1) IN GENERAL.—The Director of the Office of Rare
37 Diseases (in this section referred to as the ‘Director’), in

1 collaboration with the directors of the other relevant insti-
2 tutes and centers of the National Institutes of Health, may
3 enter into cooperative agreements with and make grants to
4 public or private nonprofit entities to pay all or part of the
5 cost of planning, establishing, or strengthening, and pro-
6 viding basic operating support for regional centers of excel-
7 lence for clinical research into, training in, and demonstra-
8 tion of diagnostic, prevention, control, and treatment meth-
9 ods for rare diseases.

10 “(2) POLICIES.—A cooperative agreement or grant
11 under paragraph (1) shall be entered into in accordance
12 with policies established by the Director of NIH.

13 “(b) COORDINATION WITH OTHER INSTITUTES.—The Di-
14 rector shall coordinate the activities under this section with
15 similar activities conducted by other national research insti-
16 tutes, centers and agencies of the National Institutes of Health
17 and by the Food and Drug Administration to the extent that
18 such institutes, centers and agencies have responsibilities that
19 are related to rare diseases.

20 “(c) USES FOR FEDERAL PAYMENTS UNDER COOPERA-
21 TIVE AGREEMENTS OR GRANTS.—Federal payments made
22 under a cooperative agreement or grant under subsection (a)
23 may be used for—

24 “(1) staffing, administrative, and other basic operating
25 costs, including such patient care costs as are required for
26 research;

27 “(2) clinical training, including training for allied
28 health professionals, continuing education for health profes-
29 sionals and allied health professions personnel, and infor-
30 mation programs for the public with respect to rare dis-
31 eases; and

32 “(3) clinical research and demonstration programs.

33 “(d) PERIOD OF SUPPORT; ADDITIONAL PERIODS.—Sup-
34 port of a center under subsection (a) may be for a period of
35 not to exceed 5 years. Such period may be extended by the Di-
36 rector for additional periods of not more than 5 years if the
37 operations of such center have been reviewed by an appropriate

1 technical and scientific peer review group established by the Di-
2 rector and if such group has recommended to the Director that
3 such period should be extended.

4 “(e) AUTHORIZATION OF APPROPRIATIONS.—For the pur-
5 pose of carrying out this section, there are authorized to be ap-
6 propriated such sums as already have been appropriated for fis-
7 cal year 2002, and \$20,000,000 for each of the fiscal years
8 2003 through 2006.”.

9 **Subtitle D—Other Provisions**

10 **Relating to Drugs**

11 **SEC. 731. GAO STUDY REGARDING DIRECT-TO-CON-**

12 **SUMER ADVERTISING OF PRESCRIPTION**

13 **DRUGS.**

14 (a) IN GENERAL.—The Comptroller General of the United
15 States shall conduct a study for the purpose of determining—

16 (1) whether and to what extent there have been in-
17 creases in utilization rates of prescription drugs that are
18 attributable to guidance regarding direct-to-consumer ad-
19 vertising of such drugs that has been issued by the Food
20 and Drug Administration under section 502(n) of the Fed-
21 eral Food, Drug, and Cosmetic Act; and

22 (2) if so, whether and to what extent such increased
23 utilization rates have resulted in increases in the costs of
24 public or private health plans, health insurance, or other
25 health programs.

26 (b) CERTAIN DETERMINATIONS.—The study under sub-
27 section (a) shall include determinations of the following:

28 (1) The extent to which advertisements referred to in
29 such subsection have resulted in effective consumer edu-
30 cation about the prescription drugs involved, including an
31 understanding of the risks of the drugs relative to the bene-
32 fits.

33 (2) The extent of consumer satisfaction with such ad-
34 vertisements.

35 (3) The extent of physician satisfaction with the ad-
36 vertisements, including determining whether physicians be-
37 lieve that the advertisements interfere with the exercise of

1 their medical judgment by influencing consumers to prefer
2 advertised drugs over alternative therapies.

3 (4) The extent to which the advertisements have re-
4 sulted in increases in health care costs for taxpayers, for
5 employers, or for consumers due to consumer decisions to
6 seek advertised drugs rather than lower-costs alternative
7 therapies.

8 (5) The extent to which the advertisements have re-
9 sulted in decreases in health care costs for taxpayers, for
10 employers, or for consumers due to decreased hospitaliza-
11 tion rates, fewer physician visits (not related to hospitaliza-
12 tion), lower treatment costs, or reduced instances of em-
13 ployee absences to care for family members with diseases
14 or disorders.

15 (c) REPORT.—Not later than two years after the date of
16 the enactment of this Act, the Comptroller General of the
17 United States shall submit to the Congress a report providing
18 the findings of the study under subsection (a).

19 **SEC. 732. CERTAIN HEALTH PROFESSIONS PROGRAMS**
20 **REGARDING PRACTICE OF PHARMACY.**

21 Part E of title VII of the Public Health Service Act (42
22 U.S.C. 294n et seq.) is amended by adding at the end the fol-
23 lowing subpart:

24 **“Subpart 3—Pharmacist Workforce Programs**

25 **“SEC. 771. PUBLIC SERVICE ANNOUNCEMENTS.**

26 “(a) PUBLIC SERVICE ANNOUNCEMENTS.—

27 “(1) IN GENERAL.—The Secretary shall develop and
28 issue public service announcements that advertise and pro-
29 mote the pharmacist profession, highlight the advantages
30 and rewards of being a pharmacist, and encourage individ-
31 uals to enter the pharmacist profession.

32 “(2) METHOD.—The public service announcements de-
33 scribed in subsection (a) shall be broadcast through appro-
34 priate media outlets, including television or radio, in a
35 manner intended to reach as wide and diverse an audience
36 as possible.

1 “(b) STATE AND LOCAL PUBLIC SERVICE ANNOUNCE-
2 MENTS.—

3 “(1) IN GENERAL.—The Secretary shall award grants
4 to entities to support State and local advertising campaigns
5 through appropriate media outlets to promote the phar-
6 macist profession, highlight the advantages and rewards of
7 being a pharmacist, and encourage individuals from dis-
8 advantaged backgrounds to enter the pharmacist profes-
9 sion.

10 “(2) USE OF FUNDS.—An entity that receives a grant
11 under subsection (a) shall use funds received through such
12 grant to acquire local television and radio time, place ad-
13 vertisements in local newspapers, and post information on
14 billboards or on the Internet, in order to—

15 “(A) advertise and promote the pharmacist profes-
16 sion;

17 “(B) promote pharmacist education programs;

18 “(C) inform the public of public assistance regard-
19 ing such education programs;

20 “(D) highlight individuals in the community that
21 are presently practicing as pharmacists to recruit new
22 pharmacists; and

23 “(E) provide any other information to recruit indi-
24 viduals for the pharmacist profession.

25 “(3) METHOD.—The campaigns described in sub-
26 section (a) shall be broadcast on television or radio, placed
27 in newspapers as advertisements, or posted on billboards or
28 the Internet, in a manner intended to reach as wide and
29 diverse an audience as possible.

30 **“SEC. 772. DEMONSTRATION PROJECT.**

31 “(a) IN GENERAL.—The Secretary shall establish a dem-
32 onstration project to enhance the participation of individuals
33 who are pharmacists in the National Health Service Corps
34 Loan Repayment Program described in section 338B.

35 “(b) SERVICES.—Services that may be provided by phar-
36 macists pursuant to the demonstration project established
37 under this section include medication therapy management

1 services to assure that medications are used appropriately by
2 patients, to enhance patients' understanding of the appropriate
3 use of medications, to increase patients' adherence to prescrip-
4 tion medication regimens, to reduce the risk of adverse events
5 associated with medications, and to reduce the need for other
6 costly medical services through better management of medica-
7 tion therapy. Such services may include case management, dis-
8 ease management, drug therapy management, patient training
9 and education, counseling, drug therapy problem resolution,
10 medication administration, the provision of special packaging,
11 or other services that enhance the use of prescription medica-
12 tions.

13 “(c) PROCEDURE.—The Secretary may not provide assist-
14 ance to an individual under this section unless the individual
15 agrees to comply with all requirements described in sections
16 338B and 338E.

17 “(d) LIMITATIONS.—The demonstration project described
18 in this section shall provide for the participation of—

19 “(1) individuals to provide services in rural and urban
20 areas; and

21 “(2) enough individuals to allow the Secretary to prop-
22 erly analyze the effectiveness of such project.

23 “(e) DESIGNATIONS.—The demonstration project de-
24 scribed in this section, and any pharmacists who are selected
25 to participate in such project, shall not be considered by the
26 Secretary in the designation of a health professional shortage
27 area under section 332 during fiscal years 2003 through 2005.

28 “(f) RULE OF CONSTRUCTION.—This section shall not be
29 construed to require any State to participate in the project de-
30 scribed in this section.

31 “(g) REPORT.—The Secretary shall prepare and submit a
32 report on the project to—

33 “(1) the Committee on Health, Education, Labor, and
34 Pensions of the Senate;

35 “(2) the Subcommittee on Labor, Health and Human
36 Services, and Education of the Committee on Appropria-
37 tions of the Senate;

1 “(3) the Committee on Energy and Commerce of the
2 House of Representatives; and

3 “(4) the Subcommittee on Labor, Health and Human
4 Services, and Education of the Committee on Appropria-
5 tions of the House of Representatives.

6 **“SEC. 773. INFORMATION TECHNOLOGY.**

7 “(a) GRANTS AND CONTRACTS.—The Secretary may make
8 awards of grants or contracts to qualifying schools of pharmacy
9 for the purpose of assisting such schools in acquiring and in-
10 stalling computer-based systems to provide pharmaceutical edu-
11 cation. Education provided through such systems may be grad-
12 uate education, professional education, or continuing education.
13 The computer-based systems may be designed to provide on-site
14 education, or education at remote sites (commonly referred to
15 as distance learning), or both.

16 “(b) QUALIFYING SCHOOL OF PHARMACY.—For purposes
17 of this section, the term ‘qualifying school of pharmacy’ means
18 a school of pharmacy (as defined in section 799B) that requires
19 students to serve in a clinical rotation in which pharmacist
20 services are part of the curriculum.

21 **“SEC. 774. AUTHORIZATION OF APPROPRIATIONS.**

22 “For the purpose of carrying out this subpart, there are
23 authorized to be appropriated such sums as may be necessary
24 for each of the fiscal years 2003 through 2006.”.